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Abstract 
The primary cytomegalovirus infection is the most frequent congenital infection worldwide, 
potentially leading to disorders of the central nervous system and hearing loss, following 
maternofetal transmission to the fetus (Picone et al., 2013). In the absence of an effective 
vaccination against HCMV, the focus should be set on the early identification of HCMV-primary 
infections in pregnant women, as well as on the determination of risk factors for maternofetal 
transmission. 
Hygiene counseling of seronegative pregnant women was shown to be a very effective tool to 
reduce the risk of maternal infection and transmission to the fetus by up to 50% (Revello et al., 
2015). Hyperimmunoglobulins were reported to be able to reduce the risk of HCMV-
transmission during pregnancy after proven HCMV-primary infection of the mother. However, 
HIGs are controversially discussed in literature (Nigro et al., 2005; Visentin et al., 2012; Revello 
et al., 2014 and Kagan et al., 2018). Intravenous HIG administrations are still the only available 
treatment option for women with HCMV-primary infections in combination with early hygiene 
counseling of both seronegative and seropositive pregnant women, who exhibit an increased 
risk of HCMV acquisition by intrafamiliar or professional exposure to viral shedding infants 
below 3 years of age (Hamilton et al., 2014). Actually, there is no recommendation for HIG 
treatment outside of clinical trials (Rawlinson et al., 2017). 
In this PhD thesis, HCMV-specific antibodies in HIG and IVIGs which are directed against 
UL130 peptides and a recombinant pentameric complex, revealed strong in vitro neutralizing 
capacities (Schampera et al., 2018). Therefore, the vaccine development on the base of the 
viral pentameric complex could be successful which might lead to a potent vaccine in the future 
(Gerna et al., 2017).  
In a next step, up-coming monoclonal antibodies against PC have to proof their therapeutic 
value in in vivo studies, while in vitro results were highly promising, regarding to viral binding, 
neutralization and prevention of cellular infection, compared to HIG preparation (Ha et al., 
2017). The treatment with antibodies and accompanying antiviral drug therapy with VACV in 
second trimester of pregnancy could further improve the outcome of newborns in cases of 
maternofetal transmission with low viral load in fetal blood (Leruez-Ville et al., 2016). 
Furthermore, the involvement of HCMV-specific CD8+ T-cells might contribute in future 
studies of therapy-naive and HIG-treated pregnant women to identify maternal HCMV-
transmitters during early pregnancy. In this context, the results in this work suggest, that 
determination of IFN-γ concentration and/or IFN-γ producing PBMCs in these mothers could 
be used as potential surrogate marker, using T-Track EliSPOT CMV® and QuantiFERON 
CMV®. This could improve the diagnostic prediction for an increased risk of HCMV 
transmission, after maternal HCMV-primary infection (Saldan et al., 2015).
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1 Introduction 
1.1 Human Cytomegalovirus (HCMV) 
HCMV was firstly described in the year 1881 by the pathologist Dr. Moritz Wilhelm Hugo 
Ribbert. He characterized the histo-morphology of HCMV in the year 1904 for the first time. 
However, the isolation of the functional virus and its DNA succeeded in cell culture by Smith, 
Rowe and Weller in the years 1956 and 1957, three years after the discovery of DNA itself by 
Watson and Crick. The age of the human-related virus is estimated at about 80 million years 
(McGeoch et al., 1995). 
The cytomegaly (Greek: cyto-, "cell", and megalo-, "large") is an atypical enlargement of cells 
which are infected with HCMV. The infected cells show sloughing, endoplasmic vesicles inside 
the cells and detach from the cell culture matrix. (Goodpasture, 1920). The viral infection cycle 
may lead to a complete lysis of the cells, while the degree of the infection is described by the 
cytopathic effect (CPE) in cell culture (Knowles, 1979). Figure 1 illustrates the appearance of 
multiple CPEs in human foreskin fibroblasts (HFF) and human retinal pigmented epithelium 
cells (ARPE-19 cells). 
 
Figure 1: (A1) uninfected control monolayers of human foreskin fibroblasts (HFF,CRL-2429, ATCC®) 100x; 
(A2) CPE of HCMV-infected human fibroblasts (HFF, CRL-2429, ATCC®, Strain: H2497) 100x; (B1) uninfected 
control monolayers of retinal pigment epithelium cells (ARPE-19, CRL-2302 ATCC®) 100x; (B2) (A2) CPE of 
HCMV-infected human retinal pigmented epithelium cells (ARPE-19, CRL-2302 ATCC®, Strain: H2497) 100x 
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1.2 Taxonomy 
HCMV is a member of the Herpesviridae family and is defined as human herpesvirus 5 (HHV-
5) (Roizmann et al., 1992). The Herpesviridae family counts 8 members which includes 
Herpes-Simplex-Virus Type 1 and 2 (HSV), Varicella Zoster Virus (VZV) and Epstein-Barr-
Virus (EBV), as well as HHV-6 to 8. The characteristic attribute of this virus family is the 
generation of life-long latency after successful infection of the host with different tissues as site 
of persistence like liver, kidney, lung, heart, pancreas and bone marrow (Koffron et al., 1997). 
Table 1: Herpesvirus classification (modified after Davison et al., 2004) 
 
 
The Herpesviridae family can be divided into α-, β- und γ-Herpesviruses. These subclasses 
differ in several biological attributes which includes differences in replication cycle, tissue 
pathogenicity and host specificity. HCMV belongs together with HHV-6 and HHV-7 to the β-
Herpesvirus family. Characteristics for this family are high host specificities and slower 
replications cycle compared to other herpes families ((Roizmann et al., 1981; Stinski et al., 
1983; Ho et al., 1991). 
Herpesvirus Abbreviation Genome size 
(kb) Common Formal 
α-Herpesviridae    
   Simplexvirus HSV-1 HHV-1 152 
      Herpes Simplex Virus type 1 HSV-2 HHV-2 155 
      Herpes Simplex Virus type 2    
 
   Varicellovirus    
      Varicella Zoster virus VZV HHV-3 125 
 
β-Herpesviridae    
   Cytomegalovirus  HCMV HHV-5 227-236 
    
   Roseolovirus    
      Human herpesvirus type 6 HHV-6 HHV-6 159-162 
      Human herpesvirus type 7 HHV-7 HHV-7 144-153 
 
γ-Herpesviridae    
   Lymphocryptovirus    
   Epstein-Barr-Virus EBV HHV-4 172-173 
   Rhadinovirus    
      Human herpes type 8 HHV-8 HHV-8 134-138 
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1.3 Genome structure and function 
The genome of HCMV has a linear, double-stranded DNA which consists of about 192 “open 
reading frames” (ORFs) with approximately 750 translational products (Stern-Ginossar et al., 
2012). Therefore, it counts to the largest species among human Herpesviruses with a number 
of approximately 230.000 bps in general. At this point, wild type strains have to be differentiated 
from laboratory strains, as well as low passage in vitro strains like Toledo from high passage 
in vitro strains like Towne. The size and composition of the genome may differ, depending on 
their mutation profile, in context of cell tropism and potential drug resistance. For instance, a 
high passage strain adapts to in vitro cell culture, by spontaneous mutation of unnecessary or 
unused genes to improve their replication efficiency. However, they lose the ability to infect 
other cell types like the high passage strain AD169 which was highly propagated on fibroblasts 
and is unable to infect epithelial cells any more since a mutation of the specific binding receptor 
occurred (Wilkinson et al., 2015). 
 
Figure 2: Diagram of HCMV genome struture; strain:AD169 (Chee et al., 1990) 
The viral genome of HCMV the can be divided into a short and a long subunit in general which 
are descripted as „unique short“ (US) and “unique long” (UL) (Fig.2). Each subunit is bordered 
by „terminal inverted repeats“ (TRL, TRS) and “internal inverted repeats“ (IRL, IRS). For the US 
segment the coding reading frames are defined as US1–US36 and for the UL segment from 
UL1 to UL150 (Chee et al., 1990).  
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In detail, 165 protein coding genes of HCMV with different functions were identified for the 
genome of the Merlin strain (Dolan et al., 2004). Figure 3 shows a general overview of gene-
coding regions for HCMV. There are diverse genes which code for entry-related proteins, 
inhibitors or are associated with antiviral resistance like UL97 and UL54 (Boeckh et al., 2011; 
Douglas et al., 1997 and 1998). 
 
Figure 3: Overview of gene-coding regions for HCMV (Boeckh et al., 2011) 
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1.4 Morphology and viral entry 
The outer diameter of HCVM is about 150 to 200 nm. Therefore, it counts to the largest known 
human pathogenic viruses. The genome of HCMV is enclosed by an icosahedral capsid (T16 
symmetry) with an inner diameter between 100 to 110 nm and 162 capsomeres. The viral 
capsid is surrounded by an amorphous inner and outer tegument. It contains several phospho-
proteins (pp) (Fig.4). For example, the phospho-proteins pp65, pp71 and pp150 form an 
essential part of those proteins (Varnum et al., 2004).  
 
Figure 4: Model of a HCMV virion (URL: Education.expasy.org) 
The typical shape of a herpes virus consists of an envelope with a lipid bilayer from the host 
cell. In addition, there are viral glycoproteins (g), localized on the surface of the virus. They are 
described as gM, gN, gO, gH, gL and gB. There are also a trimer complex (TP) and a 
pentameric complex (PC) which play an important role in receptor recognition and viral entry 
into different cell types. 
 
 
Figure 5: Model and neutralizing regions of the trimer and pentameric complex (modified after Ciferri et 
al., 2015) 
  
 6/144 
The trimer and the pentameric complex contain the same sub unit (gH/gL) which is formed by 
gH and gL (green circle). The trimer complex additionally contains gO and the pentameric 
complex has the UL128 to 131A region (short: UL128L (L= locus)) (blue circles) (Fig.5) (Ciferri 
et al., 2015). The pentameric complex plays a key role in successfully entry of HCMV into both 
epithelial and endothelial cells, especially in context of maternofetal transmission (Tuzigov et 
al., 1998; Wang et al., 2005; Ryckman et al., 2008, Fouts et al., 2012). It was observed, that 
single mutations spontaneously occurred in the UL128-131A gene region after a few in vitro 
passages of HCMV wildtypes strains (WT) in human fibroblasts which disrupts the epithelial 
and endothelial tropism (Sinzger et al., 1999; Hahn et a., 2004).  
Moreover, it was demonstrated, that an overexpressed gHgL-UL128-131A complex is involved 
in viral entry into epithelial cells which does not appear in fibroblasts, supporting the 
suggestion, that PC is a cell-type dependent viral complex (Wang et al., 2005; Ryckman et al., 
2008; Lilleri et al., 2013). The entry into fibroblasts is mainly mediated by the trimer complex 
gH/gL/gO together with gB as fusion protein. (Compton et al., 1992; Li et al., 1992; Huber et 
al., 1998; Isaacson et al., 2009; Vanarsdall et la., 2011). The glycoprotein O has a high level 
of glycosylations and interferes covalently with gH and gL (Huber et al., 1997; Wang et al., 
20051).  
However, latest results indicate, that the fusion protein gB (UL55) together with gH/gL/gO are 
generally responsible for viral entry in many different or maybe all cell types, considering 
comparable homologies to others herpes viruses as proof of evidence (Stegmann et al., 2017). 
The pentameric complex is additionally necessary for the specific entry into epithelial, 
endothelial and also myeloid cells, besides gH/gL/gO and gB (Connolly et al., 2011; Zhou et 
al., 2015; Heldwein et al., 2016). But many points of the HCMV-specific entry mechanism, 
especially how the pentameric complex interacts with the target cells are still unknown. 
The trimer and the penatmeric complex have a higher frequency on the HCMV surface than 
gH/gL dimers (Zhou et al., 2013). At the same time, viral structures like glycoproteins are in 
immunogenetic points of particular importance, especially for the immune response in form of 
antigen presentation and antibody production (Britt et al., 1996). 
The phospho-protein pp65 has been reported to possess an immunological function as an 
essential antigen for the cellular immune response, especially for the MHC-1 antigen 
presentation path way to activate CD8+ T-cells which control an HCMV infection effectively by 
proliferation and precisely killing of virus-infected cells (Britt et al., 1986; Jahn et al., 1987).  
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The phospho-protein pp71 shows comparable immunogenic properties in T-cell activation and 
mediates the expression of early viral genes as transactivator. The pp71-dependent induction 
and transcription of these „immediate early (IE) genes“ initiates the first part of the lytic 
replication cycle which finally ends with the release of infectious HCMV virions from the dying 
cell (Liu & Stinski, 1992). Furthermore, pp150 exhibit a very high amount of phosphorylations 
which gathers a highly immunogenic potential. Therefore, it can be used in HCMV immunoblot 
assays and obtains a diagnostic character, as well as the glycoprotein gB2 (Jahn et al., 1987). 
1.5 Viral replication 
While the attachment of HCMV to the target cell via viral glycoproteins to the cell receptors is 
well described, the mechanism of viral entry itself is not fully understood. The mediated entry 
depends on the target cell type, in which HCMV invades using either endocytosis or fusion at 
the cell membrane (Fig. 6A). In the next step, the viral proteins of the tegument facilitate the 
intracellular release and transport of the viral capsid to the cell nucleus, using the microtubule 
machinery of the cell. Then, the viral DNA is transferred into the nucleus through nuclear pores 
(Fig. 6B). 
 
Figure 6: Overview of HCMV replication cycle (modified after Jean Beltran et al., 2014) 
The replication cycle can be subdivided by time-dependent expressed genes of the virus which 
involve immediate early (IE), delayed early (DE) and late (L) genes. The IE and DE genes are 
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mainly responsible for transcriptional regulation of modulatory proteins which promote the viral 
DNA replication in the cell nucleus. As additional function, they also shut down the innate 
immune response of the host, protecting the viral replication (Fig.6C). 
Interestingly, HCMV possesses its own functional DNA polymerase, but uses the cellular RNA 
polymerase II for viral mRNA synthesis (Snaar et al., 1999). The L genes regulate the 
production of structural proteins and the assembly of the capsid in the nucleus, followed by 
passaging through the endoplasmic reticulum (ER) into the cell plasma. On its further way from 
the ER and Golgi to the final release at the plasma membrane, it acquires its tegument and 
viral envelope which include the earlier described viral proteins (Fig.6D).  
HCMV also established persistence after infection in different cell tissues which can be inactive 
for decades. At this point, attention should be paid to the fact, that one single individual can 
acquire and carry several different HCMV strains in different organs or tissues during a lifetime. 
The “de novo” viral replication can be triggered by various events, like oxidative stress or 
immune suppression after transplantation (Jean Beltran et al., 2014). 
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1.6 Epidemiology 
HCMV is a ubiquitous human pathogenic virus with a seroprevalence of >95% in several 
countries. The percentage of the population which is infected with HCMV differs in each 
country and depends on manifold factors like geographic location, ethical and sexual behavior, 
as well as on social and economic conditions (Fig.7) (Adland et al., 2015). A general tendency 
to a lower prevalence of HCMV was observed in industrialized countries compared to 
developing countries. However, it has to be considered, that worldwide data for all countries 
are not available (Mocarski et al., 2007). 
 
Figure 7: HCMV seroprevalence rates in adults worldwide (Adland et al., 2015) 
1.7 Transmission and pathogenesis 
HCMV cannot cross species and can be transmitted via both the horizontal person-to-person 
and vertical mother-to-child infection path way. The horizontal transmission needs the direct 
contact of “open wounds” or mucosa with infectious body fluids like blood, urine or saliva, as 
well as sperm and vaginal secretion. The typical entry gates for HCMV are epithelial cells of 
the respiratory-, gastrointestinal- and urogenital tract. 
In addition, virus-contaminated blood may promote the transmission of HCMV, as well as 
transplantations of exogenous organs, tissue or bone marrow.   
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HCMV is able to invade macrophages which are part of the innate immune system (Sinzger 
et. al., 1995 and 1996; Sinzger & Jahn, 1996). During infection, the virus shows a characteristic 
cell-to-cell spread, but also disseminates through the hematogenic path way (Rinaldo et. al., 
1977). An interesting fact is, that the viral replication rate is generally slower in epi- and 
endothelial cells than in fibroblasts which is typically for Herpesviruses (Kahl et al., 2000). 
In contrast, the vertical mother-to-child infection may take place prenatally during pregnancy 
through placentally transmission, perinatally during birth over maternal blood contact to the 
fetus or postpartum, including breast feeding. (Reynolds et al., 1973; Lang et al., 1975 and 
Stagno et al., 1982). In general, the infection and reinfection with HCMV is asymptomatic in 
immune competent patients and pregnant women. In rare cases, symptoms of a mild cold are 
reported, followed by headaches, fatigue and lassitude, combined with light fever (Cohen et 
al., 1985; Jordan et al., 1973). 
1.8 Clinical relevance  
HCMV holds its clinical importance in immune compromised patients after transplantation, as 
well as during and after pregnancy. This thesis will focus on the viral transmission during 
pregnancy after HCMV primary infection, especially in the first trimenon (T1). In addition, 
HCMV was found postpartum during lactation in breast milk of seropositive mothers in up to 
85% of cases and transmitted in 35% cases to the newborns. While the viral infection of term 
infants is generally asymptomatic, neutropenia, thrombocytopenia and sepsis like symptoms 
may occur in high risk preterm infants with a birth weight of <1000g and a gestational age 
under 30 weeks (Vochem et al.,1998; Maschmann et al., 2001; Jim et al.,2004; Hamprecht et 
al., 2005 and 2008; Capretti et al., 2009). 
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1.9  Congenital HCMV infection 
HCMV has an incidence of congenital infection of about 0.2-2% in all live births. The 
maternofetal HCMV transmission can be highlighted as most frequent intrauterine viral 
infection with 30 to 40% cases worldwide. During course of pregnancy, the transmission rate 
to the fetus increases from ~9% preconceptionally to ~65% in the last trimenon of pregnancy 
(Picone et al., 2013). While the HCMV primary infection is mostly asymptomatic for the mother, 
the intrauterine transmission may cause fulminant and permanent central nervous system 
disabilities (Manicklal et al., 2013). However, the degree of severity of the clinical outcome 
depends on manifold factors like dose and time point of infection and extension period of 
transmission to the fetus, as well as on the immune response of the mother. In particularly, the 
T-cell response can strongly differ between individuals, as previously reported (Jackson et al., 
2014; Klenerman et al., 2016). 
 
 
Figure 8: HCMV-seroprevalence compared to congenital HCMV prevalence worldwide (Manicklal et al., 
2013) 
While the HCMV seroprevalence can almost reach 100%, the congenital HCMV prevalence 
fluctuates between 0.2 to 1.5% worldwide (Fig.8). In this context, countries like India, Brazil 
and Japan are especially affected by maternofetal HCMV transmission which occurs despite 
high HCMV seroprevalence rates, maybe caused by other social or ethnical reasons (Manickl 
al et al., 2013). 
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The increased transmission rate during an HCMV primary infection is caused by a not existing 
preconceptional immunity of the mother. The maternal placenta is not a suitable barrier to 
prevent the transmission of HCMV, because of a lack of highly affine IgG-antibodies, combined 
with no T-cell response against HCMV. It is important to know, that early induced IgM 
antibodies are not able to pass the placenta to protect the fetus successfully during a HCMV 
primary infection (Fowler et al., 1992). The maternofetal HCMV transmission in the first 
trimenon can lead to a termination of pregnancy in worst cases. For all other congenital 
infections, the mortality rate is about 8-10% for symptomatic infants at birth during the first year 
of life. Approximately 12% of the infected newborns show clinical symptoms like jaundice, 
pinpoint bleeding and hepatosplenomegaly, followed by long-term sequelae which includes 
mental retardation and hearing loss in the first two years of life (Mocarski et al., 2001; Landolfo 
et al., 2003; Mocarski et al., 2007).  
In a comprehensive review of Buxmann et al., 2017 which was published in the “Deutsches 
Ärzteblatt”, a cohort of 1000 pregnant women were investigated to exemplify the average risk 
for permanent disabilities, depending on the HCMV-serostatus of the mother at the beginning 
of pregnancy and the potential symptoms of the fetus (Fig.9). 
 
Figure 9: A breakdown of data for maternofetal HCMV-transmission rates and resulting risk of permanent 
disabilities of the newborns, depending on maternal HCMV-serostatus and potential symptoms of the fetus 
(Buxmann et al., 2017) 
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The cohort is representative for pregnant women of the Middle East of the European Union 
with a seroprevalence of 40 to 50%. The data of the review is based on relevant publications 
from the years 2000 to 2016. With 30 to 40%, the highest rate for permanent disabilities were 
found in HCMV-primary infected women with a symptomatic newborn which is mainly 
responsible for 700 to 1400 HCMV-affected births every year in Germany. Furthermore, 
permanent disabilities were observed in asymptomatic newborns in up to 15% of cases and 
the overall risk in HCMV-seropositive mothers was given with ~8%. 
The data of Buxmann et al., 2017 matched with a former and independent review of De Vries 
et al., 2011 which showed summarized data for the risk of permanent sequelae, caused by 
HCMV primary and recurrent infections during pregnancy without comprehensive 
determination of maternal HCMV-serostatus at the beginning of pregnancy (Fig.10). 
 
Figure 10: Congenital HCMV cases in the EU-27 (De Vries et al., 2011) 
The congenital HCMV was investigated in 27 countries of the EU (Fig.10). In general, there 
were 0.7% HCMV congenital infected newborns of all life births until the year 2011. The infants 
were in about 12% of cases symptomatic which leads to a probability of 49% for permanent 
sequelae and a death rate of 4%. While ~90% of the infants were asymptomatic at birth, they 
developed sequelae in about 13% of cases. In a summary, the overall risk to observe 
permanent sequelae was ~20% (De Vries et al., 2011). 
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1.9.1 Maternal placenta and IgG transfer  
The successful HCMV infection of the maternal placenta is an essential precondition for the 
intrauterine transmission to the fetus (Mostoufi-Zadeh et al., 1984). However, not every 
placenta HCMV infection results in a transmission to the fetus.  
An important fact is the presence and the concentration of IgG antibodies which bind and 
effectively neutralize HCMV virions with a high affinity by passing the placental blood barrier, 
in contrast to IgM antibodies (Adler et al., 1988; Pereira et al., 2006). Furthermore, the 
transplacental transfer of IgG subclasses 1 and 4 was significantly more efficient than IgG 
subclasses 2 and 3 (Garty et al, 1994). 
 
Figure 11: Schematic model of maternal placenta and maternofetal blood transfer (modified after Blundell 
et al., 2016) 
The human placenta is built after the conception and nidation of the fertilized blastocyst in 
maternal uterus which can reach a diameter of about 20 cm and a weight of approximately  
500 g until full maturity. 
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At the beginning, the placenta can be subdivided into the maternal and the fetal side which is 
bordered by the placental barrier and allows no direct blood transfer between the mother and 
the fetus.  
In detail, the maternal side consists of the decidua which is the basal plate of the placenta. On 
the fetal side, the chorion leads to the umbilical cord and further to the fetus. The intervillous 
space takes its position between the decidua and the chorion which is filled with freely 
circulating maternal blood. The villus reaches from the fetal chorion into the intervillous space 
and manages the exchange of substances by connecting the maternal and fetal blood system 
(Fig.11). For the fetus, the provision nutrients and oxygen, as wells as the elimination of wastes 
are the most important tasks of the placenta.  
In context of immune tolerance, the separation of the maternal and fetal blood system is of 
particular immunological importance. The mother and the fetus are genetically heterogeneous, 
as well as all generated cells and resulting components. Therefore, the immune system of the 
mother would recognize the foreign fetal cells and would initiate an immune response against 
these cells which would finally result in the loss of the fetus otherwise.  
The exchange of molecular weight <500 Da takes place, using 4 pathways: diffusion, facilitated 
diffusion, pinocytosis and receptor-mediated endocytosis. On this base, the transport of 
elementary substances, like O2 and H2O is managed by diffusion. This is also true for drugs 
like alcohol which explains its fatal teratogenic potential.  
On the other way, proteins like maternal IgG antibodies are transmitted with a mass of ~160 
kDa by pinocytosis and constitute the passive immune protection of the fetus which is called 
“nest protection” in common use. The fetal immune system is not able to produce sufficient 
amounts of highly affine antibodies to protect itself from infections (Carlson et al., 2013). 
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The transfer of maternal IgG-antibodies is performed by multinucleated syncytiotrophoblasts 
which is illustrated in figure 12. These cells are located on the surface of the villus and bind 
IgG-antibodies using the neonatal Fc-receptor (FcRn receptor) from maternal blood which 
protects these antibodies against lysosomal degeneration in the acidic inner milieu of 
endosomes. Interestingly, FcRn receptors have structural homologs to the major 
histocompatibility complex MHC I.  
 
Figure 12: Schematic transfer of IgG-antibodies through the placenta, using FcRn receptors (modified 
after Palmeira et al., 2012) 
After transcytosis, the endosomes melt with the membrane of cytrophoblasts and the IgG 
antibodies are released from the FcRn receptors, induced by the physiological pH shift from 6 
to 7.4. The FcRn receptor possesses a pH-dependent affinity for binding of IgG-antibodies, in 
contrast to Fcγ-receptors. This can be demonstrated in endosomes. At a pH-value of 6, the 
binding activity of FcRn receptors to IgG-antibodies is increased by a 100-fold, compared to 
the physiological pH value which triggers the antibody release on the fetal side of the placenta. 
However, high concentrations of IgG antibodies lead to lysosomal degeneration, initiated by 
oversaturation of FcRn receptors. In addition, used FcRn receptors can be delivered back to 
the maternal membrane and recycled for a second transcytosis of IgG-antibodies (Palmeira et 
al., 2012).  
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1.9.2 Diaplazental HCMV transmission 
The diaplazental transmission of HCMV and the immune response can be explained in 3 
different scenarios, shown in figure 13 (Maidji et al., 2006). 
 
Figure 13: FcRn-mediated transcytosis of IgG antibodies and HCMV virions given in 3 scenarios (Maidji et 
al., 2006). 
1. Latent infection: It shows the transcytosis of a healthy, HCMV-IgG seropositive 
(“immune”) pregnant woman. IgG antibodies are delivered through pinocytosis using 
FcRn receptors. The transcytosis follows via endosomes to the fetal side of the 
placenta, as well as recycled FcRn receptors vice versa.  
2. Recurrent infection: The recent infection of the placenta is suppressed in an 
immunocompetent latently infected mother after reactivation of HCMV (red spots) 
(Fig.13). At low pH value, the virus will be bound and neutralized by highly affine 
HCMV-specific antibodies during pinocytosis and are trapped in caveosomes (Cav) at 
neutral pH value. Afterwards, saturated caveosomes are transcytosed across the 
syncytiotrophoblasts to the membrane of cytrophoblasts. Villus core macrophages (Mϕ) 
capture the released virus-antibody complexes at this place and store them inside of 
vacuoles afterwards. 
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3. Primary infection: On the 3rd route through the placenta, an HCMV primary viral 
infection is given. IgG-antibodies with low avidity are presented in the maternal blood 
which are not able to bind and neutralize the virions efficiently to prevent the infection 
of the placental cells. Therefore, active HCMV virions are delivered to the fetal side of 
the placenta via endosomes. In a next step, released virions infect cytrophoblasts and 
surrounding fetal fibroblasts. Furthermore, the virus invades into fetal capillaries via 
infected endothelial cells which is shown in a cross section in the bottom right-hand 
corner of figure 13 (Pereira et al., 2003 and 2006). Leukocytes will be finally infected 
as well which may end up in a viral dissemination and organ manifestation with a 
potentially critical clinical outcome, if the infection took place in the first trimester of 
pregnancy (Fisher et al., 2000). 
1.10 HCMV diagnostics in pregnancy  
In general, diagnosis of fetal HCMV infection through ultrasound as imaging technique is 
inefficient, because of its high non-specificity to detect HCMV-specific infection in the early 
state of pregnancy. Only about 20% can be diagnosed using ultrasound detection during 
pregnancy and strongly depends on the experience and interpretation of the gynecologist 
(Benoist et al. 2008; Guerra et al., 2008).  
In Germany, the AWMF “Labordiagnostik schwangerschaftsrelevanter Virusinfektionen 
(AWMF Registernummer 0093/001; 2014)” regulates the diagnostics of viral infections during 
pregnancy. The direct HCMV detection is performed using quantitative PCR via isolated DNA 
and cell culture for diagnosis of active viral replication (Tab.2).  
Table 2: Overview of methods is given for direct HCMV detection. When testing follow-up samples using 
quantitative PCR, the same starting material must always be used for DNA isolation (modified after AWMF 
registration number 0093/001; 2014). 
Principle Method Source 
HCMV-DNA detection quantitative PCR 
Result: Specific genome 
copies/ml 
Leukocytes, EDTA blood, 
whole blood, plasma* 
(determination of infection 
status) Urine, throat 
swab/flush (determination of 
HCMV excretion, diagnosis 
in newborns) Amniotic fluid, 
umbilical cord blood 
(diagnosis of fetal infection) 
HCMV isolation Propagation in cell culture 
(human foreskin fibroblasts) 
Short-term microculture for 
HCMV antigen detection by 
immunofluorescence  
Urine, throat swab/flushing 
(determination of HCMV 
excretion; diagnosis in 
newborns) 
Amniotic fluid (diagnosis of 
fetal infection) 
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For further analysis, the determination of HCMV infection will be checked by analysis of HCMV-
specific serology. 
 
Figure 14: Overview of laboratory diagnostics. Blue font: Constellation of results, red font: Interpretation, 
green: Interventions; red border: further clarification required (modified after AWMF registration number 
0093/001, 2014). 
Figure 14 shows the general procedure of laboratory diagnostics to clarify the HCMV infection 
status in pregnant women, combined with optional interventions. The laboratory diagnosis of 
HCMV primary infection during pregnancy should be made by determining the HCMV-specific 
antibodies in the sense of a step-by-step diagnosis with a combination of different test systems. 
Table 3 gives an overview of methods for detection of HCMV-specific antibodies (AWMF 
registration number 0093/001, 2014). 
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Table 3: Overview of methods for the detection of HCMV-specific antibodies (modified after AWMF 
registration number 0093/001; 2014). 
Method Comments 
Ligand assays  
(e.g. ELISA, CLIA, CMIA, ECLIA) 
Determination and differentiation of Ig classes 
(IgG, IgM) in serum or plasma Simple 
execution, commercially available, partially 
automated 
Immuno/ Western blot 
(recomLine® Immunoblot) 
 
Determination and differentiation of IgG classes 
(IgG, IgM) in serum or plasma 
Determination of IgG reactivities against defined 
HCMV proteins (anti-gB IgG not detectable in 
fresh HCMV primary infection) 
Simple execution, commercially available 
HCMV-IgG-avidity (ELISA, 
Immunoblot)  
 
Differentiation between HCMV primary infection 
and HCMV latency/HCMV recurrence stage 
diagnosis for IgM detection in pregnancy 
Neutralisation assays Functional antibody test: Differentiation between 
HCMV primary infection and HCMV 
latency/HCMV recurrence primary infection: 
detection of neutralizing antibodies within 3-4 
weeks in epithelial cell culture; within 3-4 months 
in fibroblast cell culture 
 
The detection and interpretation of maternal IgM antibody index is more accurate to detect an 
HCMV primary infection, in combination with avidity testing and quantitative determination of 
HCMV-specific IgG antibodies. The detection of HCMV epitope-specific antibodies is also a 
useful diagnostic tool to confirm or to deny an HCMV primary infection. Therefore, several 
immuno assays and immunoblots are available (Guerra et al. 2008; Fabbri et al., 2011). 
In general, a latent HCMV infection can be characterized by high avidity of HCMV-specific IgG 
antibodies and missing of IgM at the same time. However, the presence of IgM antibodies 
against HCMV is not a proof for an HCMV primary infection.  
Both, primary and a recurrent HCMV infection may show IgM antibodies during pregnancy. 
Commercial antibody test systems include ELISA (enzyme linked immuno absorbent assay), 
ECLIA (electro chemoluminescence immuno assay), CLIA (chemoluminescence linked 
immuno absorbent assay) and CMIA (chemoluminescence micro particle assay). The 
recomLine® Immunoblot from Mikrogen is able to detect HCMV epitope-specific antibodies 
like p150 and gB2 by semi-quantitative scoring of epitope-specific reactivity.  
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1.11 In vitro neutralization assays 
The serum of pregnant women can also be incubated with reference viral strains to check for 
specific neutralizing activity of IgG-antibodies by characterization of immunoglobulin 
preparations in vitro. A routine testing of maternal serum during pregnancy may help to narrow 
down the time point of infection.  
In general, there are 2 different approaches of neutralization testing and different target cell 
were used, including human foreskin fibroblasts (HFF), human embryonic lung fibroblasts 
(HELF) or retina pigment epithelial cells (RPE) (Tab.4).  
Eggers et al., 2000 and Gerna et al., 2008 worked with cell-free virus strains which were shed 
into supernatant after several cell culture passages. Cell-free virus was preincubated with 
dilution series of potentially neutralizing sera. Then virus-antibody complex was transferred to 
non-infected target cell monolayers, using micro titer plates to determine NT50-values. Free 
unbound virus is able to infect target cells. The NT50-value describes the dilution of serum 
which is able to bind and neutralize 50% of the used viral particles via antibodies after a defined 
duration of time (usually 18h). After 18h incubation the single infected cell nuclei are counted, 
using p72 (IE1) staining.  
In contrast, Frenzel et al., 2012 used cell-associated virus and a defined number of previous 
infected cells which are transferred to non-infected cells in a coculture of 200 infected cells/ 
20.000 not infected cells. The cell-to-cell spread will be prevented by adding of diluted series 
of potential neutralizing sera. NT50-value will also be determined. After a defined incubation 
time of generally 72 h, the plates are fixed and the formed viral plaques are counted in this 
approach, in contrast to the first approach with single infected nuclei. In both approaches, the 
inactivation of complement is performed by heat incubation over time. 
Table 4: Summary of published HCMV neutralization protocols 
Publication / 
Parameters 
Eggers et al., 
2000 
Gerna et al., 
2008 
Frenzel et al., 
2012 
Schampera et 
al., 2017 
Viral strain 
AD 169  
cell-free 
AD169 / VR1814 
cell-free 
AD169 / TB40 
cell-associated 
H2497 
cell-free 
cell-associated 
Sera / Controls 
Pool (n = 227) 
pregnant women  
after HCMV-PI 
Pool (n = 18) 
pregnant women  
after HCMV-PI 
HIG, IVIG 
2 Pools (n = 100) 
HCMV-PI / LI 
HIG, IVIG 
Target cells HFF  HFF, RPE HELF, RPE HFF, RPE 
Serum 
preincubation 
90min, 37°C 60min, 37°C 30min, RT 90min, 37°C 
Centrifugation 30min, 800rpm 30min, 700g 60min 16k.rpm  30min, 300g 
Microculture 
incubation 
16-18h, 37°C 48h, 37°C 72h, 37°C 18h-72h, 37°C 
Read out p72 (IE1) p72 (IE1) p72 (IE1) p72 (IE1) 
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1.12 Prevention of HCMV primary infection 
1.12.1 Antiviral drugs 
Several preparations are currently licensed for antiviral therapy after acute HCMV infection in 
immunosuppressed patients after stem cell or organ transplantation (Tab.5). 
Table 5: Overview of antiviral treatment options against HCMV 
Antiviral drug Mode of action Side effects / toxicity in pregnancy 
Ganciclovir® Nucleoside analog (guanine) 
Inhibition of viral DNA polymerase 
Bone marrow toxicity 
Neutropenia 
Ljungman et 
al., 2004 
Puliyanda et 
al., 2005 
Valganciclovir® 
 
Nucleoside analog (guanine) 
Prodrug of Ganciclovir ® (per 
oral) Valinester 
Inhibition of viral DNA polymerase 
Bone marrow toxicity 
Neutropenia 
 
Seidel et al., 
2017 
Valaciclovir® 
 
Nucleoside analog (guanine) 
Prodrug of Acyclovir® (per oral) 
Inhibition of viral DNA polymerase 
Bone marrow toxicity 
Neutropenia 
 
Leruez-Ville et 
al., 2016 
Cidofovir® Acyclic Nucleoside analog 
(phosphonate)  
Inhibition of viral DNA synthesis 
Nephrotoxicity No data 
Foscarnet® Non-nucleoside analog 
(pyrophosphate) 
Inhibition of viral DNA polymerase 
Nephrotoxicity No data 
Letermovir® 
(current release) 
DNA terminase inhibitor 
Inhibition of viral DNA packaging 
Not sufficiently 
investigated 
No data 
 
The first line of antiviral treatment options for HCMV infections in the transplant setting are 
Ganciclovir® (GCV) and Valganciclovir® (VGCV) which is a prodrug (Valinester) of GCV 
(Ljungman et al., 2004). First, both antiviral drugs have to be activated by mono-
phosphorylation which is performed by the viral phosphotransferase (UL97), before they are 
able to inhibit the viral DNA polymerase (UL54). The successful use of GCV was confirmed in 
a case report to treat intrauterine HCMV infection (Puliyanda et al., 2005). 
VGCV is a generic drug which revealed a 10-fold higher bioavailability (60%) than GCV in a 
clinical study which was reached by oral application and showed comparable antiviral 
treatment effects to GCV intravenously (Cvetković et al., 2005).  
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The study of VGCV to treat congenital HCMV infection indicates to be safe for the mother and 
the fetus (Seidel et al., 2017). Furthermore, no negative effects on the fetus were reported in 
four cases of maternal HCMV infection which described the use of GCV or VGCV during 
pregnancy. 
In a clinical transplant setup, antiviral resistance occurred in mutations of the UL54 or UL97 
gene region. Usually, mutations in UL97 were observed first, but mutations in UL54 reached 
higher IC50-values in context of GCV resistance and showed cross-resistance to the second-
line drugs Cidofovir® (CDV) and Foscarnet® (FOS) (Lurain et al., 2010; Gilbert et al., 2011). 
However, CDV and FOS are no treatment options during pregnancy, because of their high 
levels of nephrotoxicity (Enders et al., 2006; Kimberlin et al., 2005). Valaciclovir® (VACV) 
showed like VGCV a higher bioavailability than Acyclovir®. There is a multicenter, open-label, 
phase II study of congenital cytomegalovirus infection with VACV. Their results demonstrated 
that, VACV could be used during pregnancy by improving the clinical outcome of symptomatic 
HCMV-infected fetuses (Leruez-Ville et al., 2016) which was indicated by Jacquemard et al., 
2007. 
 
Figure 15: Molecular structure of the novel antiviral drug Letermovir® modified after (Marty et al., 2017) 
Recently, an antiviral drug with a new mechanism of action is available for treatment recently 
(Fig.15). Letermovir® is a viral terminase complex inhibitor which inhibits the capsid packaging 
of the viral DNA (UL51 and UL56). While its mechanism completely differs from the previous 
described antiviral drugs, there is no known cross-resistance of Letermovir® to those DNA 
polymerase inhibitors (Marty et al., 2017). It was shown in a study, that Letermovir® 
prophylaxis resulted in a significantly lower risk of clinically significant HCMV infection than 
placebo in patients after allogeneic hematopoietic-cell transplantation. Letermovir® had low 
toxicity at the same time. Therefore, it could be a promising treatment option for HCMV infected 
mothers (Marty et al., 2017). But more data are necessary to evaluate Letermovir® for an “off 
label use” in pregnant women with an HCMV infection. 
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1.12.1 Vaccines against HCMV 
There are no efficient vaccines against HCMV available up to now, but the development of a 
vaccine against HCMV is a major public health priority (Anderholm et al., 2016). Table 6 gives 
an overview of current vaccine candidates in clinical trials (Poltkin et al., 2018). 
Table 6: Overview of vaccine candidates in clinical trials (modified after Poltkin et al., 2018) 
Vaccine Developer 
Antigen 
Reference 
gB PC pp65 
Adenovirus 
vector 
Queensland 
Institute 
X   Zhong et al., 2008 
Alphavirus 
replicons 
GSK X  X Bernstein et al., 2009 
Canarypox 
vector 
Sanofi   X Berencsi et al.,2001 
Dense bodies Vaccine Project 
Management, 
Serum Institute, 
India 
X X X Cayatte et al., 2013 
Plachter, 2016 
DNA plasmids Astellas, Inovio X  X Shedlock et la., 2012;  
Smith et al., 2013  
Lentivirus 
particles 
Variations Bio X  X Kirchmeier et al.,2014 
Live attenuated Medimmune X  X Adler et al., 2016; 
Plotkin et al., 1984 
Live 
replication-
defective 
Merck X X X Fu et al.,2014 
LHCMV vector Hookipa X  X Schleiss et al., 2017 
mRNA GSK, Moderna X   Brito et al., 2014 
MVA vector City of Hope X X  La Rosa et al., 2017 
Peptides City of Hope, 
University of 
Heidelberg 
  X Nakamura et al., 2016 
Soluble 
pentamer 
complex 
Humabs, 
Redbiotech GSK 
 X  Kabanova et al., 2014 
Subunit gB Sanofi, GSK X   Pass et al., 2009 
Bernstein et al., 2016 
Griffiths et al., 2011 
VSV vector VSV vector X   Wilson et a., 2008 
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While the experiments with a life-attenuated vaccine against HCMV were not successful, 
another randomized, double-blind, placebo-controlled phase 2 study using recombinant 
vaccine gB/MF59 reached only a vaccination efficacy of 50% in healthy, postpartum women, 
combined with a decrease of congenital infections (Pass et al., 2009; Rieder et al., 2013 and 
2014).  
 
Figure 16: Results of the clinical phase II study, including gB/MF59 (Pass et al., 2009) 
The study involved 225 healthy women, who were treated with gB/MF59 and 216 women got 
placebo (Fig.16). After vaccination, the HCMV infection rate was lower in the treated group 
(8%) than in the placebo group (14%). In addition, the antibody titers against HCMV were 
significantly higher in the vaccinated group than in the placebo group.  
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The next step to an effective vaccine could be the development of a pentameric complex based 
vaccination (Rieder & Steiniger, 2013). During the last years the potential of the pentameric 
complex to induce antibodies and the influence on the immune system were investigated 
extensively. It showed that the majority of strong neutralizing antibodies are directed against 
the pentameric complex (Gerna et al., 2017). These findings pushed the development of a 
potentially protective HCMV vaccine like the expression of recombinant pentameric complex 
for vaccine use in a CHO system (Hofmann et al., 2015). In terms of serology diagnostics, 
neutralizing antibodies to the PC could be potentially used as surrogate marker for possible 
reduced risk of maternofetal transmission (Lilleri et al., 2012). 
 
 
Figure 17: Model of the pentameric complex gH/gL/Ul128-131 (Ryckman et al., 2008) 
Interestingly, the UL128, UL130 and UL131 genes also seem to influence the response of 
MHC class I and class II-restricted CD8+ T-cells by inhibition of the viral epitope recognition 
(Hansen et al., 2013). 
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1.12.2 Hyperimmunoglobulin preparations  
Hyperimmunoglobulin preparations (HIG) are pooled sera of healthy donors with high antibody 
titers against HCMV. The sera are collected and purified, followed by an enrichment of the 
HCMV-specific antibodies via ethanol-fractionation. They were generally indicated for the use 
in immunocompromised patients after solid organ transplantation in combination with antiviral 
drugs like GCV (Ljungman et al., 2004; Bonaros et al., 2008).  
There are two HIGs preparation for HCMV commercially available. The HIG Cytotect® from 
Biotest Pharma AG has a license in the EU and its counterpart Cytogam® from CLS Behring. 
It has a license for the US market. In general, the long-time experience with immunoglobulins 
showed weak signs of side effects and a good patient compatibility, compared to antiviral 
drugs. Possible side effects of HIG are intermittent shivering, nausea, headache, mild fever 
and/or joint pains (Manufacturer specifications Cytotect®; Biotest Pharma AG, Germany). 
The first study for prevention of fetal HCMV transmission in pregnancy was published in 2005 
which officially introduced the “off label use” of HIGs in a non-randomized trial (Nigro et al., 
2005). 
 
Figure 18: First non-randomized HIG study in pregnancy - Primary end point (modified after Nigro et al., 
2005). 
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The study included 181 pregnant women with a proven HCMV primary infection (Fig.18). The 
women were divided into a “prevention group” of 102 members which had no amniocentesis 
and a “therapy group” of 79 women, who underwent an amniocentesis before or at enrollment 
plus <6 weeks after maternal seroconversion.  
On the one side, 37 women of the prevention group received HIG (100 U/kg monthly) until 
delivery. 31 uninfected and 6 HCMV-infected newborns were born which corresponded with a 
transmission rate of 16%. The untreated part of the prevention group had a maternofetal 
transmission rate of about 40% which reflected a significant decrease between the treated and 
untreated women.  
On the other side, 55 pregnant women of the therapy group were HCMV positive in amniotic 
fluid. 31 of the enrolled women were elected to receive HIG (200U/kg), 14 women were not 
treated and 10 women had a termination of pregnancy (TOP). After the treatment, only one 
woman had a symptomatic infected newborn at birth which correlated with an infection rate of 
3% compared to the untreated 14 women. 7 of the 14 women (50%) gave birth to symptomatic 
HCMV-infected newborns which also revealed a significant difference between the treated and 
the placebo group. The recruiting standards of the Nigro study were critically discussed and a 
repeated enrollment of a comparable collective is no more possible, considering current ethical 
approvals. 
Further studies of the HIG treatment of primary HCMV-infected women confirmed the improved 
outcome of reduced congenitally HCMV-infected infants, as well as the decease number of 
newborns with sensorineural hearing loss (Buxmann et al., 2012; Visentin et al., 2012). 
Table 7: Summarized results of the studies Buxmann and Visentin 2012. 
Study HIG treated 
HIG untreated 
(Control group) 
Buxmann et al., 
2012 
Therapy group 
25% (1/4) 
Prevention group 
23% (9/39)  
Not performed 
Visentin et al., 
2012 
Therapy group 
13% (4/31) 
 
43% (16/37) 
 
In the Buxmann study, 1 of 4 congenitally infected infants was symptomatic at birth in the 
therapy group (Tab.7). For the prevention group, 9 out of 39 were HCMV-infected, but no infant 
was symptomatic at birth. The study of Visentin revealed an observed absolute reduction of 
30% between the HIG treated and untreated therapy group. 
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Almost one decade after the first HIG study of Nigro, a phase 2, randomized, placebo-
controlled (RCT) study was performed to validate the importance of passive immunization 
during pregnancy against HCMV primary infection (Revello et al., 2014). 
 
Figure 19: A randomized controlled trail of HIG to prevent maternofetal transmission. (A) 61 women 
received HIG. (B) 62 women received placebo (modified after Revello et al., 2014) 
This study consisted of a prevention group which was subdivided into 61 women, who received 
HIG and a placebo group of 62 women (Fig.19). Only pregnant women were enrolled with a 
proven HCMV primary infection. In the treated group, 33 women underwent an amniocentesis, 
in which 8 infected fetuses were diagnosed. The primary end point of the study was the number 
of congenitally HCMV-infected newborns. The HIG treatment was discontinued in women with 
HCMV-positive amniotic fluid. In the placebo group, 10 infected fetuses were found during 
amniocentesis of 26 pregnant women. The overall transmission rate in the HIG group was 30% 
with 18 infected newborns out of 61, compared to 44% with 27 infected newborns out of 62. 
This result reached no statistically significant difference between both groups. A recent 
consensus review, based on the RCT study of Revello did not recommend the use of 
immunoglobulins in pregnant women outside of clinical trials (Rawlinson et al., 2017). 
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However, the underlying study design and the resulting outcome of the RCT study were 
controversially discussed in several “letters to the editor” in Revello et al., 2014. It can be 
highlighted, that both studies of Nigro and Revello, as well as the observational retrospective 
study of Buxmann et al., 2012 used a monthly interval for HIG administration to pregnant 
women with an HCMV primary infection. The time interval of HIG treatment was assumed on 
the base of a terminal elimination half-life of 22.4 days for total IgG antibodies (Thurmann et 
al., 1995). In an index case, a further single investigation of the HCMV antibody 
pharmacokinetics of a volunteer HCMV-primary infected pregnant woman revealed a half-life 
time of about 11 days after a 4-week interval HIG treatment. The shorted half-life time was 
paired along with strong fluctuations in epitope-specific recombinant HCMV IgG avidity and 
repeated decreases in neutralization activity, using ARPE-19 cells as target cells (Hamprecht 
et al., 2014). It is also necessary to consider, that the between-group difference in the Revello 
study was not significant, but the observed absolute reduction in HCMV infection was 14 % 
between the HIG-treated and untreated women. The 95% confidence interval ranged from −3 
to 31 which does not exclude a clinically relevant effect (van Leeuwen, Letter to the editor, 
Revello et al., 2014). Furthermore, a meta-analysis of both studies showed a highly significant 
trend in a Forest plot (Blobbogram) analysis. The same study design of Nigro and Revello 
enabled this comparison (Rawlinson et al., 2016). 
The appearing issues of the performed studies formed an interdisciplinary initiative which 
ended up in a novel HIG study in Tuebingen to investigate the formulated assumptions which 
was encouraged by authors of the Revello study (Spinillo and Gerna, response 
communication, letter to the editor, Revello et al., 2014).  
As background, the risk for long-term sequelae after HCMV primary infection of the mother is 
up to 20%, depending on the gestational age at the time of maternal infection (Manicklal et al., 
2013). Individual studies confirmed, that the risk for a symptomatic newborn decreases 
proportional to the increase of gestational age at infection and has its peak at the beginning of 
the first trimenon (T1) of pregnancy (Enders et al., 2011; Lipitz et al., 2013 and Picone et al., 
2013). Therefore, the time point of maternal seroconversion during pregnancy plays a very 
important role for the clinical outcome at birth and sequelae, especially in T1. In a further study, 
138 children were analyzed, who underwent a congenital HCMV infection during pregnancy. 
An amniocentesis was performed in all pregnant women at a GA between 20 to 23 weeks, 
checking for viral DNA in amitotic fluid (Bilacsky et al., 2016). A correlation was found between 
children without long-term sequelae and no presence of viral DNA in amitotic fluid and vice 
versa. 14% of the children suffered from long-term sequelae and were HCMV DNApositive in 
amitotic fluid. In conclusion, no detection of viral DNA in amitotic fluid promises a better clinical 
outcome for the growing fetus.  
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In this context, the Tuebingen HIG study aimed for the prevention of maternofetal HCMV 
transmission in the first trimenon of pregnancy. Therefore, a modified study design was used 
which based on the studies of Nigro and Revello. However, HIG (Cytotect®, Biotest Pharma 
AG, Germany) was administered in a biweekly interval with double dose concentration (HIGiv: 
200 IU/kg maternal bodyweight), compared to both previous studies. Only women with a 
gestational age (GA) less than 14 weeks (T1) were included in the study cohort and were 
treated until week 20 or maternal mean HCMV IgG levels were above 100 U/ml, seven days 
after the last HIG administration. Importantly, the HIG treatment started as fast as possible 
after diagnosis of a proven HCMV primary infection of the mother. 
The final end point of the study was an amniocentesis after the 20th week of GA. The harvested 
amniotic fluid was tested for viral DNA to confirm or decline the maternofetal HCMV 
transmission. In addition, the newborns were tested for viral DNA. For negative control, a 
historic cohort was used to compare the prevalence of maternal-fetal transmission. It consisted 
of pregnant women with a primary HCMV infection in T1 without HIG treatment. However, the 
results of the Tuebingen HIG study were not published at the beginning of this PhD thesis. 
1.13 Hygiene-counseling 
In general, the infectious saliva and the urine of small children are the main sources of 
infection. Therefore, contaminated surfaces and the use of daily-life objects should be avoided 
by pregnant HCMV-seronegative women, when they have contact with potentially infected 
small children. The sequential hand wash, combined with virus-killing disinfection agents are 
simple, but effective tools to prevent a transmission of HCMV (Ross et al., 2006). 
In addition to HIG treatment options, an early hygiene-counseling of pregnant women is an 
important tool to prevent maternofetal HCMV transmission in the first place. It was 
demonstrated, that objective information about HCMV infection during pregnancy, combined 
with followed HCMV-screening of the pregnant women could decrease the rate of 
seroconversion compared to no hygiene-counseling. This fact was confirmed in a 2-year and 
another 3-year prospective study in French hospitals (Picone et al., 2009; Vauloup-Fellous et 
al., 2009). However, there is no general recommendation for an HCMV antibody screening in 
Germany, referring to the “Mutterschaftsrichtlinien”.  
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1.14 Monoclonal antibodies against HCMV  
In future, monoclonal antibodies (mABs) against the pentameric complex might be also a 
promising option to treat HCMV primary infections in pregnant women and therefore to prevent 
maternofetal-transmission. For instance, MS109 is a highly neutralizing mAB against 
glycoprotein H which is part of both the timer and pentameric complex (Fouts et al., 2014). 
Latest studies of Fu et al., 2017 identified and characterized further mABs against different 
binding sides of the pentameric complex which were separated in 4 immunogenic regions (IRs 
1 to 4) (Fig.20A). The IC50 determination of the generated mABs is shown in figure 20B on 
ARPE-19 and MRC-5 cells. Importantly, the mABs against IR1 (orange) revealed the most 
effective IC50 values in terms of viral binding and neutralization which consists of the UL128-
131A region (UL128L). 
 
Figure 20: (A) Visualized binding sites of generated monoclonal antibodies, separated in 4 immunogenic 
regions (IRs) using an EM 3D reconstruction of pentameric complex; (B) IC50 concentrations of generated 
monoclonal antibodies against the pentameric complex on ARPE-19 and MRC-5 cells (modified after Ha et 
al., 2017) 
In this context a former paper demonstrated that neutralizing mAbs were directed against at 
least a combination of two genes of the UL128L (UL128/UL130 and UL128/UL131A) (Macagno 
et al., 2010). In addition, the epithelial cell syncytium formation after a HCMV primary infection 
was prevented using mAbs against the trimer and pentameric complex, performed by the group 
of Gerna et al., 2016.  
However, the increased risk of appearance of resistant HCMV mutants against monoclonal 
antibodies is to be considered which was artificially induced using the MS109 mAB in inefficient 
concentrations over time in in vitro experiments (Fouts et al., 2014). At this point, the advantage 
is on the usage of polyclonal HIGs instead of mABs against HCMV.  
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1.15 Objectives 
The aim of the study was to characterize hyperimmunoglobulins (HIG) in the background of a 
novel “off label use” study design (Tuebingen HIG study) to prevent maternofetal transmission 
after HCMV primary infection during the first trimenon (T1) of pregnancy. Scientific issues were 
investigated which included the validation of the HIG efficacy in in vitro neutralization (NT) 
experiments under defined circumstances, as well as the immunomodulatory effects of the 
treated mothers during HIG treatment. 
Following scientific issues were investigated: 
 
1. Standardization of an HCMV neutralization assay and performance 
characteristics 
First, a standardized assay protocol for HCMV neutralization was established to 
optimize already existing NT assays and to form a base for further characterization of 
HIGs and Standard intravenous immunoglobulin (IVIGs) preparations. Therefore, NT 
assay protocols in literature were considered at this point (Eggers et al., 2000; Gerna 
et al., 2008; Frenzel et al., 2012). Importantly, the focus was set on the performance of 
NT assays in routine diagnostics. 
 
2. Cytotect® neutralization activity against HCMV isolates, resistant to antiviral 
compounds 
In a second step, the established NT assay protocol was performed to compare the NT 
capacity of the HIG Cytotect® to other IgG preparations, using two clinical HCMV 
isolates with drug resistance to Ganciclovir® and Cidofovir®. As reference, a sensitive 
HCMV isolate was used. 
 
3. Characterization of Cytotect® neutralization activities against HCMV isolates 
with different gB-genotypes 
In next investigations, the HIG Cytotect® was further characterized by analysis its NT 
capacity on four HCMV isolates with different HCMV glycoprotein B genotypes (gB1, 
gB2, gB3 and gB4) compared to Cytogam® and two IVIGs (Kiovig® and Octagam®). 
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4. Role of pentamer-specific antibodies in HCMV hyperimmunoglobulin and 
standard intravenous IgG preparations 
UL130-specific and pentamer-specific antibodies were depleted from HIG and IVIG in 
order to analyze their contribution to in vitro neutralization capacity. A modified UL130 
peptide (TANQNPSPPWSKLTYSKPH) was used which based on original sequence of 
Saccoccio et al., 2011 (SWSTLTANQNPSPPWSKLTY). As depletions strategy, both 
UL130-peptides and a recombinant-HCMV-pentameric complex were bound via a 6-
fold HisTag and anti-HisTag mAbs to magnetic beads (Schampera et al., 2018). 
 
5. Depletion of HCMV hyperimmunoglobulin IgG subclass 3 from Cytotect® and 
analysis of its functional activity 
In a paper of Planitzer et al, 2011, IgG subclass 3 was postulated as decisive factor for 
HCMV neutralization, but not IgG subclass 1 or 2. The results of Schampera et al., 
2017 strongly contrast to the findings of Planitzer et al., 2011. In this context, IgG 
subclass 3 depletions were depleted from Cytotect®, Kiovig® to analyze their impact 
on in vitro neutralization via a modified depletion concept, using anti-IgG subclass 3 
mAbs (Schampera et al., 2018). 
 
6. Modulation of the T cell response by HCMV hyperimmunoglobulin 
IgG antibodies have been reported to modulate the innate and adaptive immune 
response via Fcγ-receptors and IFN-γ production. Therefore, further in vivo 
investigations were performed in this PhD thesis to analyze, whether the HIG 
administration could beneficially induce cellular immunomodulatory effects, using  
IFN-γ secretions assays. Longitudinal lithium-heparin (LiHep) blood samples were 
collected from pregnant women with HCMV primary infection during T1, directly before 
and after HIG treatment. The possible immunomodulatory effect of HIG on peripheral 
blood mononuclear cells (PBMCs) was analyzed by their IFN-γ production upon 
stimulation. IFN-γ is generated during the adaptive immune response of CD4+ and 
CD8+ T cells, as well as during the innate immune response of NK cells and NK-T cells. 
The ex vivo samples were derived from women of our Tuebingen HIG study (Kagan et 
al., 2018). 
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2 Material and Methods 
2.1 Target cells 
For in vitro experiments, two different cell types were used as target cells. The neutralization 
capacities of IgG preparations were investigated on human foreskin fibroblasts (HFF: SCRC-
1041TM) and human retinal pigment epithelial cells (ARPE-19 cells: CRL-2302TM). Both 
adherent-growing cell types were derived from ATCC® and cultivated as monolayers in T25-, 
T75- and T175-flasks. Cell passage numbers between 16 to maximal 28 were used for NT 
experiments.  
ARPE-19 cells were cultivated, using a DMEM: F12 Medium (ATCC® 302006™) with 10% 
fetal bovine serum (FBS) and 1% Penicillin-Streptomycin. Accordingly, DMEM (1x) (Dulbecco's 
Modified Eagle Medium, Thermo Fisher Scientific, USA) with 10% FBS and 1% Penicillin-
Streptomycin was used for HFF cultivation. These cell types were chosen, because of their 
presence in different human tissues and their different viral entry pathways (Fig.5). 
2.2 Virus isolates 
Several clinical isolates were used for NT assays, depending on the particular investigated 
scientific issue.  
In general, the clinical isolate “H2497-11” was chosen as therapy-naive reference strain. It was 
isolated from amniotic fluid of a pregnant woman after feticide, resulting in a termination of 
pregnancy (TOP) in Tuebingen, 2011. One isolate was primary adapted to HFF “H2497-HFF” 
and the other one to ARPE-19 cells “H2497-ARPE-19”. It has to be considered at this point, 
that a primary adaptation of HCMV strains to ARPE-19 cells usually failed and a previous 
adaptation on HFF, followed by a secondary adaptation to ARPE-19 cell was necessary. The 
HCMV strain “H2497-11” was isolated by K. Schweizer and S. Preisetanz (Preisetanz, 2012) 
For NT experiments, both H2497-HFF and H2497-ARPE-19 were treated as separated viral 
strains from the same source. They were separately cultivated and cell-free viral stocks of 
these strains were produced after viral shedding into the supernatants (passage 21 for the 
H2497-HFF strain and passage 22 for the H2497-ARPE-19 strain. Cell propagation was done 
by weekly passaging. The strains were frozen at -80°C and the infectivity of the viral stocks 
was determined by TCID50/ml testing, according to method point 2.6. The H2497-HFF strain 
reached a TCID50/ml of 6.1 and the H2497-ARPE-19 strain a TCID50/ml of 5.4.  
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The number of passages until cell-free a virus strain was harvested and frozen at -80°C as 
stock depends on the concentration of released cell free infectious virus particles into the 
medium supernatant of the cell culture at the end of each passage incubation. Therefore, each 
passage was tested with TCID50 determination. Additionally, all supernatants, containing cell-
free virus were centrifugalized at 50.000x g for 1h to concentrate infectious virus particles once 
more. 
As drug-resistant HCMV strains, 2 different cell-free HCMV strains were examined (Tab.8). 
The strain “40571” was isolated from urine (date: 1998) after a bone marrow transplantation 
(BMT) and carries a resistance to Ganciclovir® (GCV) (Mutation: UL97 [A591V]). The strain 
was propagated to passage 24 until viral shedding (Prix et al., 1999). 
Table 8: Overview of the used HCMV strains with drug resistance, tested in NT assays 
HCMV 
strain 
Source Patient ID Patient 
indication 
Viral isolate TCID50/ml 
40571 Urine 7-year-old 
child (male) 
BMT Urine 
UL97 [A591V] 
4.1 
H815-06 EDTA 
blood 
ZP (male) SCT Leukocytes  
(multi-drug 
resistant) 
UL97 [L595S] 
UL54 [V715M] 
4.4 
 
The strain “H815-06” was isolated from leukocytes (date: 2006) and had a multi-resistance 
against GCV (Mutation: UL97 [L595S]) and Cidofovir® (CDV) (Mutation: UL54 [V715M]). The 
passage number was 26 until viral shedding into the supernatant (Göhring et al., 2013). The 
generation of virus stocks and TCID50 determination were performed, according to the 
reference strain. The TCID50/ml-value for “40571” was 4.1 and “H815-06” reached a TCID50/ml 
value of 4.4. Both resistant HCMV strains were cultivated in the presence of GCV unit harvest 
at an antiviral concentration of 6µM/ml1. The usage of CDV is not necessary for cultivation and 
for the NT assays, because the CDV resistance of the investigated HCMV strain “H815-06” 
only appears in a combination of a GCV resistance. 
  
                                               
1 HCMV strain with an IC50 > 6µM/ml GCV are considered as resistant (Göhring et al., 2013) 
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In table 9, the in NT assays investigated HCMV strains with 4 different gB (UL55) types are 
displayed. 
Table 9: Overview of the HCMV strains used with different gB types, tested in NT assays. 
gB 
type 
HCMV 
strain 
Source Patient ID Patient 
indication 
Viral 
isolate 
TCID50/ml 
1 H1241-16 Breast milk  
(dpp = 79) 
EL (female) HCMV- 
reactivation 
Milk whey 4.5 
2 AD169 Adenoid 
tissue 
(ATCC® 
VR538™) 
7-year-old 
Child 
(female) 
HCMV 
infection 
Nasal 
discharge 
2.2 
3 H1058-10 Breast milk 
(dpp= 46) 
SA (female) HCMV- 
reactivation 
Milk whey 3.9 
4 H487-06 EDTA blood ZP (male) SCT Leukocytes  
(multi-drug 
resistant) 
UL97 
[L595S] 
UL54 
[V715M] 
4.3 
For this purpose, an HCMV wild type strain H1241-16 from breast milk (day postpartum (dpp) 
= 79) was used after a local reactivation of HCMV in the breast tissue (gB type 1). The HCMV 
strain AD169 is a high-passaged laboratory reference isolate which was primary isolated from 
a 7 years old child after a HCMV infection from adenoid tissue (gB type 2). The HCMV strain 
H1058-10 was isolated from milk whey after a reactivation of HCMV (dpp = 46) (gB type 3). 
The HCMV strain H487-06 is a multidrug-resistant isolate which emerged after stem cell 
transplantation (SCT) in leukocytes and was isolated from EDTA blood (gB type 4) (Göhring 
et al., 2013). In a preliminary in silico sequence alignment analysis of the UL55 region, the gB 
types of the selected HCMV strains were analyzed by nested PCR (nPCR) and Sanger 
sequencing via LGC Genomics GmbH, Germany, followed by a comparison to reference 
sequences of gB type 1 to 4 which were extracted from the NCBI National Center for 
Biotechnology Information (NCBI) database (Tab.10) (Murthy et al., 2011). 
Table 10: Extracted UL55 sequences of gB type 1 to 4 with corresponding accession number and protein 
ID (upload date: 2016) (Murthy et al., 2011) 
gB type (UL55) Accession Number Protein ID Corresponding HCMV strain 
1 GU365817 ADO30523.1 H1241-16 
2 GU365820 ADO30526.1 AD169 
3 GU365822 ADO30528.1 H1058-10 
4 GU365824 ADO30530.1 H487-06 
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The following alignment analysis was done via Vector NTI® program, Thermo Fisher Scientific, 
USA. The generated project data were transferred afterwards to the sequence analysis 
program Jalview®, University of Dundee, Scotland (Version 2.10.4b1) to calculate a 
phylogenetical tree, using the “Neighbour-Joining-Algorithm”. This specific algorithm is termed 
as phonetic bottom-up cluster method to hierarchically compare data sets via a bifurcal (2-
way-crossing) resampling (Fig.21). 
 
Figure 21: Phylogenetical tree which displayed and confirmed the gB types of the selected HCMV strains 
The nested PCR had 2 rounds which contained 30 heat cycles (1st PCR: heat up at 94°C,  
4 min; Start: 94°C, 1 min => 60°C, 1 min =>72°C, 1 min; End: 72°C, 10 min / 2ndPCR: heat up 
at 94°C for 4 min; Start: 94°C, 1 min => 65°C, 1 min =>72°C, 1 min; End: 72°C, 10 min). The 
used primer pairs are shown in table 11 (in-house protocol, modified after Chou et al., 1991). 
The master mix preparations are described in method point 2.4.1. 
Table 11: nPCR gB primer pairs 
PCR 1 gB  Type Strand 
gB1138 5`CAA GAR GTG AAC ATC TCC GA 3` Outer sense 
gB1596 5`ÀTG GCC GAG AGA ATT GCR GA 3` Outer antisense 
PCR 2 gB    
gB1276 5`GGT TTG GTG GTG TTC TGG CA 3` Internal sense 
gB1524 5`CAC ACA CCA GGC TTC TGC GA 3` Internal antisense 
 
The enzymatic gB typification was additionally performed which confirmed the in-silico 
sequence analysis of the UL55 region, according to Tarragó et al., 2003. Restriction 
endonucleases were ordered from BioLabs, New England® (Tab.12). 
 39/144 
Table 12: gB typification via enzymatic digestion after PCR. Predicted band patterns in bps for the used 
restriction endonucleases 
Genotype / Enzyme Alu I (R0137S) Taq I (R01495) Hin6 I (R108T) 
gB1 583bps, 166bps 459bps, 290bps 607bps, 82bps, 
9bps, 35bps, 6bps 
gB2 411bps, 169bps, 
166bps 
288bps, 271bps, 
108bps, 79bps 
308bps, 219bps, 82, 
77bps, 35bps, 
19bps, 6bps 
gB3 583bps, 130bps, 
36bps 
0bps 524bps, 82bps, 
77bps, 35bps, 25bps 
gB4 583bps, 130bps, 
36bps 
391bps, 290bps, 63bps 311bps, 296bps, 
82bps, 60bps 
 
The digested viral DNA was separated via gel electrophoresis on a 1% agarose gel Tris-borate-
EDTA (TBE) buffer, resulting in the predicted band patterns of base pairs (bps). 
  
 40/144 
NT experiments in this work were also performed using the RV-TB40-BACKL7-SE-EGFP 
strain variant of HCMV (TB40E-L7) which was originally established by Christian Sinziger in 
Tuebingen and enhanced by Kerstin Sampaio (Sinziger et al., 2008; Sampaio et al., 2017). 
Therefore, an improved BAC cassette was inserted downstream of US34A, expressing eGFP 
(Green fluorescent protein – Excitation: 488 nm / Emission: 509 nm). This strain was used to 
offer an alternative “read out” to the performed NT assay system.  
The TB40/E-L7 strain enabled an in vitro life observation of the NT capacity using HIGs and 
IVIGs from day 1 to day 5 without an end point fixation (Acetone/Ethanol), followed by 
visualization via p72 IE-antigen-immunperoxidase staining. 
 
Figure 22: Example for TB40E-L7 infected HFFs on 1, 3, 5 day post infection (dpi); 200x TCID50; 100x. Light 
microscope figures compared to fluorescent figures of the same microtiter well (Filter set 38 HE®: 
Excitation BP 470/40; Emission BP525/50 ZEIZZ) 
However, for better handling, the NT assay could be fixed on day 5 with 4% Paraformaldehyde 
(PFA)2 for 10min at RT, if the “read out” analysis of infected target cells was not possible on 
the same day. A viral stock of TB40/E-L7 was prepared and stored at -80°C with a TCID50/ml 
of 4.6 until NT analysis. Figure 22 shows an example for HFFs on day 1 to 5 post infection 
(dpi) which were infected with cell-free TB40E-L7 with 400xTCID50/ml. The eGF-protein 
cumulated through virus production in the infected target cell over time which resulted in 
increased green glowing of these cells until day 5 post infection.  
                                               
2 A fixation of TB40/E-L7-infected cells with Acetone/Ethanol would denature the eGF-protein. 
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2.1 Samples 
2.1.1 NT assay reference pools 
For calibration of NT assays, two reference serum pools were generated as controls. The first 
serum pool contained sera of n = 100 HCMV-IgM-/IgG- women at birth. The second serum pool 
was made of n = 100 HCMV-IgM-/IgG+ women which were HCMV-latently infected at birth. The 
serum samples were collected during the Tuebingen congenital HCMV study 2011 (Ethical 
approval EK number: 506/2015BO2). All women of this study were analyzed with 5 different 
HCMV serological test systems, including Enzygnost-ELISA® (Siemens), CLIA® (Diasorin) 
and CMIA® (Abbott), as well as ECLIA® (Roche) and ELISA® (Medac). For each pool, women 
were enclosed which showed concordantly equal test results in all 5 test systems. Therefore, 
2 different serum pools were used which represented a comprehensive amount of 2 specific 
cohorts of mothers at birth. Equal serum volumes of 100 µl per sample were combined to 
create both pools, followed by freezing of the serum pools in 500 µL aliquots at -80°C until 
usage in NT assays. 
2.2 IgG preparations 
2.2.1 HIG Cytotect® and Cytogam® 
Cytotect® and Cytogam® are hyperimmunoglobulin preparations (Tab.13). They consist of 
pooled sera, derived from healthy donors with high HCMV-specific IgG-titers. Cytotect® is a 
product of Biotest Pharma GmbH, Germany and has an official license as “Orphan Drug” in 
Europe and USA for intravenous application after transplantation of solid organs (2007). 
Besides its intended purpose, it was used via “off label use” to prevent maternofetal viral 
transmission after HCMV-primary infection. However, the usage is not recommended outside 
of clinical trials (Rawlinson et al., 2017). 
In contrast, Cytogam® is made by CSL Behring, USA and has only a license for the US market. 
Both preparations were produced, using the same “Ethanol-fraction-process” to purify the IgG 
antibodies from the sera. But for sterilization, Biotest uses β-propiolacton, followed by an ultra-
centrifugation and CSL Behring takes Tri(n-butyl) phosphate plus Triton X-100 in a “Solvent-
detergent-process” to inactivate virus. 
Table 13: Manufacturer specifications of HIGs 
Preparation Manufacturer Charge Concentration HCMV PEI Units/ml 
Cytotect® Biotest Pharma B797033 50 mg/ml 150.3 
Cytogam® CSL Behring® 4359000037 50 mg/ml 118.6  
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2.2.2 IVIGs 
IVIGs are standard immunoglobulin preparations. In general, they are used after solid organ 
transplantation, but there is also a study which used Kiovig® in case of HCMV-primary 
infections in pregnant women (Pollili et al., 2012). Table 14 shows the specifications of the 
investigated IVIGs. 
Table 14: IVIGs specifications 
Preparation Manufacturer Charge Concentration HCMV PEI Units/ml 
Kiovig® Baxter® LE12M265BC 100 mg/ml 42.0 
Octagam® Octapharma® A303B853A 100 mg/ml 62.4 
 
According to Schampera et al., 2017, all investigated IgG preparations (HIGs, IVIGs), as well 
as the generated HCMV-IgG+-pool showed high HCMV-specific IgG, high IgG avidity and no 
HCMV-specific IgM, analyzed with HCMV recomBlot®; Mikrogen, Germany. 
2.2.3 UL130 peptides and recombinant pentameric complex 
The UL130 peptide design was previously performed by Jose Arellano-Galindo (AG 
Hamprecht) (Tab.15). It was established by the modification of amino acid sequences and 
based on a UL130 SWS-peptide of Saccocio et al., 2011. The computer analysis showed, that 
the modified UL130 TAN-peptide showed the highest “percentage of probability” (>75%) for 
epitope similarity. For the antibody depletion experiments, both peptides were synthesized by 
Intavis Peptide Services, Germany with an additionally 6x fold HisTag on the respective C-
terminus (TANQNSPPWSKLTYSKPHHHHHHH) for magnetic bead anti-HisTag antibody 
labeling.  
Table 15: The UL130 peptide design on the base of Saccocio et al., 2011 
No. Peptide Amino acid 
Position 
Ratio E-B 
1 TANQNPSPPWSKLTYSKPH 
TAN-peptide 
32-50 
E= 17/19 
B= 2/19 
2 SWSTLTANQNPSPPSKLTY  
SWS-peptide 
E = 14/15 
B= 1/15 
 E = Exposed residue B= Buried residue 
 Antigenicity scale (Yang et al., 2009) 
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Both peptides were delivered with a concentration of 10 mg/ml and a purity of at least 90%, 
achieved with HPLC (214 nm). The analysis was done via MALDI-MS and RP-HPLC. 
In a following NT experiment, a pentameric complex was used for antibody depletion. The 
investigated HCMV-PC is a recombinant product which was generated by The Native Antigen 
Company, Oxfordshire UK (Product Code: HCMV-PENT). This native-like PC is produced in 
human embryonic kidney cells (HEK293) to ensure that all proteins are properly folded and 
possess their native glycosylation pattern. The presence of all five proteins in the purified 
complex is confirmed by mass spectrometry, according to the manufacturer. There is an 
additional 6xfold HisTag linked to gH. The genetic sequence origin for the recombinant HCMV 
pentameric complex was the VR1814 strain (NativeAntigen Company, Oxfordshire UK).  
For the depletion experiments of PC-specific polyclonal antibodies (pAbs), magnetic beads 
and anti-HisTag mAbs were used from Cell Signaling Technology, USA, as well as a 6 Tube 
magnetic separation rack to remove the magnetic beads after incubation (Fig.23). 
 
Figure 23: 6 Tube magnetic separation rack. Product documentation Cell Signaling Technology 
Anti-IgG subclass 3 mAbs (Product code: 5247-9850, Clone: 5G12, Mouse-anti-human; 
BioRad laboratories, USA) were used which were bound to magnetic beads, to deplete IgG 
subclass 3 antibodies from Cytotect® and Kiovig®. 
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2.3 Laboratory systems 
Device / Equipment Company 
Architect i1000SR® Abbot 
Camera ExwaveHAD N50® Sony 
Cell counter Z1 Beckman Coulter® Beckman Life Sciences 
Centrifuge 5417 R® Eppendorf 
Centrifuge 5804 R® Eppendorf 
Centrifuge 5810 R® Eppendorf 
Centrifuge Universal 32 R  Hettich 
Cobas 6000 Analyzer® Roche 
Cold-storage room 4°C/ -20°C NER 
Extraction unit CVC 2000® Vaccubrand 
Fine scale 770® KERN 
Fridge-freezer at -20°C Liebherr 
Fridge-freezer at -80°C Heraeus 
Heat bath GFL 1086® Memmert 
Incubator 37°C; 5% CO2; 97% rAh BBD 6220® Heraeus 
Incubator 37°C; 5% CO2; 97% rAh C200® Labotect 
Multipette plus 8-fold® (50 μl -1200 μl) Eppendorf 
Optical microscope Axiovert 25/100® Zeiss 
pH-measuring instrument pH level 2® inoLab 
Pipette (10 μl / 100 μl / 200 μl / 500 μl / 1000 μl) Eppendorf 
Thermomixer comfort® Eppendorf 
Ultra-centrifuge Biofuge Stratos®  Thermo Scientific 
Vortexer / Shaker MR 3001 K® Heidolph 
Vortexer / Shaker REAX top® Heidolph 
Workbench (laminar air flow) HS 12® BDK/Heraeus/UntiyLabServices 
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2.4 Reagents and Materials 
Material Company 
96 well microtiter plates Nunc/Greiner 
Acetone LaboChem international 
Adhesive foil Masterscreen permanent® ERA 
Cell culture medium DMEM: Medium Dulecco´s Modified 
Eagle Medium®, 500 ml 
ATCC 
Cell culture medium Ham´s Nutrient Mixture F-12, L-
Glutamine, HEPES; 500ml 
ATCC 
Counting chamber C-Chip® Digital Bio 
Culture flask T25; T75; T175 Nunc 
Disinfection agent DESCOSEPT AT® Dr. Schuhmacher GmbH 
Disinfection agent Sterillium® BODE CHEMIE 
DMSO MERCK 
Ethanol 99,9% NORMAPUR 
Examination gloves ProLine® powder-free, Latex ASID BONZ 
FALCON® tubes (15 ml / 50 ml) Becton Dickinson 
Fetal Bovine Serum (FBS) 500 ml, sterile filtrated (Ø 0,22 μl) Thermo Fisher Scientific 
Glass containers (250 ml / 500 ml / 1000 ml) SCHOTT 
Glycerin ROTH 
Laboratory coat (H50) Waldner 
Pancoll® (sterile filtrated) PAN BIOTECH 
Paraformaldehyde (PFA) powder 95% SIGMA-ALDRICH 
PBS: Dulbecco´s Phosphate-buffered saline (-CaCl2, 
+MgCl2); 500 ml 
Thermo Fisher Scientific 
Penicillin/Streptomycin; 100ml Thermo Fisher Scientific 
Pipette tips (10 μl / 100 μl / 200 μl / 50 μl / 1000 μl) Eppendorf 
Primary monoclonal anti-HCMV IgG-mouse-antibody E13-
Klon, target IE1(UL122) anti-pp72 
BioMérieux 
QuantiFERON-HCMV 2 Plate Kit ELISA® 0350-0201 Qiagen 
QuantiFERON-HCMV Blood Colletion Tubes® 0192-0301 Qiagen 
Reaction tubes (0,2 ml / 0,5 ml / 1,5 ml / 5 ml) Eppendorf 
Secondary monoclonal anti-mouse IgG-rabbit-antibody + 
horseradish peroxidase (POD) 
Agilent Technologies 
Sterile filter MILLEX®-GS (Ø 0,22 μm, 0,44 μm) MILLIPORE 
TBE buffer 10x Thermo Fisher Scientific 
Trypsin-EDTA; 100 ml Thermo Fisher Scientific 
T-Track ELISpot kit human IFN-y HISpecificity® Lophius biosciences 
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2.4.1 nPCR Master Mix for gB typification 
PCR 1: 50 µL final volume: 
• 36,75 µL Ampuwa 
• + 0.25 µL (0.5 µM Primer gB1138) 
• + 0.25 µL (0.5 µM Primer gB1596) 
• + 0.20 µL (100 µM dNTP mix) 
• + 5,0 µL Puffer Roche (10x) 
• + 0.005 µL (0.01% Tween) 
• + 2.5 µL Taq polymerase 
• + 2.0 µL Template 50 ng/µg DNA  
 
PCR 2: 100µL final volume: 
• 86.15 µL Ampuwa 
• + 0.05 µL (0.1µM Primer gB1276) 
• + 0.05 µL (0.1µM Primer gB1524) 
• + 0.20 µL (100µM dNTP mix) 
• 10 µL Puffer Roche (10x) 
• 0.01 µL (0.01% Tween) 
• 2.5 µL Taq polymerase 
• + 1.0 µL Template from PCR 1 (1:50 dilution) 
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2.4.2 Buffers 
TBS-wash buffer: Tris-buffered Saline 
Stock solution (10x): 
• 60.57 g Tris-base  
• 87 g sodium chloride (NaCl)  
• solved in 800 ml ddH2O  
• pH 7.6 adjusted with 2N hydrochloric acid (HCl)  
• filled up to 1000 ml + sterile filtrated (Ø 0.22μl)  
Ready-to-use solution: Dilution factor (1:10)  
• 100 ml stock solution+900ml ddH2O+2ml Tween20  
 
Sodium acetate buffer (0,1 [M]) 
 
Stock solution (10x): 
• 82.5 g sodium acetate  
• add 28.88 ml glacial acetic acid (100 %)  
• solved in 900 ml ddH2O  
• pH 4.9 adjusted with 2N hydrochloric acid (HCl)  
 
Ready-to-use solution: Dilution factor: (1:10)  
• 100 ml stock solution + 900ml ddH2O 
 
2.4.3 Immunperoxidase Substrate 
AEC stock solution (20x) 
• 10 mg 3-amino-9-ethylcarbazol-substrat (AEC)  
• + 0.1 M sodium acetate buffer 
• solved in 2.5 ml N,N-dimethylformamide  
Ready-to-use solution: Dilution factor (1:20)  
• 100 ml stock solution + 1900ml sodium acetate buffer 
• add H2O2 Dilution factor (1:1000)  
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2.4.4 Paraformaldehyde (PFA) solution 
PFA ready-to-use solution 4% 
• 450 ml of dH2O in 1L glass vessel with screw cap 
• heated to 60°C3 using hot plate with agitator + magnetic stirrer 
• add slowly 20 g PFA powder 95% to the heated water during stirring 
• add 5 single drops of 2 N NaOH in until the solution cleared up each time 
• remove from heat + add 50 ml PBS (10x)  
Final volume 500 µL 
• adjust to pH 7.2 using HCl 
• filtrate using 0,22 µM filter 
• freeze 10x50 ml aliquots at -20°C until use 
• use immediately after thawing process 
Remaining PFA solution was be stored at 4°C for 2 weeks, covered from light. 
The PFA solution was generated under an extractor hood, wearing gloves and protection 
glasses at any time. 
2.4.5 GCV-dilution scheme to determinate IC50 
GCV stock solution 
• Aliquots were generated at a concentration of 50 mg/ml(1) ≙ 196 mM in ddH2O 
Dilution series (7x): 
•  1 mM(2) ⇨ 50 µL GCV(1) +9750 µL MEM(+10% FCS) (Dilution factor 1:196) 
• 50 µM(3) ⇨ 500 µL(3) + 9500 µL MEM(+10% FCS) (Dilution factor 1:20) 
• 25 µM(4) ⇨ 5000 µL(3) + 5000 µL MEM(+10% FCS) (Dilution factor 1:2) 
• 10 µM(5) ⇨ 5000 µL(4) + 5000 µL MEM(+10% FCS) (Dilution factor 1:2) 
• 5 µM(6) ⇨ 5000 µL(5) + 7500 µL MEM(+10% FCS) (Dilution factor 1:2,5) 
• 2,5 µM(7) ⇨ 5000 µL(6) + 5000 µL MEM(+10% FCS) (Dilution factor 1:2) 
• 0,5 µM ⇨ 2500 µL(7) + 10000 µL MEM(+10% FCS) (Dilution factor 1:5) 
                                               
3PFA is unstable at temperatures above 70°C 
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2.5 Cell culture and virus propagation 
2.5.1 Cultivation of human cells (ARPE-19 cells, HFF) 
In general, the cultivation of cells and microtiter platepreparation were separated from virus 
isolation and propagation, as well as neutralization assays. Therefore, the laboratory work took 
place in different lab rooms to avoid unwanted viral contamination of target cells. Furthermore, 
all studies were carried out under a sterile workbench using “Single-Use-Systems”, appropriate 
protective clothing and gloves at all times. 
For cultivation, the cells were stored in intended incubators under defined culture conditions of 
37°C, 5% CO2 and 95% relative air humidity (rAh). T25-, T75- and T175-culture flasks Nunc® 
were used, depending on the needed number of cells. Afterwards, the cells were counted via 
Trypan blue staining and transferred afterwards to 96-well microtiter plates for NT-testing. The 
cells were passaged every 14 days, combined with monthly mycoplasmas testing. Only 
mycoplasma-free cells were used for studies. In addition, the cells were checked visually for 
bacterial or fungal contaminations before using in NT assays and the final passage number of 
the cell cultures was documented.  
2.5.2 Passaging of human cells 
The cells were passaged after reaching 80% confluence in the culture flask. Firstly, the medium 
was removed, followed by a wash step of the cells with phosphate-buffered saline (PBS) 
+1% Penicillin-Streptomycin, Thermo Fisher Scientific, USA. Trypsin was added to the culture 
flask (1 ml for T25, 3 ml for T75 or 6 ml for T175) for duration of 5-8 min, remaining in the 
incubator. Afterwards, the culture flask was gently tapped until the cells detached from the 
inner surface of the flask, checked by using a microscope (solution: 100x). On demand, the 
cells were usually split and transferred into 2 or 3 new culture flasks, containing fresh medium 
(5ml for T25, 12ml for T75 or 24ml for T175). The change of medium was performed every 4 
days for ARPE-19 cells and every 7 days for HFF. 
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2.5.3 Cell counting and cell vitality testing 
Trypan blue was used for vital staining of cells. Trypan blue is able to penetrate the membrane 
of dead cells which resulted in dark blue dead cells, compared to living cells (Fig.24A). after 
Therefore, adherent cells were detached by gently shacking with trypsin until they were present 
as single cells. The cells were mixed with trypan blue (1:2), transferred directly to the Neubauer 
counting chamber.  
 
Figure 24: (A) Visualization of death/live cells via trypan blue staining; (B) schematical model of a 
“Neubauer counting chamber” URL1: modified after Celeromics documents (date: 02.02.2018)” 
By using the 4 “grey” squares (Fig 24B), the cells were counted and the number of cells per 
milliliter were calculated using a mathematical equation (Eq.1). 
Equation 1: Calculation of cell number /ml Neubauer counting chamber  
Cell number ml⁄ =   
NlC
NlQ
x  Df x 10^4  
 
 
The vitality of cells describes the ratio between dead and living cells for the counted cells and 
was calculated, using equation 2. 
Equation 2: Vitality of cells 
VC =
NdC
NlC
 % 
Legend to equation 1: 
NlC = Number of counted living cells 
NlQ = Number of used large square 
Df = Dilution factor 
104 = Chamber factor 
Legend to equation 2: 
VC = Vitality of cells 
NdC = Number of counted dead cells 
NlC = Number of counted living cells 
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2.5.4 Cryopreservation of human cells 
Cryopreservation is used for long time storage of cell stocks with a low passage number. 
Stocks of HFF and ARPE-19 cells were prepared and frozen for this work to ensure the 
comparability and quality of the performed experiments. The cells were enzymatically 
detached from the culture flasks and transferred to fresh culture medium, followed by cell 
counting via trypan blue staining. After adjustment of the cell concentration to (5 million cells/ml 
per cryogenic vial), a centrifugation was performed at 300x g for 5 min. The supernatant was 
removed and the cells were re-suspended in cryomedium with a temperature of 4°C. 
Afterwards, the cells were transferred to marked cryo-vials. Immediately, the cells were frozen 
at -80°C in a fridge. The cryomedium contained additionally 5% dimethyl-sulfoxide (DMSO) 
and 25% FBS, compared to standard culture medium to avoid crystallization of the water during 
the freezing process. For infected cells, 10% glycerin and 20% FBS were used instead to 
preserve the viral infectivity. However, DMSO inhibits the crystallization better than glycerin. 
2.5.5 Reinitialization of cryopreserved cells 
DMSO shows cell toxicity at room temperature (RT). Therefore, it should be removed 
immediately after the thawing process. The cryogenic vials were put into a warm water bath at 
37°C to ensure a quick defrost.  
After thawing, the cells were transferred into fresh culture medium without DMSO and 
centrifuged at 300x g for 5 min. Afterwards, the medium was replaced by fresh medium. In 
order to remove DMSO completely from the cell culture, the wash process was repeated and 
the cells were finally placed in T25 culture flasks and for further cultivation into T75 or T175 
culture flasks on demand. 
2.5.6 Virus cultivation 
HCMV replicates only in specific living and growing eukaryotic cells. Therefore, HFF and 
ARPE-19 monolayers were used in a culture flask with a confluence of approximately 80% for 
virus cultivation. The medium was removed and the cell culture was washed with PBS. At this 
point, cell-free virus supernatant or already infected cells were added to the cell culture. After 
an incubation of 10 min at 37°C, 5% CO2, cell culture flasks were filled with fresh medium and 
stored in an incubator at 37°C, 5% CO2. For NT experiments, the concentration of virus was 
defined via tissue culture infective dose 50% (TCID50)-determination.  
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2.6 TCID50 determination 
The determination of TCID50 (tissue culture infective dose 50%) is defined as concentration 
which is necessary to infect half of the non-infected cells after inoculation with viral lysates in 
a given time, normally 18 h to 72 h at 37°C, 5% CO2. In detail, the TCID50 value reflects the 
reciprocal logarithmic dilution which corresponds to the potency of the dilution. For the 
determination, 96 well microtiter plates were used with 20.000 non-infected cells in each well. 
Cells were previously counted and transferred to the microtiter plate until they reached 
adherence, usually in 4-5 h at 37°C, 5% CO2. A dilution series of cell free virus was created in 
log10 steps from 10-0 to 10-9. 
Table 16: Scheme for TCID50 determination; CC = cell control; VC = virus control 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 10-0 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 CC VC 
B 10-0 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 CC VC 
C 10-0 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 CC VC 
D 10-0 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 CC VC 
E 10-0 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 CC VC 
F 10-0 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 CC VC 
G 10-0 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 CC VC 
H 10-0 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 CC VC 
 
An overview for the TCID50 determination is given in table 16, whereby each 8 replica (A-H) of 
dilutions 10-0 to 10-9 are shown (column 1 to 10) on the microtiter plate in 8 replicas (A to H). 
100 µL of each dilution was added to the intended wells. Cell control (CC) and virus control 
(VC) were additionally prepared and added. Afterwards, the microtiter plate was centrifuged 
for 30 min at 300x g; RT, followed by an additional incubation of 30 min at 37°C, 5% CO2. 
Finally, 100µL fresh culture media was added to each well, followed by an incubation for the 
next 17 h at 37°C, 5% CO2. After inoculation, the infected nuclei were visualized under the light 
microscope via p72 IE-antigen immunoperoxidase staining. Under this condition, the TCID50 
value is the potency of the dilution which contains 4 of 8 infected wells. One infected cell core 
defines infection in a well. 
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For calculation of the TCID50, the single dilutions were defined as class borders and values 
exactly between the class borders (x+ 0.5) were called “middle of class” (Tab.17). The 
mathematical product was calculated through the increase of the number of infected wells from 
dilution to dilution and the corresponding middle of class of dilution. In the next step, the 
products were summed up and divided through the number of replicas of each dilution, in this 
setup 8. This TCID50-value is equal to the logarithm (basis 10) per 100µL. The potency must be 
added by +1 to gain the logarithm per ml (Method after Spearman-Kaerber; Bonin, 1973). 
Table 17: TCID50 calculation example 
Class borders -9 -8 -7 -6 -5 -4 -3 -2 -1 
Number of infected wells 0 0 0 2 4 6 8 8 8 
Middle of dilution class  -8,5 -7,5 -6,5 -5,5 -4,5 -3,5 -2,5 -1,5 
Increase of infected wells  0 0 2 2 2 2 0 0 
Product  0 0 -13 -11 -9 -7 0 0 
 
Equation 3: Calculation of TCID50 using an example 
𝑙𝑜𝑔
𝑇𝐶𝐼𝐷50
𝑚𝐿
(18ℎ) = |
𝑆𝑢𝑚 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑟𝑒𝑝𝑙𝑖𝑐𝑎𝑠 (8)
| + 1 = |
−40
8
| + 1 = | − 5 | + 1 = 𝟔 
Table 17 and equation 3 explain the calculation using a chosen example. The TCID50/ml for 
18h was calculated and resulted in 6. The TCID50/ml can be used as indicator for infectivity of 
the virus and the used concentration of cell-free virus in neutralization assays can be described 
as (x)-fold of the TCID50/ml value to induce 100 SICs (single infected cell cores) or 100 PFUs 
(plaque forming units) which were defined as n ≥10 linked infected cell cores in the negative 
control after a defined incubation time (18 h or 5 d) at 37°C, 5% CO2.  
Equation 4: Calculation of the (x)-fold TCID50 value for NT assays 
(x) − fold 
TCID50
ml
(18h) =
106
800
= 1250 
For example, of calculation, the virus supernatant corresponds in a dilution of 1:800 to a 1250-
fold TCID50/ml, as shown in equation 4. 
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2.7 p72 IE-antigen-immunperoxidase staining (in situ ELISA) 
The p72 IE-antigen immunoperoxidase staining is an ELISA (Enzyme-linked Immunosorbent 
Assay) which is used for detection of HCMV infection in cell culture in routine diagnostics. The 
immediate early antigen p72 of HCMV is recognized by a monoclonal anti-p72 primary mouse 
antibody, BioMérieux, France in the nucleus of infected cells. After a wash step, a monoclonal 
secondary anti-mouse antibody, Agilent Technologies, USA conjugated with a horseradish 
peroxidase (HRP) binds on the Fc-part of the primary anti-p72 mAB. HRP is able to catalyze 
3-amino-9-ethylcarbazole (AEC) in a redox reaction which results in a red crystalline water-
insoluble color and can be detected under a light microscope by eye (Fig.25). 
 
Figure 25: Visualization of HCMV-infected cell nuclei  
(ARPE-19 cells) using p72 IE-antigen-immunperoxidase staining (160x) 
The reaction needs the use of hydrogen peroxide (H2O2) which will be reduced to water (H2O) 
by the enzyme. H2O2 delivers the necessary biochemical energy to catalyze the reaction. For 
this purpose, the enzyme possesses a trivalent iron +cation in its active center. In a redox 
reaction, the substrate AEC will be oxidized and forms a red azomethine at the same time 
(Burstone, 1960). However, in order to perform this procedure, the infected cell culture had to 
be previously fixed with a 1:1 mixture of ethanol and acetone for 90 s, after removing the culture 
medium. For safety, the mixture was prepared under a hood.  
After the incubation of 90 s, the cells were washed with 200 µL/well tris-buffered saline (TBS) 
buffer and incubated with 100 µL/well of the primary anti-p72 mAb in a concentration of 1:500. 
A second incubation of 1h at 37°C, 5% CO2 took place, followed by a 3 wash steps with TBS 
buffer to remove unbound primary mAb. Next, 100µL/well of the secondary anti-mouse mAb 
was added, used in a concentration of 1:400 to bind the primary mAB for the next 1 h at 37°C. 
Afterwards, the cells were washed 3-times with TBS buffer. Meanwhile, the substrate solution 
was prepared which included AEC and sodium acetate buffer in a ratio of 1:20. The ACE was 
previously solved in N, N-dimethylformamide. The generated solution contains coarse crystals 
which had to be removed by a 22 µm filter.  
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The 100 µL of the ACE solution was transferred to each well and hydrogen peroxide was 
separately given to the wells to initiate the reaction. The color development was supported by 
a light-protected incubation for about 20 to 30 min, 37°C. After reaching the desired coloration, 
the reaction was stopped by removing the solution, followed by 2 wash steps with TBS buffer. 
Finally, the wells were filled with 200 µL PBS and the SICs/PFUs were counted under the light 
microscope. For storage, the plates were placed at 4°C, covered from light. 
2.8 In vitro neutralization assays 
First investigations focused on in vitro neutralization assays to characterize the HIG Cytotect® 
in context of its ability to neutralize HCMV effectively. The neutralization protocols were 
modified after a previous work of Schampera et al., 2017 which originally based on Eggers et 
al., 2000 and Abai et al., 2007. 
Two different approaches of NT-assays, including a short-term cell-free HCMV neutralization 
assays (CFNT) of 18h for binding and the prevention of viral infection of cells and a long-term 
cell-adapted neutralization-plaque-reduction assays (PRANT) of 3 days to demonstrate 
inhibition of cell-to-cell spread via plaque formation (Schampera et al., 2017). 
In this work, the NT-assay protocols were multiple adapted to combine the advantages of both 
approaches of Schampera et al., 2017 to investigate viral infection and detect active viral 
cycles, as well as using less volume of the IgG preparations at the same time. In general, the 
performed NT-protocol used different cell-free virus strains which were incubated with dilution 
series of IgG-preparations (1:50; 1:500; 1:1.000; 1:5.000; 1:10.000; 1:50.000) in a ratio of 1:1 
for 90 min at 37°C, 5% CO2 under defined conditions, depending on the specific question 
(referring to 1.15.). Then, 100µL of the incubated virus-antibody solution was transferred to 
ARPE-19 cell and/or HFF monolayers, followed by a centrifugation at 300xg, RT for 30 min 
and a further incubation at 37°C, 5% CO2 for 30 min.  
Afterwards, all wells were filled with 100 µL of fresh culture medium and an incubation of 5 
days took place at 37°C, 5% CO2. While this time, the virus had time to infect the cell culture. 
In preliminary test, the concentrations of each used viral strain were determined, that induce 
approximately 100 PFUs after 5 days of incubation in the negative reference pool. As additional 
control, a positive pool was used in each NT assay which represented the average NT-capacity 
of latently infected women at birth. 
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The read out was performed by p72 IE-antigen-immunperoxidase staining. An example for a 
read out of 1 PFU ≥ 10 SICs is given after performance of a NT assay with a duration of 5 days 
(2 images of the virus control) (Fig.26). The reference serum pools were preincubated for  
30 min, at 56°C on a heat block for complement inactivation. The used IgG-preparations 
contain no complement and additional heat incubations showed no effect on in vitro NT-
capacity in preliminary NT-activity testing. 
 
Figure 26: Example for read out of PFUs ≥10 after 5d incubation (25x) 
In order to standardize the “read out” of the NT assay system, each well of the microtiter plate 
was counted 2 times (blue and red), using defined squares and according to the scheme in 
Figure 27. Afterwards, the numbers between both counts were summarized and divided by 
1.5. Therefore, the “field of view” of the microscope was adjusted at a resolution of 50x to the 
outer corners of the squares which touched the edge line of the microtiter well, marked with 
red circles. This read out pattern was used to reduce variabilities between the counts of 
different experimenters, using the same assay test system.  
 
Figure 27: Read out scheme for the NT assay systems  
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2.8.1 Statistical analysis 
The NT assays were performed to calculate NT50 titers. Therefore, all compiled data were 
measured in triplicates, calculating mean and standard deviation (SD). For PROBIT®-analysis 
and statistical valuation the programs PASW-Statistics version 18 (SPSSInc® Company) and 
JMP-version 18 (SAS® Company) were used. The Wilcoxon-signed-rank test was used to 
compare quantitative values between groups. Calculated statistical p-values were visualized 
as follows: ns4= 0.05>p; p*≤0.05; p**≤0.01; p***≤0.001. 
2.8.2 Analysis of anti-viral drug resistance and NT testing 
The GCV resistant strain “40571” and the multi-drug resistant strain “H815-06” were used in 
NT assays to analyze the impact of HCMV-specific IgG on anti-viral drug resistant strains. In 
this setup, the NT-capacities of IgG-preparations were investigated in the presence of GCV in 
increasing concentrations. The inhibitory concentration 25% (IC25), IC50 and IC75 of both stains 
were determined in preliminary tests, according to Göhring et al., 2013 and were used in the 
NT assays. Therefore, the GCV depended IC-values were determined by serial dilution of GCV 
(50 µM, 25 µM, 10 µM, 5µM, 2.5 µM, 0.5 µM) which were added to cocultures of 100 infected 
and 20.000 non-infected cells in triplicates, using 96 well microtiter plates. After an incubation 
of 5 days at 37°C, 5% CO2, the cells were fixed and PFUs were counted, followed by statistical 
Probit® analysis to calculate the strain-dependent IC-values. The NT results of both drug-
resistant strains were compared to the drug-sensitive strain “H2497-11” as reference.  
Prior to NT testing, routine-based PCRs and Sanger sequencing were performed for UL97 
or/and UL54 which confirmed the already described mutations of 40571 and H815-06, resulting 
in drug-resistance to GCV or/and CDV (Göhring et al., 2013).  
  
                                               
4ns = not significant 
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2.8.3 HCMV-specific antibody depletion strategies 
Two UL130 peptides and a recombinant whole PC were used to deplete specific antibodies 
from IgG-preparations in order to analyze their impact on in vitro NT-capacity.  
 
Figure 28: HCMV pentameric depletion scheme: two UL130-peptides and a recombinant pentameric 
complex (Schampera et al., 2018) 
UL130 TAN/SWS peptide with an additional 6xfold HisTag on the C-terminus and a 
recombinant PC with a linked 6xfold HisTag on glycoprotein H (gH) were used. For the pAb 
depletion strategy, magnetic beads were coated with protein G to attach monoclonal anti-
HisTag-antibodies on the bead surface (Fig.28). After incubation for 24 h at 37°C, 5% CO2, 
bead-fixed immune complexes were formed.  
On the next step, the magnetic bead peptide complexes and samples of HCMV IgG 
preparations were mixed (1:2), followed by incubation for 24 h at 37°C, 5% CO2. Then a “6 
tube magnetic separation rack” was used to deplete the potentially bound HCMV-specific anti-
PC and anti-TAN/SWS peptide pAbs. The supernatants with unbound antibodies were 
transferred into new tubes (Schampera et al., 2018)  
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In following neutralization assays, the neutralization capacities of native samples were 
compared to depleted samples of the investigated IgG preparations and the HCMV IgG+/IgM-
-serum pool as reference. The magnetic beads plus anti-HisTag-monoclonal antibodies 
(27E8), as well as the 6-tube magnet separation rack (7017) were derived from Cell Signaling 
Technology, UK. 
In a precalibration, the TAN peptide was diluted in log10 steps (0.001 to 1 mg/ml) to determinate 
the concentration which resulted in the maximal reachable depletion effect of in vitro 
neutralization capacity for Cytotect®, Kiovig® and HCMV IgG+pool (Fig.29). 
 
Figure 29: Calibration of the TAN-peptide concentration, revealing the maximal reachable reduction of NT-
capacity 
The peaks of in vitro neutralization reduction, taken from each NT assay revealed that the best 
valuable in vitro NT-depletion effect which was detectable at a concentration of 0.01 mg/ml 
without risking of unspecific depletion effects. This unspecific depletion effects are caused by 
protein masking - too high protein concentrations could interfere with the formed virus-antibody 
complex. The UL130 TAN/SWS peptide and the pentameric complex were used in a 
concentration 0.01 mg/ml, mixed with 1% magnetic bead solution in order to deplete specific 
antibodies from IgG preparations. 
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2.8.4 IgG 3 subclass depletion strategy 
In a next depletion experiment, the influence of the IgG subclass 3 antibodies on in vitro NT-
capacity was characterized. Therefore, a modified depletion concept was established (Fig.30). 
 
Figure 30: IgG subclass 3 depletion (Schampera et al., 2018) 
Anti-human IgG subclass 3 mAbs were bound via protein G to magnetic beads to deplete IgG 
subclass 3 specific pAbs from IgG preparations. For control, the IgG+/IgM- reference pool was 
also depleted (Schampera et al., 2018). 
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2.9 Calibration of NT assays using a PEI reference standard preparation 
In the absence of an international WHO unit standard and in order to increase the reliability of 
the NT assays, a reference preparation was used for HCMV-IgG calibration which was derived 
from the Paul-Ehrlich Institute, Germany. It was generated in the year 1996 and contains 110 
PEI Units/ml which was measured with Enzygnost Anti HCMV/IgG® from Siemens Healthcare 
Diagnostics Products, Germany. 
Table 18: Biochemical specifications of the PEI HCMV-IgG reference 
Bioch. parameter PEI standard [g/dl] Normal serum [g/dl] 
Total protein 49,3 6,1-8,1 
Total IgG 47,7 0,7-1,6 
Total IgA 1,49 0,04-0,23 
Total IgM 0,05 0,07-0,38 
 
The biochemical specifications were given from the Paul-Ehrlich institute (Tab.18). Compared 
to parameters of normal human serum, there is a clear increase of total protein which is caused 
by the high concentration of IgG. The concentration of IgA is also remarkably higher than in 
normal human serum. 
 
Figure 31: Calibration of NT assays, using PEI Units and ECLIA Units 
On the base of PEI units, HIGs and IVIGs can be compared to specify HCMV-specific IgG. 
Additionally, the results of this work can be placed in context to other publications which 
already used PEI units to illustrate and interpret their data (Filipovich et al.,1992; Miescher et 
al., 2015; Germer et al., 2016; Schampera et al., 2017).  
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Therefore, in a preliminary experiment, the PEI reference standard was firstly diluted in 2-fold 
steps from (undiluted), 1:2, 1:4, 1:8, 1:16; 1:32; 1;64, 1:128, 1:256, 1:512 to 1:1024, then 
measured in triplicates with the ECLIA CMV Cobas 6000 Analyzer® from Roche to generate 
a dilution standard curve of HCMV-specific IgG (Fig.31).  
Equation 5: Transformation from ELCIA Units to PEI Units 
𝒚[𝑃𝐸𝐼 𝑈 ∕ 𝑚𝑙] =   0,0318𝒙[𝐸𝐶𝐿𝐼𝐴  𝑈 𝑚𝑙⁄ ] + 0,0762   
The standard curve allowed the transformation from ECLIA units to PEI standard units using 
the mathematical equation 5 with a correlation coefficient of R2= 0.9995. The ECLIA test 
system is generally used in routine diagnostic of the HCMV serostatus which includes HCMV-
IgG, IgG avidity (Sandwich principle) and HCMV-IgM (μ-Capture test principle) (Roche SOP 
documents URL2 / URL3: date: 06.04.2018). 
2.10 Normalization of the HCMV-specific IgG concentration of HIGs and IVIGs 
The investigated HIGs and IVIGs contain different concentrations of HCMV specific IgG, as 
previous reported (Miescher et al., 2015; Germer et al., 2016; Schampera et al., 2017). In order 
to compare the qualitative NT capacity, the HCMV specific IgG concentration of these IgG 
preparations were normalized to the HCMV specific-IgG concentration of the generated 
HCMV-IgG+-pool using PEI Units (Tab.19), according to Schampera et al., 2017. The 
normalized IgG preparations were analyzed in following NT assays with different HCMV 
strains. 
Table 19: Normalization of HCMV-specific IgG concentration 
using the HCMV+pool as reference 
Preparation 
Mean  
PEI Unit/ml 
Dilution factor 
HCMV-IgG+pool 41.2 --- 
Cytogam® 118.7 1:2,9 
Cytotect® 150.3 1:3,6 
Kiovig® 42 1:1 
Octagam® 62.4 1:1,5 
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2.11 HCMV-specific T-cell modulation after HIG administration of pregnant 
women with proven HCMV-primary infection in T1 
The second part of this work was addressed to the impact of HIG administration on the 
modulation of HCMV-specific T-cells via the indirect measurement of produced IFN-γ. 
Therefore, the QuantiFERON CMV® from Qiagen and the T-Track ELISpot CMV® from 
Lophius were performed. The whole blood samples of pregnant women were collected, who 
were treated with Cytotect® biweekly after a proven HCMV primary infection in T1 (under week 
14 of gestational age) (Kagan et al., 2018). 4x 5 ml LiHep whole blood was drawn from treated 
women with their previous permission and based on the ethical approval (EK number: 
506/2015BO2). The samples were taken at the beginning of the HIG administration (day of 
treatment (dot) = 0) and every 7 days, until GA = 21 week. In two selected cases, additional 
blood samples on day 2, 4, 7, 9 and 11 were collected between the first and second HIG 
administration. 
2.11.1 QuantiFERON CMV® Qiagen  
QuantiFERON CMV® is an in vitro interferon-γ release assay which 
uses heparinized whole blood samples to detect cell-mediated 
immunity against human cytomegalovirus. Therefore, the assay 
quantifies immune modulatory responses to a cocktail of specific 
HCMV-antigens during infection by measuring levels of interferon-
γ secretion via an “Enzyme-Linked Immunosorbent Assay” (ELISA) 
test principle. IFN-γ is generated during the adaptive immune 
response of CD4+ and CD8+ T cells, as well as during the innate 
immune response of NK cells and NK-T cells. In this context, IFN-γ 
production can be a functional surrogate marker for the 
identification of HCMV-specific CD8+ T cells and the number of 
HCMV-specific CD8+T cells can be predictive for the risk of 
developing HCMV-related diseases (Zaia et al., 1993). In general, 
this assay is used to monitor the immune situation of solid organ 
transplant (SOT) recipients (Kobayashi et al., 2017; Kwon et al., 
2017). 
  
Figure 32: Process of 
antigen regcogniton and 
presenting through APC 
resulting in IFN-γ 
production. (Qiagen test 
principle QuantiFERON 
CMV® Documentation) 
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The assay covers over 98% of the human population via the included HLA types (Tab.20). The 
whole blood samples were incubated in “Blood Collection Tubes 1 ml” which are surface-
labeled inside the tubes with HCMV antigens (Giulieri et al., 2011). 
Table 20: Included HLA antigens which covering >98% of human population. 
Included HLA types 
A1, A2, A3, A11, A23, A24, A26 
B7, B8, B27, B35, B40, B41, B44, B51, B52, 
B57, B58, B60  
Cw6 (A30, B13) HLA Class I haplotypes 
Each collected sample had its own negative and positive control tube. Mitogen was used as 
positive control to stimulate unspecific IFN-γ secretion. The sample collection, incubation and 
ELISA assay were performed, according to the test protocols of Qiagen test kit. The OD (optical 
density)-values were measured via Photometer Microplate Reader, BEP-systeme Siemens 
AG, Germany with a 450 nm filter and a reference filter at 620/650 nm. The data analysis was 
performed using the calculation program Cellestic HCMV QuantiFERON Analysis Software® 
(version 3.03), provided from Qiagen. The quantitative determination of IFN-γ concentrations 
was measured in two-fold replica by establishing an IFN-γ standard curve via known IFN-γ 
concentration solutions. Therefore, the samples were diluted 1:10 for quantification, according 
to the Qiagen test protocol. 
2.11.2 T-Track EliSPOT CMV® Lophius 
In contrast to the QuantiFERON CMV®, the T-Track EliSPOT CMV® (Enzyme-linked 
immunosorbent spot) CMV® from Lophius recognizes the number of IFN-γ producing cells 
after purification of peripheral blood mononuclear cells (PMBCs). The whole blood was mixed 
with PBS (1:1) in a 50 ml Falcon® tube. Then, 15 ml of Pancoll® (density: 1.077 g/ml, at RT) 
was filled and in other 50 ml Falcon® tube and was slowly covered with the diluted blood, 
followed by a centrifugation at 880x g for 30 min, RT. During this time, an interphase was 
formed which included the PMBCs. The PMBCs were carefully transferred to a new tube using 
a pipette and were washed 2-times with PBS afterwards. The cells were washed 2-times via a 
centrifugation at 300x g for 10 min. Meanwhile, the microtiter plates were prepared with a 
negative control (medium), a positive control (PHA5; 1:10) and overlapping HCMV pp65 
(ppUL83) antigens in a concentration (1:20). All samples were performed in duplicates.  
  
                                               
5 Phytohemagglutinin-L 
 65/144 
After the centrifugation of the cells, the supernatant was removed and the cells were resolved 
in 1ml AIM-V®+ AlbuMAX® medium from Thermo Fisher Scientific, USA. In a next step, the 
number of cells was adjusted to (2x106 cells/ml) using the Z1 Beckman Coulter® Life Sciences, 
USA (upper size border: 13 µM, lower size border: 8 µM). 
The system was calibrated before each measurement via a cell count standard for leucocytes. 
100µL/well of the adjusted PBMCs were transferred to the prepared microtiter plate for an 
incubation of 20-24 h at 37°C, 5% CO2. Afterwards, the cells were removed and the bound  
IFN-y was visualized on the surface, according to the test protocol for HiSpecifificityPRO® (for 
research only) (Lophius).  
 
Figure 33: EliSPOT test principle; T-Track EliSPOT CMV® (Modified after URL:Mstechno.co.jp) 
The ELISpot test principle uses anti-IFN-γ mAbs which were coated on the bottom membrane 
of the wells (Fig.33). During incubation, stimulated cells produce IFN- γ which is captured by 
the anti-IFN-γ mAbs. After incubation, the wells were repeatedly washed. A secondary mAB 
bound to the IFN-γ at a different epitope and visualized the spots through a substrate color 
reaction. The spots are a negative image of the removed IFN-γ reactive PBMCs (Barabas et 
al., 2017; Banas et al., 2017). 
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3 Results 
3.1 Standardization of HCMV neutralization plaque reduction assay (PRA) and 
assay performance characteristics 
The first step was to establish a NT assay protocol which was used for all investigation of 
previously determined issues in the objectives (point 1.15). The results are given for the final 
NT assay protocol with ARPE-19 cells (Fig.34A1) and HFF (Fig.34B1) as target cells. The 
clinical strain H2497-11 was used as target for viral neutralization and prevention of infection 
via selected IgG preparations. In this context, stock solutions of the HIGs Cytotect®/Cytogam® 
were compared to stock solutions of the IVIGs Octagam®/Kiovig®. Additionally, the HCMV-
IgG+pool served as control reference and reflected the average NT-capacity of latently infected 
mothers at birth.  
 
Figure 34: (A1) In vitro NT assay (stock solutions), Target cells: ARPE-19 cells , HCMV strain: H2497-11, 
Cell culture incubation 5d; (A2) NT50 PROBIT analysis of the tested IgG-preparations (stock solutions) on 
ARPE-19 cells; (B1) In vitro NT assay (stock solutions), Target cells: HFF, HCMV strain: H2497-11, Cell 
culture incubation 5d; (B2) NT50 PROBIT analysis of the tested IgG-preparations (stock solutions) on HFF6 
The corresponding NT50 values were shown in Figure 34A2/B2 as reciprocal value of the stock 
solutions which were calculated by Probit analysis. While the minimal and maximal border 
described the 95% confidence interval of the tested IgG-preparations, the analysis of statistical 
significance was performed, using JMP18® software. 
                                               
6 ns(not significant) 0.05>p; p*≤0.05; p**≤0.01; p***≤0.001 
HCMV strain: H2497-11 
Target cells: ARPE-19 
 
HCMV strain: H2497-11 
Target cells: HFF 
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The HIGs Cytotect®/Cytogam® revealed significant higher in vitro NT capacities than the 
IVIGs Octagam®/Kiovig®, while the NT capacities of both HIGs were comparable which was 
confirmed on ARPE-19 cells and HFF. 
The HCMV-IgG+pool reached the lowest in vitro NT capacity in the performed NT assays. In 
general, the calculated NT50 values of all investigated IgG preparations were significant higher 
(~3.5-fold) in ARPE-19 than in HFF (p>0.001) (Fig33A2/B2). For better understanding, NT50 
values were displayed as reciprocal value of the stock HCMV-IgG concentration of the 
investigated HIGs and IVIGs. 
In a next step, the generated NT assay protocol was additionally performed 6 times under the 
same conditions at different days to validate the average percentage deviation of the test-
dependent in vitro NT-capacity between observed NT50 results of the analyzed IgG 
preparations (Fig.35). 
 
Figure 35: Determination of the average percentage of 
deviation of the test-dependent in vitro NT-capacity 
(NT50) between observed results using the NT assays 
protocol 
The highest percentage of deviation to mean of NT-capacity was found in Cytotect® with 
±4.5% and Cytogam® with ±4.2%. Octagam® had a percentage deviation to NT-capacity 
mean of ±3.8%, followed by Kiovig® with ±3.6%. The lowest deviation was observed in the 
reference HCMV-IgG+pool of 100 latently infected mothers at birth, regarding to ±2.3%. The 
deviations between repeated NT assay approaches were considered during interpretation of 
the collected data in this work.  
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In a next experiment, the differences in the quantitative in vitro NT capacity [NT50/HCMV PEI 
U] of the IgG preparations were investigated to answer the question, if the same HCMV-
specific concentrations of the different IgG-preparations resulted in similar or different in vitro 
NT capacities against HCMV (H2497-11) (Fig.36). Therefore, the IgG preparations were pre-
diluted before NT assay, according to table 19 and normalized to HCMV-specific IgG 
concentration of the HCMV-IgG+pool. 
 
Figure 36: (A1) In vitro NT assay (HCMV-IgG normalization), Target cells: ARPE-19 cells , HCMV strain: 
H2497-11, Cell culture incubation 5d; (A2) NT50 PROBIT analysis of the tested IgG-preparations on ARPE-
19 cells; (B1) In vitro NT assay (HCMV-IgG normalization), Target cells: HFF, HCMV strain: H2497-11, Cell 
culture incubation 5d; (B2) NT50 PROBIT analysis of the tested IgG-preparations on HFF 
The in vitro NT assay was performed with the HCMV strain H2497-11 on ARPE-19 cells and 
HFF (Fig.36A1B1), while the corresponding NT50 values were illustrated in Figure 36A2/B2. 
For better understanding, NT50 values were displayed as reciprocal value of the normalized 
HCMV-IgG concentration of the investigated HIGs and IVIGs. 
After HCMV-IgG normalization, all IgG preparations revealed no significant differences in in 
vitro NT-capacity, comparing of NT50 values. This was observed on both used target cell type 
cultures. Additionally, the in vitro NT capacities were about 3.5-fold higher in ARPE-19 cells 
than in HFF which confirmed the first results with IgG stock solutions (Fig.34A2/B2).  
  
HCMV strain: H2497-11 
Target cells: ARPE-19 
HCMV strain H2497-11 
Target cells: HFF 
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Following HCMV IgG normalization, the sample dilutions of the IgG preparations were 
transformed into HCMV PEI Unit/ml, as shown in Figure 37. For better visualization, the HCMV 
PEI values were displayed as log10 as an approximated-linearized course. 
 
Figure 37: Transformation of sample dilution into HCMV PEI Unit/ml 
The results showed no quantitative differences in in vitro NT-capacity per HCMV PEI Unit 
between the investigated IgG preparations using the clinical isolate H2497-11 on HFF and on 
ARPE-19 cells (Fig.37).  
The NT assay protocol was additionally tested under the usage of a genetically modified 
HCMV-strain TB40E variant (RV-TB40-BACKL7-SE-EGFP) to establish an alternative read 
out system via an inserted BAC cassette at US34A downstream which intracellularly expresses 
GFP (Green fluorescent protein) (Fig.38). 
 
Figure 38: (A1) In vitro NT assay (HCMV-IgG normalization), Target cells: HFF, HCMV strain: TB40E, Cell 
culture incubation 5d; (A2) NT50 PROBIT analysis of the tested IgG-preparations on HFF 
In comparison with the clinical HCMV isolate H2497-11, all IgG preparations and the generated 
HCMV-IgG+pool were able to reach comparable in vitro NT-capacities to the H2497-HFF strain 
after incubation time of 5 days, using the TB40E variant on HFF (Fig.38A/B). 
  
HCVM strain: TB40E 
Target cells HFF 
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In addition, the usage of the TB40E variant allowed a live investigation of the viral reproduction 
and spread in cell culture during the NT assay from day 1 to day 5 of the experiment under a 
fluorescence microscope, without p72-staining via antibodies at the end of the incubation. For 
a better visualization of the in vitro NT assay using the TB40E variant, live images were taken 
from the corresponding microtiter plates. 
 
Figure 39: in vitro NT assay (TB40 E variant) example figures of analyzed IgG preparations on HFF, sample 
dilution 1:5000, 50x; (A) HCMV-IgG+pool; (B) Kiovig®; (C) Octagam® (D) Cytotect® (E) Cytogam® 
Figure 39 shows images of the HCMV-IgG+pool and each analyzed IgG preparation on HFF 
at a sample dilution of 1:5000. While the HCMV-IgG+pool showed the most HCMV-specific 
PFUs at this dilution, only few PFUs were found in the HIGs Cytotect® and Cytogam®. The 
number of PFUs of the IVIGs ranged between the HCMV reference pool and the HIGs.  
  
 71/144 
In contrast to the successfully performed NT assay on HFF, the TB40E variant induced not 
enough PFU numbers in ARPE-19 cells for an evaluable NT analysis. 
 
Figure 40: in vitro NT assay (TB40 E variant) example figures of analyzed IgG preparations on ARPE-19 
cells, sample dilution 1:5000, 50x; (A) HCMV-IgG+pool; (B) Kiovig®; (C) Octagam® (D) Cytotect® (E) 
Cytogam® 
Sample images were taken from NT assay, using ARPE-19 cells as target cells (Fig.40). The 
TB40E variant hardly tended to induce infection or viral plaque formation in ARPE-19 cells. 
There were few evaluable HCMV-PFUs found in the HCMV reference pool and in Kiovig, but 
the NT assay showed no sufficient results for Octagam®, Cytogam® and Cytotect®. 
Further NT experiments on ARPE-19 cells were performed using the viral isolate H2497-11 
and p72-staining as read out system. 
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3.2 Cytotect® neutralization activity against HCMV isolates, resistant to 
antiviral compounds 
For this experiment, the GCV IC25, IC50 and IC75 values of the drug-resistant HCMV strains 
H815-06 and 40571 were determined (Fig.41).  
 
Figure 41: GCV IC25/50/75 dose analysis of both investigated resistant HCMV strain (H815-06, 40571) 
The analysis of the strain-dependent GCV IC50 concentration confirmed, that both HCMV 
strains were resistant against Ganciclovir®, according to the threshold value for GCV 
resistance of ≥6 µM (Prix et al., 1999, Göhring et al., 2013). Interestingly, both HCMV strains 
were comparable in context of GCV resistance, considering IC25, IC50 and IC75 values. 
The HCMV strain 40571 and H815-06 were analyzed in PRA using the established NT assay 
protocol and were compared to the sensitive reference HCMV strain H2497-11. The following 
NT assays were performed on HFF monolayers, because the drug-resistant HCMV strains 
were initially isolated from primary material and cultivated exclusively on fibroblasts afterwards 
without adaption to epithelial cells.  
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Figure 42: (A) In vitro NT assay (stock solutions), Target cells: ARPE-19 cells , HCMV strain: H2497-11, Cell 
culture incubation 5d; (B) In vitro NT assay (stock solutions), Target cells: ARPE-19 cells , HCMV strain: 
40571, Cell culture incubation 5d; (C) In vitro NT assay (stock solutions), Target cells: ARPE-19 cells , HCMV 
strain: H815-06, Cell culture incubation 5d; (D) Meta-analysis of NT50-values via JMP software, comparing 
selected IgG preparations on a drug-sensitive and 2 drug-resistant HCMV strains 
In general, the HIGs Cytotect® and Cytogam® showed the highest in vitro NT-capacities in all 
3 performed NT assays with drug-sensitive and drug-resistant HCMV isolates, followed by the 
IVIGs Octagam®, Kiovig® and the reference HCMV-IgG+pool (Fig.42ABC). This observation 
correlated with the first results in point 3.1. In a further comparison, all IgG preparations 
showed not similar, but comparable in vitro NT-capacities (Fig.42D). In a statistical analysis of 
NT50-values via JMP in a comprehensive meta-analysis, all 3 investigated HCMV strains 
revealed no significant difference in in vitro NT-capacity, if each HCMV strain was individually 
compared to all other HCMV strains (All p-values were >0.05 ≙ ns (not significant)). This 
approach was repeatedly preformed with no appearance of significant differences in in vitro 
NT-capacity between the HCMV strains.  
HCMV strain: H2497-11 
Target cells: HFF 
HCMV strain: H815-06 
Target cells: HFF 
HCMV strain: 40571 
Target cells: HFF 
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3.3 Characterization of Cytotect® neutralization activities against HCMV 
isolates with different gB-genotypes 
In order to continue the characterization of Cytotect®, all IgG preparations were compared in 
these NT assays using 4 HCMV strains with different gB types 1 to 4. 
 
Figure 43: (A) gB type 1 in vitro NT assay (stock solutions), Target cells: HFF, HCMV strain: H1241-16, Cell 
culture incubation 5d; (B) gB type 2 in vitro NT assay (stock solutions), Target cells: HFF , HCMV strain: 
AD169, Cell culture incubation 5d; (C) gB type 3 in vitro NT assay (stock solutions), Target cells: HFF, HCMV 
strain: H1058-10; (D) gB type 4 in vitro NT assay (stock solutions), Target cells: HFF, HCMV strain: H487-
06; (E) Meta-analysis of all investigated HCMV strains, using NT50 values via JMP software 
The results for this experiment confirmed, that HIGs Cytotect® and Cytogam® reached the 
highest NT-capacities on all used HCMV strains, followed by the IVIGs Octagam®, Kiovig® 
and the generated HCMV-IgG+pool (Fig.43ABCD). The statistical meta-analysis compared the 
NT50-values of all IgG-preparations of one HCMV strain to each other used HCMV strain 
(Fig.43E). It revealed no significant differences in NT-capacity, therefore all IgG preparations 
performed comparable on the investigated HCMV strains, independently to gB types (All p-
values were >0.05 ≙ ns (not significant)). 
HCMV strain: H1241-16 
Target cells: HFF 
gB type 1 
HCMV strain: AD169 
Target cells: HFF 
gB type 2 
HCMV strain: H1058-10 
Target cells: HFF 
gB type 3 
HCMV strain: H487-06 
Target cells: HFF 
gB type 4 
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During the establishment of viral stocks and NT assay protocols, differences in viral spread 
and morphology between the investigated HCMV isolates were observed. The HCMV strains 
tended differently to generate different PFUs in cell culture in terms of form and size. There 
were also differences in appearance time from SICs to PFU and the degree of lysis differed in 
speed and strength which resulted in cell-free areas in the cell monolayers. These observations 
complicated the “read out” via p72 staining. Under these conditions, the HCMV strain H2497-
11 has shown to be suitable for NT-testing and was used for the next antibody depletions and 
NT assays. 
3.4 Role of pentamer-specific antibodies in HCMV hyperimmunoglobulin and 
standard intravenous IgG preparations 
The NT experiments in this setting focused on the impact of PC-specific antibodies in IgG 
preparations using stock solutions. A depletion concept was established, using magnetic bead 
separation. The results of NT assays are given on ARPE-19 cells and on HFF (Fig.44A1/B1) 
with statistical analysis of NT50 and p-values (Fig.44A2/B2). The reference HCMV strain 
H2497-11 was used. A comparison of native and depleted samples of the IgG preparations 
was performed to detect the difference in resulting NT-capacities, following antibody depletion. 
 
Figure 44: (A1) In vitro NT assay (stock solutions), TAN-peptide antibody depletion, Target cells: ARPE-19 
cells, HCMV strain: H2497-11, Cell culture incubation 5d; (A2) NT50 PROBIT analysis of the tested IgG-
preparations (stock solutions) on ARPE-19 cells; (B1) In vitro NT assay (stock solutions), TAN-peptide 
antibody depletion, Target cells: HFF, HCMV strain: H2497-11, Cell culture incubation 5d; (B2) NT50 PROBIT 
analysis of the tested IgG-preparations (stock solutions) on HFF (Modified after Schampera et al., 2018) 
TAN-peptide 
HCMV strain: H2497-11 
Target cells: ARPE-19 
TAN-peptide 
HCMV strain: H2497-11 
Target cells: HFF 
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The results for the NT assay on ARPE-19 cells revealed no significant differences in in vitro 
neutralization reduction between native and HCMV antibody-depleted samples (all p-
values>0.05≙ ns) (Fig.44A2). However, a non-significant trend forward decrease of NT 
capacities was observed. In detail, the highest NC reduction effect (16%; p= 0.12) was found 
for Cytotect® at a dilution of 1:5000 which was equivalent to 30.1 mPEI U/ml. For Kiovig, the 
highest NC difference (15%; p= 0.11) was shown at dilution 1:5000, corresponding to 8.4 mPEI 
U/ml. HCMV IgG+ reference pool had its highest difference in NC at (11%; p= 0.11) at 1:1000 
which was transformed into 41.2 mPEI U/ml.  
The depletion concept, using magnetic bead separation resulted in no detectable reduction of 
in vitro neutralization capacity on HFF which was performed as proof of concept to decline 
unspecific reductions of in vitro neutralization capacities through the performance of the 
depletion process (Fig.43B2) (HCMV-IgG+pool p= 0.78; Cytotect® p= 0.65; Kiovig® p= 0.69). 
As reminder, the depletion of TAN-specific antibodies should have no impact on the in vitro 
neutralization capacity on HFF. 
In a next approach, the differences in reduction of neutralization between the TAN-peptide and 
the original SWS-peptide of Saccoccio et al., 2011 were investigated at a concentration 
0.01mg/ml, using normalized HCMV IgG concentrations of the IgG preparation Cytotect® and 
Kiovig®. ARPE-19 cells were used as target cells (Fig.45). 
 
Figure 45: (A1) In vitro NT assay (HCMV-IgG normalization), TAN-peptide antibody depletion, Target cells: 
ARPE-19 cells , HCMV strain: H2497-11, Cell culture incubation 5d; (A2) NT50 PROBIT of the tested IgG-
preparations on ARPE-19 cells after TAN-peptide antibody depletion; (B1) In vitro NT assay (HCMV-IgG 
normalization), SWS-peptide antibody depletion, Target cells: HFF, HCMV strain: H2497-11, Cell culture 
incubation 5d; (B2) NT50 PROBIT analysis of the tested IgG-preparations on ARPE-19 cells after SWS-
peptide antibody depletion (Modified after Schampera et al., 2018) 
TAN-peptide 
HCMV strain: H2497-11 
Target cells: ARPE-19  
SWS-peptide 
HCMV strain: H2497-11 
Target cells: ARPE-19  
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In general, Cytotect® and Kiovig® showed comparable in vitro neutralization capacities, 
compared to the HCMV-IgG+pool after IgG normalization in both NT assays (Fig.45A1B1). 
These results matched with previous investigations, analyzing the impact of HCMV IgG 
normalization on neutralization capacities in different IgG preparations. In contrast to the first 
depletion experiments, using the TAN peptide with IgG stock solutions, a statistically significant 
difference in NC reduction was observed between the native and depleted samples in 
Cytotect® (p=0.02) and HCMV-IgG+pool (p= 0.01) (Fig.42A2) which was not found via SWS-
peptide for HCMV-specific IgG depletion Cytotect® (p=0.11) and HCMV-IgG+pool (p= 0.13) 
(Fig.45B2). The reduction of NC was not significant for Kiovig® in both approaches. However, 
the data showed a non-significant trend forward decrease of NC after IgG depletion for the 
SWS-peptide. In comparison, the maximal reduction of resulting in vitro NC was about 15% for 
both analyzed UL130 peptides at a sample dilution of 1:1000 or 41.2 mPEI U/ml. 
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In following experiments, HCMV-specific antibodies were depleted from Cytotect® under the 
usage of a recombinant pentameric complex at a concentration of 0.01mg/ml and the 
established depletion concept. The PC (gH/gL-UL128L) contains an increased amount of 
potential neutralizing-involved and epitopes which are also non-linear in comparison to the 
analyzed UL130 peptides. The NT assays were performed on ARPE-19 cells and HFF with 
IgG stock solution of Cytotect®. The HCMV-IgG+pool was depleted as control reference.  
The results of the NT assay with native and depleted samples, resulting in differences in in 
vitro NT-capacity are given in figure 46. 
 
Figure 46: (A1) In vitro NT assay (HCMV-IgG stock solutions), PC antibody depletion, Target cells: ARPE-
19 cells , HCMV strain: H2497-11, Cell culture incubation 5d; (A2) NT50 PROBIT analysis of the tested IgG-
preparations on ARPE-19 cells after PC antibody depletion; (B1) In vitro NT assay (HCMV-IgG stock 
solutions), PC antibody depletion, Target cells: HFF, HCMV strain: H2497-11, Cell culture incubation 5d; 
(B2) NT50 PROBIT analysis of the tested IgG-preparations on ARPE-19 cells after PC antibody depletion 
(Modified after Schampera et al., 2018) 
The results showed a significant difference in the reduction in in vitro NT-capacity between 
native and PC-depleted samples for the HCMV-IgG+pool (30%, p= 0.03) at a 1:1000, 
corresponding to 41.2 mPEI U/ml, as well as for the HIG Cytotect® with a difference of 42% 
and a p-value of 0.01 (Fig.46A1/A2). The strongest difference in vitro NT-capacity in Cytotect® 
was determinated at a dilution of 1:5000 which correlated with 30.06 mPEI U/ml. The 
reductions in in vitro NT-capacity were additionally highlighted, using yellow marks (Fig46A1). 
For HFF, the usage of PC to deplete HCMV-specific antibodies from Cytotect® and the HCMV-
IgG+pool had no noticeable effect on reduction of HCMV-related NT-capacity (p>0.05; 
0.68/0.87) (Fig46B1/B2).  
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It can be highlighted that the PC-related antibody depletion reached a 2- to 3-fold higher 
reduction in NT-capacity against HCMV than the approach using single UL130 peptides 
(TAN/SWS) in ARPE-19 cells. 
The PC-depleted samples were additionally compared to the native stock solutions in the 
ELCIA HCMV test system® of Roche. Interestingly, the ECLIA was not able to detect 
differences in HCMV-specific IgG (Tab.21). 
Table 21: ELCIA HCMV® Roche analysis; Comparison of 
PC-depleted samples to native samples of Cytotect® 
(1:15) and HCMV-IgG+pool (1:5). 
ECLIA HCMV® Roche [U/ml] 
HCMV-IgG+pool (native) 105 
HCMV-IgG+pool (depleted) 99.4 
Cytotect® (native) 312.3 
Cytotect® (depleted) 322.8 
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3.5 Depletion of HCMV hyperimmunoglobulin IgG subclass 3 from Cytotect® 
and analysis of its functional activity 
In the last antibody depletion experiments, the impact of IgG subclass 3 antibodies on the NT-
capacity against HCMV was analyzed using a modified depletion strategy. IgG 3 antibodies 
were removed from stock solutions of Cytotect® and Kiovig® via anti-IgG 3 antibodies and 
magnetic bead separation. The results and the statistical analysis of the NT assays are shown 
in the figure 47. 
 
Figure 47: (A1) In vitro NT assay (HCMV-IgG stock solutions), IgG3 depletion, Target cells: ARPE-19 cells, 
HCMV strain: H2497-11, Cell culture incubation 5d; (A2) NT50 PROBIT analysis of the tested IgG-
preparations on ARPE-19; (B1) In vitro NT assay (HCMV-IgG stock solutions), IgG3 depletion, Target cells: 
HFF, HCMV strain: H2497-11, Cell culture incubation 5d; (B2) NT50 PROBIT analysis of the tested IgG-
preparations on ARPE-19 cells after PC antibody depletion (Modified after Schampera et al., 2018) 
After the IgG subclass 3 depletion, no significant differences in reduction of NT-capacity were 
found between native and depleted samples of the IVIG Kiovig®, HIG Cytotect® and the 
HCMV-IgG+pool (all p-values were >0.05 ≙ ns (not significant)). These results were confirmed 
on ARPE-19 cells as well as on HFF. The depletion of the IgG subclass 3 had no impact on 
the in vitro neutralization activity of Kiovig® and Cytotect® under the chosen depletion concept 
via magnetic bead separation. 
  
IgG3 depletion 
HCMV strain:  
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3.6 Modulation of the T cell response by HCMV hyperimmunoglobulin 
In the second part of this study, the immunomodulatory effects of repeatedly given HIG 
administrations on the cellular immune response were analyzed in pregnant women with a 
proven HCMV-primary infection in the first trimenon of pregnancy. These women were 
included in the cohort as part of the Tuebingen HIG study (Kagan et al., 2018). LiHep-Blood 
samples were longitudinally taken from women before and after HIG treatment, who achieved 
Cytotect® in a biweekly interval until gestational age of 21 weeks. The secretion of IFN-γ via 
stimulated PBMCs or whole blood was determined with two different detection systems. The 
collected blood samples were processed and analyzed via the QuantiFERON CMV® from 
Qiagen and the EliSPOT CMV® assay from Lophius, according to their derived process 
protocols.  
Table 22: Data overview of HIG-treated pregnant women, included in this study. The mothers were sorted 
on the number of administrated HIG applications 
No ID HIG applications Age GA Gravida/Para 
HCMV Non-transmitter 32±4 10.5±2.3  
1 ZeJe 3 29 13.3 G3P1 
2 BrBa 3 29 14.6 G1P0 
3 IbKa 3 32 14.3 G4P2 
4 StRe 4 36 9.5 G5P1 
5 AlDa 5 33 9.5 G2P1 
6 YuNi 5 35 9.4 G2P1 
7 ScSa 6 26 8.2 G1P0 
8 RaCa 6 31 8.5 G2P1 
HCMV Transmitter    
9 HaSa 5 41 8.6 G5P1 
 
Table 22 shows an overview of HIG-treated pregnant women, who were included and analyzed 
in this part of the study. The women achieved different numbers of HIG applications, depending 
on the time point of enrollment into the Tuebingen HIG study and the time range of GA= 21 
weeks until the therapy was stopped and amniocentesis was performed.  
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Mother 1 was investigated with both HCMV-specific IFN-γ detection systems. In this selected 
case, the first 2 weeks were longitudinally analyzed, using narrow time points for blood 
collection (day of treatment (DOT) = 0, 2, 4, 7, 9, 11, 14) to analyze kinetics of IFN-γ production 
and validate the results between the first and second HIG application. 
 
Figure 48: Kinetics of HCMV-IgG and IFN-γ production, induced by HIG administration; (A) Mother 1: 
QuantiFERON CMV® (blue) compared to HCMV IgG ECLIA® (black); (B) Mother 1: Results of the T-Track 
EliSPOT CMV® (red), compared to HCMV IgG ECLIA® (black); (C) Visualization of T-Track HCMV® IFN-γ 
rPBMCs in microtiter plate with controls and sample 
The HCMV-specific IgG was visualized as black-dashed line which, showed a recurring 
increase after each HIG applilication. After the first intravenous HIG administration of 
Cytotect®, the HCMV-specific IgG increased from a baseline of ~10 U/ml to a peak level of 
~290 U/ml, using the HCMV ECLIA® assay after 2h, followed by a constant drop to the second 
HIG application on day 14 (Fig.48AB). 
Mother 1 
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The results of the QuantiFERON CMV® showed an increased baseline of IFN-γ concentration 
at the beginning of the first HIG administration, compared to the T-Track HCMV® EliSPOT 
(Fig.48A/B). Both tests had a peak on day 7. The level of IFN-γ shortly decreased thereafter 
until day 14 and showed a repeated increase after the second HIG application and lasted to 
the third HIG dose on day 28 until the concentration of IFN-γ dropped again. In contrast, the 
number of IFN-γ reactive PBMCs7 which were messured with the T-Track HCMV® EliSPOT 
showed a comparable kinetic pattern to the IFN-γ concentration of the QuantiFERON HCMV®, 
except for the proportional lower number IFN-γ rPBMCs at the start point of HIG treatment 
than the relative high concentration of IFN-γ (Fig.48B). In addition, the following reduction of 
IFN-γ level was stronger than the number of corresponding IFN-γ producing PBMCs until day 
14. The fluctuation in IFN-γ reactive PBMCs was illustrated in figure 48C, showing an image 
of the T-Track EliSPOT sample wells (blue) with controls (red and green). 
  
                                               
7 Peripheral blood mononuclear cells 
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The IFN-γ results of mother 2, 3 and 4 were summarized in figure 46. The second and third 
woman achieved three applications of HIG like the first investigated women and the fourth 
woman got four doses of Cytotect® every 14 days. 
 
Figure 49: Kinetics of HCMV-IgG and IFN-γ production, induced by HIG administration (A1/B1/C1) Mother 
2/3/4: QuantiFERON CMV® (blue) compared to HCMV IgG ECLIA® (black); (A2/B2/C2) Mother 2/3/4: T-Track 
EliSPOT CMV® (red) compared to HCMV IgG ECLIA® (black) 
In a first comparison to mother 1, the second and third woman revealed similar kinetic patterns 
of IFN-γ and IFN-γ reactive PBMCs (Fig.49A1/A2–B1/B2). However, differences were found 
in mother 4 (Fig.49C1/C2). The fourth woman had only one major IFN-γ related peak at the 
time point of the second HIG application.  
Mother 2 
Mother 3 
Mother 4 
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The IFN-γ levels and the number of IFN-γ reactive cells constantly decreased, except for day 
35 which formed a short-lasting plateau in the T-Track HCMV® EliSPOT, but showed slower 
decreasing IFN-γ levels in QuantiFERON HCMV®.  
The fourth application to mother 4 seemed to have no further impact on IFN-γ secretion at all. 
In a general consideration, both IFN-γ based detection systems showed comparable results 
and confirmed the observation, taken from mother 1. 
In the next data set of IFN-γ results, the mothers 5 and 6 were combined and presented in 
figure 50. Both women were treated with fifth HIG administrations until the last application on 
day 56. 
 
Figure 50: Kinetics of HCMV-IgG and IFN-γ production, induced by HIG administration (A1/B1) Mother 5/6: 
QuantiFERON CMV® (blue) compared to HCMV IgG ECLIA® (black); (A2, B2) Mother 5, 6: T-Track EliSPOT 
CMV® (red) compared to HCMV IgG ECLIA® (black) 
For mother 5, it was possible to perform the same IFN-γ kinetics between the first and second 
HIG administration like in the selected case of mother 1 (Fig.50A1/A2). The proportional course 
of IFN-γ reactive PBMCs and the concentration of produced IFN-γ were similar to the 
investigated women in both IFN-γ detection systems. Interestingly, the fourth and fifth HIG 
application induced no further IFN-γ secretion which confirmed results of mother 4. 
Mother 5 
Mother 6 
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In contrast, three peaks of IFN in both tests were detected during HIG treatment of mother 6 
on day 7, 21 and 35 (Fig.50B1/B2). However, the fourth and fifth HIG application also showed 
no re-stimulation of IFN-γ activity like in mother 4 and 5. 
In a next analysis, Mother 7 and 8 got six doses of Cytotect® until 70th dot every 14 days. 
 
Figure 51: Kinetics of HCMV-IgG and IFN-γ production, induced by HIG administration; (A1/B1) Mother 7/8: 
QuantiFERON CMV® (blue) compared to HCMV IgG ECLIA® (black); (A2/B2) Mother 7/8: T-Track EliSPOT 
CMV® (red) compared to HCMV IgG ECLIA® (black) 
Mother 7 and 8 showed comparable kinetic patterns in the QuantiFERON CMV® 
(Fig.51A1/B1), compared to the results of T-Track EliSPOT CMV® of both mothers 
(Fig.51A2/B2). In both women, the number of IFN-γ reactive PBMCs and resulting IFN-γ 
concentrations reached their first peak on day 7 which was observed in the most HIG-treated 
mothers, followed by a decrease and a second longer-lasting increase of IFN-γ levels and IFN-
γ reactive cells in both detection systems. In summary, both women had three peaks during 
the treatment with HIG and the investigations revealed that more than 3 to 4 applications of 
Cytotect® resulted in no recurring IFN-γ stimulations in almost all mothers. 
  
Mother 7 
Mother 8 
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In context of HCMV-specific IgG, cumulative effects were noticed in all treated women, 
considering the rising baseline from the first HIG application to the last HIG application. In the 
exceptional case of mother 8, the woman reached the steady state for HCMV-specific IgG 
almost after the first HIG administration and only a small increase was observed during further 
HIG treatment. 
In the last case, the analysis of a 41 years old woman is described, who was the oldest woman 
in this collective and the only HCMV-transmitter to the fetus which resulted in an 
asymptomatically HCMV-infected newborn. The results of mother 9 were given in the figure 
52.  
 
Figure 52: Kinetics of HCMV-IgG and IFN-γ production, induced by HIG administration (A) Mother 9: 
QuantiFERON CMV® (blue) compared to HCMV IgG ECLIA® (black); (B) Mother 9: T-Track EliSPOT CMV® 
(red) compared to HCMV IgG ECLIA® (black); (C) Visualization of T-Track HCMV® IFN-γ rPBMCs in 
microtiter plate with controls and sample 
It has to be noticed, that the kinetic courses of IFN-γ concentration and the number of IFN-γ 
reactive PBMCs of maternofetal HCMV-transmitter strongly differed from all other investigated 
women in this cohort (Fig.52A/B).  
Mother 9 
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The woman possessed already high levels of IFN-γ and a high number of IFN-γ producing 
cells at the beginning of the HIG treatment which decreased after HIG1. Then, an increase of 
IFN-γ activity was detectable which surpassed the number of IFN-γ rPBMCs of the T-Track 
EliSPOT CMV® at starting point, but not the IFN-γ concentration. The QuantiFERON CMV® 
was already at its peak level at the start of the investigation (QUANTImax = 100 IU/ml). After its 
peak, a constant decrease was observed in both IFN-γ detection assays, independent of the 
following three HIG administrations until day 63. For visualization of T-Track EliSPOT CMV®, 
figure 52C illustrated the analyzed wells of the blood samples (blue) plus controls (green/red). 
Single spots were shown in this figure which represented the countable IFN-γ reactive PBMCs 
from a high count on HIG1 to constantly dropping numbers of these cells until HIG5. In addition, 
there was a slight deviation of HCMV-IgG concentration during the fourth and fifth HIG 
application. 
In a further overall comparison, the collected kinetic IFN-y data of QuantiFERON CMV® and 
T-Track EliSPOT CMV®, as well as the detected HCMV-specific IgG ECLIA CMV® were 
summarized by box plots of all investigated HCMV Non-transmitter during the first three HIG 
applications (Fig.53). An estimated average course was calculated for each analyzed blood 
parameter. During the HIG treatment of the HCMV primary infected women, there were 
fluctuations detectable in concentrations of IFN-γ between each individually investigated 
mother, mainly caused be single outliers.  
However, in average, there was a clear proportional increase of the mean of IFN-γ 
concentration after the first and second HIG application in the most treated mother. The 
estimated course of means of IFN-γ reactive PMBLs reflected the observation of the means of 
IFN-γ concentrations.  
In contrast, there were fewer single outliers in the T-Track EliSPOT CMV® than in the 
QuantiFERON HCMV®. Furthermore, the numbers of IFN-γ reactive PMBLs were more stable 
and underlay fewer fluctuations during HIG treatment than the detected IFN-γ concentrations. 
For the HCMV-specific IgG, two samples were collected during each HIG applications on the 
same day. The first sample was taken 15 min before the administration of Cytotect® and the 
second sample was harvested 2 h after each woman achieved the HIG dose. In average, the 
means of HCMV-specific IgG showed a repeated rise after each HIG application and the 
described cumulative effect of HCMV-specific IgG enrichment was already noticed after the 
first three HIG applications in the investigated women. Comparing IFN-γ data and HCMV-
specific IgG, the IFN-γ reactive cells responded with a delay in producing IFN-γ after the first 
HIG administration and further applications of Cytotect® were needed to maintain the 
production of IFN-γ in most cases. The analyzed IFN-γ related parameters were not affected 
by later HIG applications. 
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Figure 53: Longitudinal monitoring of all HCMV Non-Transmitters during the initial 3 HIG applications: (A) 
Estimated average course of IFN-γ concentration (blue); (B) Estimated average course of IFN-γ reactive 
PBMCs (red); (C) Estimated average course of HCMV-specific IgG (black) 
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4 Discussion 
4.1 Standardization of HCMV neutralization assay and assay performance 
characteristics 
The investigated scientific issues in this work were based on discordant results of Nigro et al., 
2005 and Revello et al., 2014, as well as on a currently published paper of Kagan et al., 2018. 
The studies of Nigro and Revello used the same study design in order to analyze the impact 
of HIG treatment on HCMV primary infected women during pregnancy. While the first study of 
Nigro achieved a success in therapy of HCMV infection as well as in prevention of HCMV 
transmission to the fetus under the usage of HIG, the RCT study of Revello did not find a 
significant difference between the placebo and the investigated prevention group. In a later 
formulated consensus review, no general recommendation was given for the treatment of 
HCMV primary infected pregnant women with hyperimmunoglobulins outside of clinical trials 
(Rawlinson et al., 2017). However, both studies revealed a trend towards reduction of HCMV 
transmission to the fetus in the HIG-treated group (Fig.54). Furthermore, currently available 
results of the Kagan study demonstrated a clear causal relation between a shorter interval of 
HIG applications and the prevention of maternofetal HCMV transmission under strict virologic 
inclusion parameters for the pregnant women with HCMV-primary infection in the first 
trimenon. 
 
Figure 54: Results of the Tuebingen HIG study (Kagan et al., 2018) 
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The study of Kagan et al. had one viral transmission from mother to fetus in 40 cases (2.5%) 
in the prevention group, compared to the historic cohort with 35.2%. This result represented a 
significant difference between both groups (p<0.0001). The study showed, that HCMV-IgG 
treatment of pregnant women with HCMV primary infection in the first trimenon of pregnancy 
could decrease the maternofetal transmission rate, compared to HIG untreated pregnant 
women. Therefore, the work of Kagan et al., demonstrated a promising treatment option for a 
defined cohort of HCMV-primary infected mothers during early gestation (<week 14). However, 
the improved study design, including a narrow HIG application interval and enrollment of pre-
selected mothers has to be proven in further controlled studies to evaluate the results of the 
Kagan study and to confirm the collected data. Considering kinetics of HCMV-specific IgG, 
cumulative effects were noticed in all HIG-treated pregnant women, referring to the increasing 
baseline between the first to the last HIG application. A shorter HIG application interval of two 
weeks was applied in the Kagan study than in the studies of Nigro and Revello. An incorrect 
half-life time (t1/2) of IgG antibodies was assumed in both studies which was based on studies 
of Thurmann et al., 1995. The shorter HIG application interval indicates, that the HCMV-
specific IgG was not completely eliminated by the mothers or spent for viral neutralization 
between the HIG doses. Additionally, the study of Revello reported signs of an increased rate 
of prematurity after HIG application to pregnant mothers. However, a recent paper contradicts 
with Revello and showed no evidence of obstetrical adverse events after HIG treatment to 
those mothers (Chiaie et al., 2018). 
In order to characterize the used HIG preparation Cytotect® in the Kagan study and to 
understand the possible mode of action of administrated IgG-antibodies, further investigations 
were made in the presented PhD thesis. For the first analysis of NT-capacity of IgG 
preparations, in vitro plaque reduction assays were modified after a previous publication of 
Schampera et al., 2017 which based on NT protocols of Eggers et al., 2000 and Abai et al., 
2007. The NT protocol was additionally adapted, depending on the respectively scientific 
investigation (Point 1.15).  
For calibration, two serum pools were used as reference controls to define the reference 
conditions of the in vitro NT assay. Each serum pool contained sera of 100 women, who were 
either HCMV-seronegative or HCMV-latently infected at birth, measured concordantly with five 
different HCMV serological test systems. The NT reference pools represented two different 
cohorts of mothers at birth and were derived from the Tubingen congenital HCMV study. Two 
HIG preparations, Cytotect® and Cytogam®, as well as two standard immunoglobulins, 
Kiovig® and Octagam® were characterized via defined sample dilutions in the established 
PRA. On the base of the analyzed in vitro neutralization capacities, the corresponding NT50-
values were calculated and compared, using statistical programs for significance proofing 
(Wilcoxon rank sum test for equality on unmatched data) (Fig.33).   
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The first obtained results showed consistently higher in vitro NT-capacities in HIGs than in 
IVIGs. The HCMV-IgG+pool possessed the lowest NT-capacity. While the in vitro NT-capacities 
of HIGs were comparable, differences were found between the analyzed IVIGs. Octagam® 
showed generally higher NT50-values than Kiovig®. It might be suggested that Cytogam® could 
be used as alternative product to Cytotect® in the United States under the previously given 
permission of the American food and drug administration (FDA). On the base of the presented 
in vitro results, the administration of Cytogam® may result in prognostically comparable 
successes in therapy and prevention of maternofetal HCMV transmission, using the same 
study design of Kagan et al, 2018. The application of Kiovig® also increased the NT-titer 
against HCMV in pregnant women with a HCMV-primary infection, according to a study of 
Polilli et al., 2012. This result matched with the data in this study, that Kiovig® contained high 
HCMV-specific neutralization titer. The observation of higher NT50 values in HIGs than IVIGs 
were found on both epithelial cells, as well as on human foreskin fibroblasts as target cells for 
viral infection via HCMV. But, IgG antibodies, directed against HCMV showed higher protective 
potential, combined general higher NT-titers to prevent viral infection and cell-to-cell spread in 
ARPE-19 cells than in HFF. The results of a former study confirmed these observations on 
different cell types (Fouts et al., 2012). 
 
Figure 55: Percentage of infected cells (normalized) under the usage of HIG on 4 cell types. Cytogam® was 
incubated with the low-passage clinical HCMV strain VR1814 (Fouts et al., 2012) 
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HCMV possesses two different mechanism of entry into different cells types. During a viral 
infection, HCMV uses gH/gL/gO to infect fibroblasts and the entry into epithelial and endothelial 
cells is mainly mediated via the pentameric complex (gH/gL-UL128L) (Adler et al., 2006; 
Vanarsdall et a.,2011; Hahn et al., 2004; Gerna et al., 2005; Wang et al., 2005; Sinzger et al., 
2006).  
In conclusion, different epitope-specific IgG antibodies are responsible for strong binding and 
effective neutralization in different target cells. In the study of Fouts et al., the HIG Cytogam® 
was incubated with low-passage clinical HCMV strain (VR1814) on four different cell types for 
18h. The results confirmed comparable EC50 and EC90 values for epithelial and endothelial 
cells, as wells for macrophages. However, >100-fold higher concentration of Cytogam® was 
needed to bind and neutralize HCMV on fetal lung fibroblasts (MRC-5) as target cells (red line) 
(Fig.55). The results of the PC depletion experiments in the presented PhD thesis confirm the 
data of Fouts, because the depletion of PC-specific antibodies had no impact on HFF (Fig.46). 
In another work of Cui et al., 2008, the impact on induced in vitro NT-activity through HCMV-
specific antibodies was investigated using Cytogam® and Cytotect®, as well as sera from 
donors, who achieved a vaccination with recombinant gB/MF59 subunit or an attenuated 
equivalent of the Towne virus strain as. The samples were analyzed on MRC-5 fibroblasts and 
ARPE-19 cells (Fig.56). 
 
Figure 56: Neutralizing activity of HIGs (Cytotect®▴, Cytogam®■) versus vaccination (gB/MF59; Towne), 
descripted as IC50 titers on fibroblasts (F) and epithelial cells (E) (Cui et al., 2008) 
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The results revealed a 48-fold increased NT-activity in epithelial cells than in fibroblasts which 
indicated that the humoral immune control of natural HMCV infections is mainly promoted by 
epithelial-specific neutralizing antibodies against the pentameric complex (Fig.56). In this 
context, both vaccines failed to induce HCMV-specific neutralizing antibodies which generated 
on average a 28-fold (Towne) and a 15-fold (gB/MF59) lower neutralization activity in 
comparison to HIGs on ARPE-19 cells. These results suggested that the effectivity of 
vaccination against HCMV may be improved by vaccines, based on the viral pentameric 
complex in the future. The UL130 peptide and PC depletion experiments in this work support 
this suggestion. A significant part of in vitro NT-capacity was reduced after PC-specific 
antibodies were removed from HIG (Fig.46). 
The negative and positive control were represented by a cohort of randomized blood donors 
without HCMV infection and a cohort of randomized blood donors, who were HCMV-latently 
infected after a natural infection. The results of Ciu showed additionally a comparable NT-
capacity between Cytotect® and Cytogam® on both cell types which confirmed the data in this 
thesis and a previous work of Frenzel et al., 2012 which suggested, that HCMV-specific 
infection rates and corresponding neutralization depend on the cell type.  
A current paper published in vitro NT data, comparing Cytotect® and Cytogam® to 2 different 
IVIG preparations (Vena® and Flebogamma®) (Germer et al., 2017).  
 
Figure 57: Neutralization titers of HIG preparations Cytotect®/Cytogam® and IVIG preparations 1 and 2 
(Germer et al., 2017). 
The data support both suppositions of this work, that the NT capacity of Cytotect® and 
Cytogam® are comparable and show higher neutralizing titers than IVIGs (Vena® and 
Flebogamma®) (Fig.57). The IgG of the products values were expressed using PEI Units/ml. 
Interestingly, the estimated PEI values of Cytotect® (101.8 PEI U/ml) and Cytogam® (112.5 
PEI U/ml) were comparable to the PEI values, calculated in this work (Tab.19 and Fig.31).  
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The results of another paper confirmed, that HIGs contain higher concentrations of HCMV-
specific IgG which also results in higher neutralizing antibodies than IVIGs (Fig.58) (Miescher 
et al., 2015) 
 
Figure 58: (A) HCMV-specific IgG, detected by ELISA in PEI U/g IgG for HIGs and IVIGs; (B) Resulting NT 
activities of HIGs and IVIGs, expressed as PEI U/g IgG (modified after Miescher et al., 2015) 
The HIG preparations Cytotect® (CMVIG CT) and Cytogam® (CMV CG), as well as the IVIGs 
Privigen® (P), Kiovig® and Gammagrad® (K/G) were analyzed in this study, using IgG stock 
solutions. However, their results were only examined on fibroblasts.  
Miescher et al., 2015 strongly contrasts to Planitzer et al., 2011 and postulated higher IgG 
subclass 3 concentration in Cytogam® than Kiovig®, paired with slightly higher NT-capacities 
for Cytogam® than Cytotect®. The mentioned observations were not confirmed by own 
investigations (Schampera et al., 2017). It has to be considered, that both studies of Miescher 
and Germer were funded by the manufactures of the HIGs Cytotect® (Germer et al., 2017; 
Miescher et al., 2015). 
On the base of PEI Units, HCMV-specific IgG normalization was used to analyze the in vitro 
NT-capacity per PEI Unit for each IgG preparation in a following NT experiment (Fig.37). The 
IgG preparations were quantified for the ECLIA HCMV® Roche and a generated standard 
curve with a high correlation coefficient (R2=0.99). This allowed an excellent transformation of 
ECLIA® HCMV-IgG into to PEI Units (Fig.30). The results revealed no significant differences 
in the HCMV-specific neutralization activity on APRE-19 cells and HFF. It suggested for all 
investigated preparations that the same amount HCMV-specific IgG possess the same quality 
in terms of neutralization activity per PEI Unit and only the concentration HCMV-specific IgG 
might be important to prevent HCMV infection and maternofetal transmission. Furthermore, 
the PEI units and the corresponding NT-capacity showed an approximated-linearized course 
in the established NT assay after a log10 adaption (Fig.37). The findings were contradictory to 
the data of Planitzer et al., 2011 (Fig.34/35). The authors postulated higher IgG3 
concentrations in Kiovig® than Cytotect® which resulted also in higher in vitro NT-activity in 
Kiovig® than in Cytotect® during their investigations.   
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In contrast, the results in the presented work showed consistently significantly higher NT-
capacities for Cytotect® than Kiovig® which was independent, considering IgG3 
concentrations. The impact of IgG 3 antibodies on NT-capacity point will be further discussed 
in detail on the point 4.5.  
In a next attempt, the TB40E variant (RV-TB40-BACKL7-SE-EGFP) was used to modify the 
PRA protocol to provide an alternative read out system via an intracellular-expressed eGF-
protein instead of p72 staining (Fig.38) (Sinziger et al., 2008; Sampaio et al., 2017). The 
experiment was successful on HFF with more than 100 PFUs/well and showed comparable 
NT data to the H2497-11 strain for all IgG preparations. Sample images of TB40E-plaque 
formation in microculture were given in figure 39.  
Unfortunately, the TB40E strain was not able to induce sufficient numbers of evaluable TB40E-
PFUs in ARPE-19 cells. Repeated propagation of TB40E in ARPE-19 cells, following by 
generation of multiple viral stocks at different stages did not lead to valid results in the in vitro 
PRA. Therefore, the H2497 strain was used for further investigations. 
Interestingly, multiple single infected cells were detectable (Fig.40). However, it might be 
suggested that either the viral cell-to cell spread in ARPE-19 cells is much slower than in HFF 
or the IgG preparations prevented the viral cell-to-cell spread in a more efficient way. The 
TB40E was investigated to offer an alternative readout system in contrast to p72 staining. 
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A previously published paper of Wang et al., 2017 considered the variations of NT-capacities 
between different Lots of one HIG and eight IVIG preparations using the TB40E and AD169 
strain. Firstly, an ELISA was examined to determinate their binding activities and avidity 
(Tab.23)  
Table 23: Variations in Lots of HIG (A) and IVIG products (B –I), considering anti-HCMV binding activity 
and avidity index in comparison to the PEI reference standard 1996 (modified after Wang et al., 2017) 
 
Lots of the same IgG product revealed comparable stable in NT-testing which indicates 
comparable concentrations of HCMV-specific IgG over multiple charges. The HIG showed the 
10- to 20-fold higher HCMV-binding activity (Ø: 3285 ± 501 PEI U/g IgG) than the IVIG 
preparations (Ø: 437.5 ± 153.9 PEI U/g IgG) in all three Lots. However, the avidity was high in 
both the HIGs (Ø: 84.9 ± 2.7%) as well as in the IVIGs (Ø: 68.5 ± 3.2%).  
While it was repeatedly shown, that HCMV-specific antibodies interact with a huge amount of 
HCMV proteins, binding of viral components does not necessarily result in viral neutralization 
(Britt et al., 1996 and Schoppel et al., 1997). The NT-capacity was subsequently analyzed via 
an RT-qPCR-based neutralization assays using PEI units for normalization (Wang et al., 
2017). Therefore, the infected cells were lysed after viral inoculation for 6 h to 24 h, analyzing 
the transcript of the IE1 gene UL123 in a following RT-qPCR to make conclusions about the 
genome copy numbers of the virus and corresponding neutralization activity of the IgG 
products (Fig.59).   
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The experiments were performed to compare the NT capacities against TB40E-GFP strain to 
AD169wt131 strain with a restored pentameric complex under the usage of several HIG and IVIG 
preparations. ARPE-19 cells and MRC-5 fibroblasts were used as target cells. 
Usually, the high-passaged AD169 strain lost its ability to infect epithelial cells in cell culture 
through mutations in the UL131 gene which results in a non-functional pentameric complex, 
essential for the epithelial entry process. 
 
Figure 59: Comparison of NT activity of HIG and IVIG preparations against the HCMV strains AD169wt131 and 
TB40E-GFP on ARPE-19 (A) and MRC-5 cells (B) (modified after Wang et al., 2017) 
A correlation was found in the HCMV-specific neutralization activities of IgG products between 
the HCMV strains AD169wt131 and TB40E-GFP in ARPE-19 cells and HFF. Each dot 
represented an analyzed Lot of different or the same IgG preparations. These results 
confirmed the data of in vitro NT-capacities in the HCMV strains H2479-11 and TB40E variant 
(RV-TB40-BACKL7-SE-EGFP) in this PhD thesis.  
In addition, the RT-qPCR neutralization assay system was suitable to detect the NT-capacities, 
using the TB40E-GFP strain on APRE-19 cells which was not possible in this PhD thesis 
(Fig.40). This might be caused by a different read out system, compared to the established 
plaque reduction protocol which induced insufficient PFUs for TB40E in ARPE-19 cells to 
deliver valid test results. 
Furthermore, variations were found in the viral stocks from vial to vial in this work, caused by 
freeze-thaw durability and resulted in different total numbers of HCMV-induced PFUs in the 
HCMV-IgG negative pool and in the analyzed IgG preparations. This phenomenon promoted 
different results, using different vials of the same viral stock and made a direct comparison of 
PFU numbers impossible between single performed experiments (Fig.35).   
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The viral isolates were frozen in 100 µL aliquots. It was observed, that variations were 
recognized within a box of the same viral isolate. Especially, greater variations occurred 
between edge-placed vials and vials, localized in the center of the box (up to ~15%). The 
freezing process took place at -80°C from the edges to the center of the boxes which could be 
an explanation for the differences of infectivity. However, the appearance of described effect 
was discovered early during this thesis and was reduced by preparing of a mixture of several 
vials before each NT experiment and the usage of the relative NT capacity in percentage 
instead of total HCMV-PFU numbers. 
4.2 Cytotect® neutralization activity against HCMV isolates, resistant to 
antiviral compounds 
The established in vitro PRA assay protocol was used to investigate the potential of Cytotect® 
to neutralize wildtype HCMV strains which were drug-resistant against GCV or/and CDV. It 
was clarified, whether the acquirement of a drug-resistance has an impact on the in vitro NT-
capacity of IgG products, containing HCMV-neutralizing antibodies. The NT assays and the 
following statistical analysis via JMP software revealed no significant differences between the 
drug-resistant HCMV strains and a drug-sensitive strain (H2497-11) in relation to their 
infectivity in presence of defined concentrations of IgG preparations. The results of the 
experiments suggested, that the in vitro NT capacity of Cytotect® and other analyzed IgG 
preparations seemed to be not affected by drug-resistant HCMV strains against GCV and/or 
CDV under the selected parameters of the PRA assay protocol. For the interpretation of the 
collected NT data, the neutralization capacities of the analyzed IgG preparations showed 
general high potency to prevent viral infection and cell-to cell spread, independent of the wild 
type of HCMV. Due to the fact, that especially HIGs contain high numbers of different 
neutralizing antibodies against many relevant epitopes of HCMV which are important for 
successful infection and virus production. Furthermore, the mode of action and the involvement 
of defined target gene products differ between antibodies and anti-viral drugs.  
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4.3 Characterization of Cytotect® neutralization activities against HCMV 
isolates with different gB-genotypes 
Further investigation of this work analyzed HCMV strains with different gB types in context of 
in vitro neutralization. For this purpose, HCMV strains from different human materials of 
patients with different diagnoses were chosen to increase the number possible genetically 
variations. In addition, the AD169 strain was added as gB2-strain to represent a high-passage 
laboratory-strain in comparison to the other used low-passage clinical isolates, carrying gB1, 
gB3 and gB4. The H487-06 strain (gB4) was isolated from the same patient like the H815-06 
strain which is drug-resistant. 
However, the isolate was collected on a different time point during antiviral treatment, 
possessing the same multidrug resistance against GCV and CDV (UL97 [L595S] UL54 
[V715M]) to evaluate already given results and put the presented results in context of these 
considered data. According to the results, Cytotect® and other IgG products are able to 
neutralize HCMV strains with different glycoprotein B genotypes at the same level of 
neutralization capacity. Therefore, the gB genotype seems not to be associated with a 
reduction or increase of HCMV-specific IgG NT capacity.  
These results confirmed former data in this study which showed no difference in NT activity 
between drug-resistant and drug sensitive HCMV strains. In addition to the already given 
interpretation, the polyclonal neutralizing antibodies of Cytotect® and other IgG preparation 
were harvested from different donors which were infected with different HCMV variants. These 
variants possess most likely different gB types which could explain the universally high NT-
capacity. 
Interestingly, AD169 is a high passage laboratory strain mutant with a multitude of genetically 
modifications during cell culture adaption and propagation, but the infectivity-related genes and 
the expressing protein products for production seems to be highly conserved over all strains, 
resulting in comparable high NT-capacities of the investigated IgG preparations. However, 
HIGs contain a higher mount of these high-class neutralizing antibodies than IVIGs.  
The biochemical analysis of the used IgG-preparations was previously described in the work 
of Schampera et al., 2017. In a summary, the results confirmed, that HIGs have a higher 
neutralizing potential against HCMV, compared to IVIGs. But HIGs contain lower 
concentrations of total IgG than IVIGs at stock solutions.  
In addition, the results indicate that IgG antibodies need 100-fold higher concentrations to 
prevent viral cell-to-cell spread in cell cultures in comparison to cell-free virus infection (Murrell 
et al., 2017). 
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Murrell intensively investigated this phenomenon in different viral strains of HCMV (TB40 BACs 
and Merlin-GFP variants) and showed clearly, that viral cell-to-cell spread is more efficient than 
cell-free infection. Furthermore, the IC50 values for the strains were similar under the usage of 
Cytotect® and HCMV-seropositive serum samples.  
This observation agrees with results in this thesis, analyzing the NT-capacity of Cytotect® and 
other IgG preparations against different laboratory strains and clinical isolates. The lower 
consumption of IgG preparations for analysis of cell-free in vitro HCMV infection was one of 
the main reasons for the modification of the previous NT assay protocols (CFNT versus 
PRANT), described in Schampera et al., 2017 to establish a combined PRA protocol which 
covers both the cell-free viral infection, as well as the in vitro cell-to-cell spread of HCMV. 
4.4 Role of PC-specific antibodies in IgG preparations 
The viral trimer complex (gH/gL/gO) and pentamer complex (gH/gL-UL128L) are the two 
mayor viral glycoprotein complexes for mediating the tropism-dependent cell entry via the 
membrane fusion protein gB (Wang et al., 2005; Ryckman et al., 2008; Lilleri et al., 2013, 
Ciferri et al., 2015). An interesting fact, the gene products of the UL128-131 region and gB 
compete for binding to their common gH/gL subunit which affects the ratio of timer 
complex/pentameric complex on the viral surface and consequently the cell tropism (Zhou et 
al., 2013; Li et al., 2015). 
The first antibody depletions experiments in this work were performed using a modified peptide 
of UL130 after Saccoccio et al., 2011 which induced highly HCMV-specific antibodies in 
rabbits. The TAN-peptide was analyzed via computer software analysis by Jose Arellano-
Galindo (Infectious Diseases Laboratory (Virology) Children’s Hospital Federico Gómez, 
México City, Mexico) and showed an increased probability for antibody binding than the original 
SWS-peptide, as well as optimal physical and chemical properties (Schampera et al., 2018). 
Subsequently, both UL130 peptides were used in a depletion strategy, involving magnetic 
beads. The potential of TAN- and SWS-peptides was analyzed to remove a relevant number 
of HCMV-neutralizing antibodies which are UL130-specific and resulting in decreases of in 
vitro NT-capacity in epithelial cells (ARPE-19). After HCMV-IgG-normalization, the TAN-
peptide reached a maximal decrease of 16% which formed a significant difference in reduction 
of NT-capacity in comparison to the UL130 SWS peptide (Fig.45). 
However, this result was not repeatable, using HIG/IVIG stock solutions (Fig.44). 
Nevertheless, a clear non-significant trend towards NT-reduction was visible in both UL130 
peptides after IgG antibody depletion.  
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It has to be highlighted, that the PC-related depletion of HCMV-specific IgG antibodies 
revealed a much higher effect on NT reduction with 42% at its maximum than single UL130 
peptides, due to a much higher amount of presenting linear and non-linear epitopes via 
secondary and tertiary protein folding (Fig.46). In this context, a work of Magacno et al., 
showed at least two expressed gene regions of UL128 locus are necessary to bind monoclonal 
antibodies which possess a high neutralizing activity against HCMV (Macagno et al., 2010).  
This could be an explanation for the relative low reduction of neutralization capacity for the 
UL130 peptides in comparison to a complete pentameric complex. 
Two papers investigated the impact of PC-specific antibody depletion on the infection rate of 
different HCMV strains, using Cytogam® instead of Cytotect® (Fouts et al., 2012; Loughney 
et al., 2015)  
 
Figure 60: Inhibition of infection after Mock, gB, gH/gL or PC antibody depletion on (A) ARPE-19 cells and 
(B) HFF using Cytogam® (Fouts et al., 2012) 
Using an adenovirus expression system, Fouts generated a membrane-bound pentameric 
complex as wells as gB and a gH/gL subunit from the Merlin strain on the surface of ARPE-19 
cells in order to deplete related antibodies. While 91% of the gB-specific antibodies were 
removed with this strategy, the depletions of gH/gL- and PC-specific antibodies were not as 
efficient as the gB-depletion with 67% and 79%. The IgG-depletion was determined by an 
ELISA. However, the gB-depletion (red) resulted in no remarkable decrease of “inhibition of 
infection (%)” (= identical to neutralization (%)) in following NT assay, using ARPE-19 or 
fibroblasts as target cells (Fig.60AB).  
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Interestingly, the same result was observed after gH/gL-depletion (green) in ARPE-19 cells. 
Only the PC-depletion (blue), involving a complete pentameric complex showed a strong 
reduction (85%) in inhibition of infection in ARPE-19 cells which underlines the connection 
between non-linear and neutralization-dependent epitopes once more. In addition, in HFF, a 
reduction of neutralization was observed using gH/gL subunit which is part of the trimer 
complex gH/gL/gO and responsible for fibroblast entry.  
In summary, gB-specific antibodies revealed no or weak neutralizing potential which could be 
the reason for the failing of the vaccine candidate gB/MF59 (Pass et al., 2009), but it could be 
suggested that UL128-131 region are mainly important for neutralization in epithelial cells and 
a better candidate for vaccine development. The second study of Loughney et al., showed 
similar results to Fouts for the HIG Cytogam® and used a constructed soluble PC and gH/gL 
dimers which were produced in CHO (Chinese Hamster Ovary) cells after transfection with two 
vectors (pGS-gH-gLtwn and pGSUL128-UL-130–131), presenting native epitopes on the base 
of the Merlin strain. The viral proteins were purified via Reversed Phase (RP)-HPLC and their 
conformations were analyzed using in-gel digestion, followed by Nano LC-MS/MS. Afterwards, 
96-well microtiter plates were coated with soluble purified pentameric complex and gH/gL 
dimers for protein-specific IgG depletion of Cytogam®. 
 
Figure 61: (A) Reduction of binding activity after Mock, gH/gL and PC depletion of Cytogam®, measured 
in RFU (Relative Fluorescence Units) (B) Corresponding inhibition of infection in ARPE-19 cells 
(Loughney et al., 2015) 
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The antibody depletion via gH/gL-fragment (blue triangles) induced a reduction in binding 
activity (Fig.61A), but hardly any reduction of neutralization activity (= inhibition (%)) in contrast 
to PC antibody depletion (red squares) (Fig.61B). The maximal noticeable NT reduction was 
76% after PC depletion in Cytogam®. 
The results in this thesis confirm the data of both descripted studies of Fouts and Loughney. 
The depletion via a recombinant PC resulted in higher reduction effects of NT capacity than 
single UL130 peptides. However, the depletion effects, expressed in percentage were lower 
than in both publications.  
The reason might be the different strategies, used to deplete HCMV-related IgG antibodies 
from different HIGs of both publications and this thesis which may have different efficacies to 
remove these antibodies.  
In addition, both publications investigated Cytogam®, while the results in this thesis are gained 
with Cytotect®. It may contain higher numbers of PC-specific antibodies than Cytogam®. The 
next point which must be considered critically, is the test resolution of the established PRA 
protocol which is reflected in the number of sample dilutions (here n= 6) of the investigated 
IgG preparation. The test resolution is limited to the number of wells in a microtiter plate (n= 
96), as well as to the number of examined replica, dilutions steps and respective controls. An 
increased number of sample dilutions or a variation of dilution series may detect the highest 
peak of NT depletion effect for each analyzed IgG product.  
Furthermore, both publications of Fouts and Loughney established own expression systems 
to generate a membrane bound or a soluble pentameric complex on the base of the Merlin 
strain, while the experiments in this thesis were performed with the first commercially available 
PC. It is a recombinant product of the VR1814 strain and generated in human cells (HEK293) 
by The Native Antigen Company, Oxfordshire UK. The different production methods may lead 
to different expressed PCs which may affect their natural conformation and therefore their 
potential to bind and deplete PC-specific neutralizing antibodies from polyclonal sera. 
However, a commercially available pentameric complex has the potential to generate a 
standard for further investigations. 
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Considering monoclonal antibodies (mABs) against HCMV-PC, a recent paper identified 4 
immunogenic regions (IR1 to IR4) (Fig.62A). In a further analysis, generation of PC-specific 
mAbs were tested against 2 laboratory strains (VR1814, TB40/E) and 11 clinical isolates in 
comparison to HCMV-HIG on ARPE-19 cells (Fig.62B) (Ha et al., 2017). 
 
Figure 62: (A) Visualized binding sites of PC-specific monoclonal antibodies, separated in 4 immunogenic 
regions (IRs) using an EM 3D reconstruction of pentameric complex; (B) IC50 concentrations of generated 
monoclonal antibodies against the pentameric complex against 2 laboratory strains (VR1814, TB40/E) and 
11 clinical isolates in comparison to HCMV-HIG on ARPE-19 (modified after Ha et al., 2017) 
The results revealed the neutralizing antibodies against the immunogenic regions 1 to 3 were 
highly potent against all HCMV strains which indicates that these immunogenic regions are 
highly conserved over all investigated strains. This observation confirmed data of this thesis 
which showed consistently, that HIG is effective against HCMV strains, possessing various 
genotypes. The most effective PC-mAbs emerged against IR1 which reflects the UL128-131 
region. Impressively, PC-mAbs which are directed against IR1 to IR3 showed up to 25.000-
fold higher IC50 values than an HCMV-HIG. However, the HIG preparation which was used as 
reference during the NT experiments was not mentioned (Ha et al., 2017). Therefore, 
monoclonal antibodies showed remarkable advances in prevention of viral in vitro infection and 
could be a promising alternative treatment option to HCMV-HIG in the future. 
The focus was placed on PC-specific antibodies, because of their potential ability to prevent 
viral transmission during pregnancy after HCMV-primary infection in contrast to gB-induced 
antibodies which are mostly non-neutralizing (Kabanova et al., 2014). In a former study, the 
antibody titers against gB and PC were compared between two groups of either maternofetal 
HCMV-Non-transmitters or HCMV-transmitters.   
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It suggested a correlation between a delay of PC-specific antibodies and an increased fetal 
HCMV-transmission during primary infection (Lilleri et al., 2013). The results indicated, that 
antibody titers against PC and dimers of gH/gL were significantly higher in HCMV-non-
transmitters than in HCMV-transmitters after the first 30 dpi (days post infection). 
However, in contrast to these findings, another publication characterized a monoclonal 
antibody against gB which prevented the infection of placenta-related trophoblast progenitor 
cells (TBPCs), but two monoclonal antibodies against the PC failed (Zydek et al., 2014).  
In conclusion, the maternal HCMV primary infection during pregnancy, followed by a possible 
maternofetal transmission of HCMV through the placenta depends on known and still unknown 
factors which include manifold interactions of different cell types, as well as the maturity of 
immune system. It might be suggested that the divergent findings of the discussed publications 
are part of the multistep maternofetal transmission process (Schampera et al., 2018). 
Additionally, latest findings showed that essential HCMV genes were reported to influence the 
formation of the trimer and pentameric complex. For post-entry tropism, the HCMV genes 
UL135 and UL136 were considered to be essential for HCMV replication in endothelial cells 
(Bughio et al., 2015). Modulating specific cell type tropism, the UL148 gene is suggested to 
manage the assembly of the trimer and pentameric complex into the virions through an 
encoding glycoprotein, localized in the cellular endoplasmic reticulum (Li et al., 2015).  
Furthermore, an alternative variant of gH/gL was recently described, the gH/gC subunit which 
is encoded by UL116. Its function remains unclear and its role in context of cell tropism has to 
be further evaluated (Caló et al., 2016). The dysfunction of the US16 gene might be associated 
with a reduced ratio of expressed PCs on the viral surfaces, inhibiting HCMV infection of 
endothelial and epithelial cells (Luganini et al., 2017).  
4.5 Depletion of HCMV hyperimmunoglobulin IgG subclass 3 from Cytotect® 
and analysis of its functional activity 
Further antibody depletion experiments of this work analyzed the influence of IgG subclass 3 
antibodies in HIGs and IVIGs (Schampera et al., 2018). In this context, Planitzer et al., 2011 
postulated earlier the importance of IgG antibody subclass 3 to be mainly involved in viral 
neutralization of HCMV which based on former data of Gupta et al., 1996.  
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Furthermore, Planitzer used the increased concentration of IgG 3 antibodies in Kiovig® 
(Fig.63A) as argumentation to claim, that Kiovig® showed higher HCMV-specific NT-capacity 
(NT50 values) than Cytotect® (Fig.63C). Although, the authors clearly demonstrated, that the 
HIG Cytotect® possesses more HCMV-specific IgG than Kiovig, measured in an ELISA HCMV 
system (Fig63B) which was never properly considered in this publication. 
 
Figure 63: (A) IgG subclass distribution in HIG and IVIGs, (B) Corresponding HCMV-specific IgG and (C) 
HCMV NT50 values, according to Planitzer et al., 2011 
While, comparable results for IgG subclass 3 and HCMV-specific IgG concentrations for 
Cytotect® and Kiovig® were found during the investigations of Schampera et al, 2017, the 
publication of Miescher et al., determined the highest concentration of IgG 3 in Cytogam®. In 
contrast, higher IgG 3 concentrations were found in Cytogam® than in Cytotect®, but 
Cytogam® contained lower IgG 3 levels than Kiovig® (Schampera et al., 2017). At this point, 
the results of Schampera and Miescher are contradictory. As reminder, Miescher et al. showed 
in their results, that the IgG product Cytogam® had the highest concentration of IgG subclass 
3 antibodies. HIGs and IVIGs are serum products, continuously made from hundreds to 
thousands of various human donors which indicates that there might be charge-dependent 
biological variations in composition of IgG sub classes.   
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Several time-differing charges of each product could be analyzed to clarify these different 
observations in context of IgG 3 antibodies. However, Schampera al., 2017 showed that IVIGs 
contain the double amount of total IgG, compared to HIGs which should also have a beneficial 
impact on IgG3 for IVIGs, but not necessarily for HCMV-specific IgG binding and neutralization, 
as mentioned previously. 
For NT-testing, the results in this PhD thesis strongly contrast to the findings of Planitzer et al., 
2011. But not only in terms of functional NT-capacities of HIGs versus IVIGs, even the 
depletion of IgG subclass 3 antibodies showed any significantly difference in NT50 values in 
both HFF and ARPE-19 cells for the investigated IgG preparations (Fig.47). The rebuttal was 
published in Schampera et al., 2018.  
Furthermore, two important points have to be considered. Firstly, if the IgG class distribution 
is analyzed in detail, the concentrations of IgG subclass 3 antibodies are remarkably low 
(<2%), while the IgG subclass 1 is predominantly present with about 50–70% of all IgG 
subclasses (Schampera et al., 2017). This observation could influence the impact on NT-
capacity between IgG subclass 1 to 4. As a following validation experiment, a depletion of IgG 
subclass 1, 2, 4 or combinations could be performed to deliver evidence for their neutralizing 
potentials.  
On the other hand, it has to be exclusively highlighted, that the measured IgG subclass 
concentrations refer to the total IgG amounts of each IgG product and not inevitably to the 
particular concentrations of HCMV-specific IgG. It is not known, how the IgG subclasses are 
distributed for HCMV-specific IgG in particularly which has to be evaluated, if such tests are 
available in the future. 
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4.6 T cell modulation via HIG administration after HCMV primary infection of 
pregnant women 
In the attempt to prevent maternofetal HCMV transmission, high virus-specific antibody titers 
and strong neutralizing activity seemed to be the only relevant benchmarks which were 
considered to be predictable parameters for immune protection. But it was shown that HCMV-
IgG concentrations and resulting neutralization did not necessarily correlate (Corrales-Aguilar 
et al., 2016). While highly-neutralizing antibodies play an important role to bind and effectively 
inactivate infectious HCMV virions as part of the humoral immune response, further 
immunological functions are induced by antibodies. The antibody-dependent natural killer (NK) 
cell activation (Chung et al., 2014), as well as the antibody-dependent complement deposition 
(ADCD) (Chung et al., 2015) are defense mechanisms which are also important to prevent 
viral infection. NK cells, especially the memory-like CD57+NKG2C natural killer cell subset are 
known to be the first line defense against HCMV as part of the innate immune system and 
were observed to expand during HCMV primary infection in adults, as well as in congenitally 
HCMV-infected infants (Costa-Garcia et al., 2015; Lopez-Vergès et al., 2011 and Noyola et al., 
2012). Furthermore, the antibody-dependent cellular cytotoxicity (ADCC) plays an essential 
role in binding and lysis of HCMV-infected cells via effector cells of the innate immune system 
(Ackerman et al., 2011). The subsequent activation of Fc-γ receptors allows these receptors 
to act as linkers and modulators between the innate and adaptive immune response to provide 
various inflammatory and anti-inflammatory tasks (Fig.64) (Corrales-Aquilar et al., 2011; 
Schwab et al., 2013).  
 
Figure 64: Overview of the functional outcome of Fc-γ receptors: From activation over inhibition to anti-
inflammatory activities (modified after Schwab et al., 2013). 
Further immunological investigations were performed in this PhD thesis to analyze, whether 
the HIG administration could beneficially modulate cellular immunomodulatory effects in 
pregnant women with a proven HCMV-primary infection. 
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This hypothesis based on an open question in development of an effective HCMV vaccine 
which describes the uncertainty about the establishment of a protective immunity that prevents 
virus transmission to the fetus through the placenta. Both the humoral, as well as the cellular 
immune system are necessary to protect from viral infection, but the influence of these two 
pathways in prevention of maternofetal transmission are still unknown (Schleiss et al., 2013). 
Therefore, the possible impact of HIG administrations on the cellular immunity in pregnant 
women was investigated, using indirect IFN-γ secretions assays. IFN-γ is generated during the 
adaptive immune response of CD4+ and CD8+ T-cells, as well as during the innate immune 
response of NK cells and NK-T cells (Lilleri et al., 2008; Jackson et al., 2014). 
The IFN-γ production was checked by stimulation of PBMCs with HCMV-specific peptides, 
following analysis via ELISA system QuantiFERON CMV® from Qiagen and EliSPOT HCMV® 
from Lophius. The ex vivo blood samples were derived from women of the Tuebingen HIG 
study (Kagan et al., 2018). Both different assays were used to clarify, whether IFN-γ could be 
used as a predictable parameter for stimulated PBMCs and therefore might have a protective 
cell-mediated immunity (CMI) against HCMV in the HIG-treated mothers. While the HCMV-
specific CMI protected from uncontrolled viral replication in healthy humans, the CMI is 
impaired in immune-suppressed patients after an organ transplantation. The IFN-γ secretions 
assays are usually used for the monitoring of adaptive T-cell transfer immunotherapy in 
immunocompromised patients (Feucht et al., 2015 and Günther et al., 2015). 
However, a recent report postulated the related appearance of functional impairment of CMI 
in pregnant women compared to non-pregnant women after HCMV infection (Reuschel et al., 
2017). In this context, the administration of HIG, containing highly-neutralizing antibodies 
against HCMV might counteract the impairment of CMI by an improved opsonization through 
effective viral binding, neutralizing and Fcγ-receptor activation. 
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The administration of HIG during this study seems to boost the secretion of IFN-γ which is an 
indicator for an active cellular immune response in the treated women with a HCMV-primary 
infection. This suggestion is supported by the given results in the present work (Fig.53). All 
HIG-treated mothers, who were HCMV Non-transmitters showed rising levels of IFN-γ 
concentrations and IFN-γ reactive PBMCs within 7 days after the first HIG application, followed 
by longer-lasting increases after repeated HIG doses. Interestingly, it seems, that multiple 
applications of HIG are necessary to maintain the possible T-cell stimulus after the first 
intravenous HIG administrations in the pregnant mothers.  
While the induced peak levels of IFN-γ production and corresponding numbers of IFN-γ 
reactive PBMCs strongly differed in each woman, the kinetics of IFN-γ production were 
longitudinally comparable among these pregnant women. This observation matched with 
previous described data of Jackson et al., 2014, that the T-cell response can differ between 
individuals. 
These observations were confirmed by in vitro data which were recently provided by PD Dr. 
Ludwig Deml, Chief Scientific Officer (CSO) at Lophius. The results were already represented 
at the ESOT2017 Barcelona Congress. After a formal permission of Lophius (Dr. Katharina 
Eder -Key-Account Manager Lophius), their officially presented in vitro data are available to 
discuss in this PhD thesis (Fig.65). 
 
Figure 65: In vitro stimulation of PBMCs with viral antigens in the present of HIG Cytotect® (A) CB8+ 
Cytotoxic T-cells (B) CD4+ T-helper (modified after Deml et al., 2017; ESOT2017 Barcelona Congress, 
Lophius) 
Deml et al., stimulated CD8+ T-cells and CD4+ T-cells with and without an HCMV pp65 peptide 
mixture or HCMV lysate in the presence of HIG Cytotect® for 6h. After incubation the number 
of corresponding IFN-γ reactive T-cells were determined with EliSPOT HCMV®.  
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On the one hand, the induced numbers of CD8+ T-cells (green square) which produced IFN-γ 
was significantly higher than the number of CD4+ T-cells (red square) which identified cytotoxic 
T-cells, mainly involved in CMI and not T-helper cells, according to IFN-γ secretion. This 
confirmed the in vivo boosting effect of the cellular immune system via HIG which was 
observed in the HIG-treated pregnant mothers. On the other hand, the given results also 
revealed that the presence of viral antigens is necessary for immunogenic processing which 
resulted in IFN-γ production. HIG Cytotect® alone was not able to trigger the cellular immune 
response vice versa. 
Finally, the results showed various numbers of IFN-γ producing PBMCs between different 
patients (d270, d288, d296, d302 and d370) which matched with the different IFN-y responses 
in the investigated HCMV-primary infected pregnant women, who achieved HIG 
administrations during the Tuebingen HIG study (Kagan et al., 2018) (Fig.53). 
An important point that has to be critically considered during the study of induced IFN-γ 
production in HCMV-primary infected pregnant women is the absence of control cohorts. It 
was not possible to compare the data of the HIG-treated women with a group of HCMV-primary 
infected women, who achieved no HIG or placebo. These negative controls were not enrolled 
in the Tuebingen HIG study (Kagan et al., 2018), since the study was not placebo controlled 
for ethical reasons. 
However, in the absence of a placebo control group, data of van de Berg are available for the 
correlation of viral load to IFN-γ production (Fig.66).  
 
Figure 66: Unstimulated course of IFN-γ after HCMV primary infection compared with HCMV DNA viral 
load in blood of an immunocompetent patient (van de Berg et al., 2010) 
Van de Berg demonstrated, that an HCMV primary infection of an immune competent patient 
induced a clear proinflammatory response during a natural infection which was maintained 
during latency. This response was characterized by increased levels of IFN-γ levels and other 
cytokines.  
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Figure 66 shows the kinetic of IFN-γ levels during a natural infection of HCMV in relation to the 
viral load in blood. The authors found only one major increase of IFN-γ between day 50 and 
70 which was downregulated afterwards through T-cell suppression of the immune system. 
These findings correspond with the observations of IFN-γ concentrations after the second HIG 
application, expect for the IFN-γ boosting after the first HIG administration.  
Additionally, the administration of HIG might improve the HCMV antigen recognition and thus 
it could support the cellular immune response. However, the detection of viral load was not 
observed in each individual woman of the HIG cohort during the Tuebingen HIG study. Only in 
a minority of women (6/40), low viral loads were found at the initial detection of HCMV primary 
infection in pregnancy (Kagan et al., 2018). The viral exposition to the cellular immune system 
might be detectable only in placental cytrophoblasts and syncytiotrophoblasts (Palmeira et al., 
2012). 
The increased number of Fc-fragments in blood of the women could also trigger the cellular 
immune system by Fcγ-receptor binding and could promote the IFN-γ production through IL-2 
secretion (Klenerman et al., 2016). Further HIG administrations had no longer stimulating 
effect on the IFN-γ secretion (Fig.53). This can be explained by the intrinsic cellular and 
humoral immune response which suppressed usually the T-cell reaction during the progress 
of a HCMV primary infection or reactivation (van de Berg et al., 2010).  
One pregnant woman of the HIG cohort (1/40) was an HCMV-transmitter in the Kagan study 
and was investigated in this PhD thesis. She showed a different kinetic pattern of IFN-γ 
parameters than all other maternal HCMV non-transmitters. Interestingly, the HCMV-
transmitting mother showed an already strong IFN-γ reactivity at the beginning of the HIG 
treatment in both assays (Fig.52). The IFN-γ activity weakly increased during the first two HIG 
applications and constantly decreased afterwards. It seems that the IFN-γ secretion was 
already reactive on a high level and was not further simulated by further HIG administration, 
while the serological parameter clearly indicated an early HCMV-primary infection with low 
concentration of HCMV-specific IgG and low IgG avidity, paired with high HCMV-specific IgM 
index.  
This interesting case contributes to a currently published paper of Saldan et al., 2015 which 
described this specific constellation of immunological parameters in HCMV-primary infected 
pregnant women. The Saldan study enrolled 80 pregnant women, including 57 HCMV-primary 
and 23 non-primary infected mothers. The median age of pregnant women was 31 years with 
a range of 17-42 years which correlates with the median age in the present study. The maternal 
HCMV IgM and IgG were determined via Immulite® Siemens, Germany and the HCMV IgG 
avidity was measured, using a TGS TA ELISA assay from Technogenetics KHB group, Italy.   
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The number of IFN-γ reactive PBMCs was analyzed with an EliSPOT from Autimmun 
Diagnistika, Germany (Fig.67).  
 
Figure 67: (A) Correlation between HCMV low IgG avidity and high congenital transmission rate; (B) 
Correlation between high number of IFNγ-reactive PBMCs and and high congenital transmission rate 
(Saldan et al., 2015) 
The HCMV-primary infections occurred during the first and second trimenon of pregnancy 
(median GA= 6 weeks; Range: 0-20 weeks). The given results of Saldan showed an increased 
risk for a congenital transmission at lower IgG avidity and higher numbers of IFN-γ reactive 
PBMCs at the same time. The authors further suggested that a combination of HCMV EliSPOT 
and low HCMV IgG avidity could reach a higher diagnostic validity to estimate the risk of 
maternofetal transmission after HCMV-primary infection of the mothers than either method 
alone. However, the reasons for the association between high IFN-γ PBMC numbers and 
increased risk of HCMV congenital transmission is unknown.  
But two hypotheses were addressed to this issue until now. First, during HCMV-primary 
infection, the duration and degree of the maternal viremia, corresponding to higher viral loads 
transient in blood and urine may induce a faster and stronger CMI response (Lazzarotto et al., 
2000) which was detected in the IFN-γ secretion assay (Saldan et al., 2015). However, a 
stronger maternal viremia in combination with an increased risk of HCMV-transmission was 
not reported during the Tuebingen HIG study (Kagan et al., 2018), since the presence of viral 
DNA in blood has been reported to be not associated with a greater risk of maternofetal 
transmission (Lazzarott et al., 2011) 
The second hypothesis described an indirect caused damage by the CMI which promotes a 
local proinflammatory process in the placenta and leads to unintendedly supported viral 
transmission to the fetus (Fischer et al., 2000; Tabata et al., 2008). However, these hypotheses 
have to be proven in controlled studies.  
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In this context, the impact of early inflammatory events in the placenta on the risk of HCMV 
transmission should be further investigated which could be the initial trigger and door opener 
for viral transmission to the fetus. Therefore, more inflammatory factors should be identified 
which especially reflect the status of the placenta. This could enhance the significance of 
HCMV diagnostics and evaluate the efficacy of HIG treatment during pregnancy. 
The results in the presented work correlate with the observation in the paper of Saldan et al., 
2015. However, it has to be critically considered, that only one woman was monitored with a 
HCMV-maternofetal transmission in the present study, although it was a simultaneous success 
for the HIG treatment of HCMV-primary infected women.  
Longitudinal samples have to be analyzed via IFN-γ production, using T-Track EliSPOT CMV® 
and/or QuantiFERON CMV® assay when more data on maternal transmitters are available, 
who underwent HIG treatment. Further studies have also to improve the understanding of the 
HCMV-specific cell-mediated immunity in context of HCMV-primary infections. 
In a conclusive comparison, both IFN-γ secretion assays revealed comparable results for the 
statistical median and mean in the HIG-treated women. However, there were test-dependent 
variations noticeable for single points of measurement between both assays. In detail, the 
QuantiFERON CMV® showed more single outliers than the EliSPOT HCMV® (Fig.53A versus 
Fig.53B). Saldan et al., 2016, confirmed in another paper the correlation between both test 
systems (Fig. 68).  
 
Figure 68: Comparison between QuantiFERON CMV® and HCMV EliSPOT collected data of pregnant women 
with and without HCMV primary infection. Bandwidth was 0.8 (modified after Saldan et al., 2016). 
The data were collected from 195 Caucasian women, who included 57 HCMV-primary and 23 
HCMV-nonprimary infected pregnant mothers, as well as 7 HCMV-seropositive and 4 HCMV-
seronegative nonpregnant women. The correlation between both assays was determined with 
a bandwidth of 0.8, using a “local regression-smoothing model”.  
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Interestingly, Saldan et al., 2016 reported, that the QuantiFERON CMV® seemed to fail to 
detect the difference between HCMV-primary and non-primary infected mothers in contrast to 
a used EliSPOT assay (AID Autimmun Diagnostika, Germany), while the detection of HCMV-
seronegative pregnant women was concordantly accurate in both assays.  
Furthermore, the results of Saldan showed less outliers in the EliSPOT assay than 
QuantiFERON HCMV® which matched with the given results in this PhD thesis. Concerning 
the collected data of EliSPOT HCMV® and QuantiFERON HCMV®, the different read out 
systems have always to be considered in the background of repeated HIG administrations. 
While the results of EliSPOT HCMV® based on the given number of PBMCs which were 
purified from 15 ml LiHep-blood samples via density gradient, the QuantiFERON CMV® 
detects the produced amount of IFN-γ concentration of 1ml whole blood. The stimulation of 
IFN-secretion also differs in both test assays. 
Recently, Bialas et al., 2015 underline the importance of an active CMI in a relevant primate 
model. Using pregnant rhesus macaques, Bialas depleted CD4+ T-cells these animals via 
specific anti-CD4+ T-cell antibodies. The CD4+ T-cell depletion resulted in an increased number 
of placental infections and fetal transmission which leaded to fetal death, myocarditis and 
hepatic calcination in a combination with viral load in maternal plasma and amniotic fluid. 
Furthermore, it was demonstrated, that an impaired CD8+ T-cell response was caused by the 
induced lack of CD4+ T-cells which was also the reason for a delayed maturation and 
production of HCMV-neutralizing antibodies via B-cells.  
Another work group also worked with CD4+ T cell–depleted, rhesus macaques which achieved 
either rhIVIG or rhHIG (Nelson et al., 2017) after primary infection during early pregnancy. Both 
IgG preparations were made from rhCMV-seropositive monkeys. The dose-optimized rhHIG 
administration completely prevented the placental rhCMV transmission after infection of 
pregnant macaques. At this point, the calculated rhHIG half-life time (t1/2) of about 7 days 
supports initial observations by Hamprecht et al., 2014 and Kagan et al., 2018. However, the 
pregnant rhesus macaques achieved rhHIG one hour after the rhCMV infection which is a point 
of criticism of the study and cannot be transferred to clinical routine practice in the detection of 
HCMV-primary infected pregnant women, with an HCMV exposition at least 6 to 8 weeks prior 
to start of HIG treatment. 
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In summary, the exact mode of action of HCMV-specific immunoglobulin preparations is not 
known in detail. The interaction of both, the innate and the adaptive immune response, directed 
against HCMV in pregnancy is not completely understood. Therefore, the possible beneficial 
effects of HIG on both pathways of the CMI were addressed in this work. 
 
Figure 69: Summarized response of the immune system to HMCV and potential HIG modes of action: (A) 
responsible for viral neutralization; (B) potential effect on T-cell stimulation; (C) possible modulation of DC 
maturation; (D) Suggested impact on cytokine secretion (modified after Carbone et al., 2016) 
In a summarized overview, the response of the immune system to HCMV and possible 
interactions between HIG and the cellular immune response are shown in (Fig.69). At the 
starting point, HCMV is initially detected by pathogen recognition receptors. In this context, 
Toll-like receptors (TLR) were reported to recognize the HCMV glycoprotein B which results in 
proinflammatory IFN type I and further cytokines (Boehme et al., 2006). The viral antigens are 
presented on antigen-presenting cells (APCs), including dendritic cells (DC) and 
macrophages, while TLR-4/5 stimulate the production of IL-6 and IL-8, as well as TNF-α. 
Further, CD4+ and CD8+ T-cells activation is performed by the antigen presentation via MHC-
II binding which is followed by cell signaling via IFN-γ and TNF-γ (Smith et al., 2014). This 
cascade ends in the cytolysis of infected cells and initiates HCMV-specific antibody production 
of B-cells and IgG maturation. In addition, there is an interaction of dendritic cells with NK cells, 
including IFN-γ production and ADCC, as well as a reported activation of B-cells through DCs. 
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Independently, HCMV antigens are detected by NK cells which induce the secretion of IFN-γ. 
Especially, the already mentioned CD57+NKG2C natural killer cells play an important role 
during the first two weeks after onset of infection, following viremia (Stern et al., 2008; Lopez-
Vergès et al., 2011). 
Interestingly, in murine HCMV, neutrophils were identified to act as potent antiviral effector 
cells which limited viral replication and viral associated symptoms by an induced inflammation 
(Stacey et al., 2014). While the impact of complement on the regulation of HCMV infections is 
poorly characterized, an enhancing neutralizing effect of added complement on serum was 
demonstrated in the presence of HCMV particles (Spiller et al., 1997).  
HIG has several potential interaction points with the innate and adaptive immune system. 
Administrated HCMV-specific antibodies effectively bind and neutralize free-circulating virions, 
as well as intracellular localized virions with reduced efficacy (Fig.69A). The binding of viral 
antigens may improve their opsonization to the innate immune systems (Fig.69B). A faster 
recognition of the virus after an HCMV-primary infection may boost the innate NK cells as well 
as adaptive CD4+ and CD8+ T-cell response in terms of reaction time and strength through 
specific IFN-γ receptor activation (Fig.69C). In the presented work, an indirectly-detected 
modulation of T-cell activity was demonstrated by IFN-γ secretion, as well as IFN-γ reactive 
PBMCs (Fig.53).  
Importantly, divergent results were also published in context of HIG administrations and their 
impact on T-cell and B-cell regulation in SOT patients. According to these publications, HIG 
was suggested to inhibit cytokine expression and suppress T-cell proliferation which could be 
associated with lower rates of allograft rejection. The increase of naïve B-cells levels may be 
also induced by HIG administration (Fig.69D) (Hoetzenecker et al., 2007; van Gent et al., 
2014). However, another group did not observe such inhibitory effects after solid organ 
transplantations (Bonaros et al., 2008). 
In conclusion, in the absence of an effective vaccination against HCMV, the focus should be 
set on the early identification of HCMV-primary infections in pregnant women, as well as on 
the determination of risk factors for maternofetal transmission. The results in this PhD thesis 
suggested, that the determination of IFN-γ secretion could be useful to estimate the risk of 
maternofetal HCMV transmission after maternal primary infection. Furthermore, the PC 
depletion experiments in this presented work encourage the vaccine development on the base 
of the viral pentameric complex which might lead to a potent vaccine in the future. 
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5 Zusammenfassung 
Die maternale Primärinfektion mit dem Humanen Cytomegalievirus ist die häufigste 
intrauterine Infektion weltweit. Der Krankheitsverlauf ist bei werdenden Müttern meist 
asymptomatisch und ist in seltenen Fällen von unspezifischen grippe-ähnlichen Symptomen 
begleitet. Jedoch kann das erhöhte Risiko einer diaplazentären Übertragung auf den Fetus zu 
schwerwiegenden Entwicklungsstörungen des Zentralen Nervensystems führen, sowie im 
Verlauf der ersten Lebensjahre Hörschädigungen verursachen (Picone et al., 2013). 
In der Abwesenheit eines effektiven Impfstoffes gegen das Virus, haben mehrere Studien 
verschiedene Präventionsmaßnahmen untersucht um das Risiko einer HCMV-Transmission 
auf den Feten zu reduzieren. Die Hygieneberatung von seronegativen Frauen hat sich als sehr 
effektive Methode erwiesen, dieses Risiko um bis zu 50% zu senken. Die Untersuchung der 
Serostatuses der Schwangeren ist Grundvoraussetzung, um die werdende Mutter 
entsprechend medizinisch aufzuklären. Dabei ist der bewusste Umgang mit Kleinkindern im 
Umfeld der Frau von besonderer Bedeutung. So sollte bespielhaft der körperliche Kontakt 
vermieden und gemeinsam benutzte Gegenstände und Oberflächen entsprechend gereinigt 
werden. Das routinemäßige Händewaschen hat sich dabei als erfolgreiches Werkzeug 
erwiesen (Revello et al., 2015). 
Des Weiteren konnte eine Therapie mit HCMV-spezifischen Hyperimmunoglobulinen nach 
einer bestätigten Primärinfektion der Mutter, die Übertragungsrate nachweislich reduzieren 
(Nigro et al., 2005; Visentin et al., 2012). Hyperimmunoglobuline sind gepoolte Seren von 
gesunden Spendern, die einen erhöhten HCMV-spezifischen Titer aufweisen. Jedoch sind die 
Ergebnisse verschiedener Studien, hinsichtlich der Effektivität der HIG Behandlung 
widersprüchlich. In diesem Zusammenhang konnte die einzige randomisierte kontrollierte 
Studie keinen signifikanten Unterschied zwischen der Präventions- und Placebogruppe 
feststellen (Revello et al., 2014). Jedoch konnte eine Meta-Analyse der Nigro- und Revello-
Studie einen signifikaten Trend, im Bezug auf die Reduktion der maternofetalen Transmission 
feststellen (Rawlinson et al., 2016). Es gibt allerdings keine offizielle Empfehlung für die 
Behandlung von schwangeren Frauen mit Hyperimmunoglobulinen außerhalb von klinischen 
Studien (Rawlinson et al., 2017). 
Die Untersuchungen dieser Dissertation wurden im Hintergrund einer in Tübingen 
durchgeführten HIG Studie zur Prävention von maternofetalen Transmissionen im ersten 
Trimenon der Schwangerschaft durchgeführt (Kagan et al., 2018). Parallel zu dieser Studie, 
war das Ziel, der vorliegenden Arbeit, die in vitro Evaluierung des verwendeten 
Hyperimmunoglobulin-Präparates Cytotect® (Biotest AG) durchzuführen. 
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In den ersten Experimenten konnte gezeigt werden, dass Cytotect® in der Lage ist, 
verschiedene HCMV Stämme effektiv in in vitro Untersuchungen zu neutralisieren. Dies könnte 
darauf zurückzuführen sein, das essentielle Strukturen des Virus genetisch konserviert sind, 
die für eine erfolgreiche Infektion, Vermehrung und Verbreitung des Virus notwendig sind und 
sich dies durch Hyperimmunoglobuline verhindern lässt.  
Im Folgenden wurden HCMV-spezifische Antikörper weiter untersucht, die in HIG vorhanden 
sind und sich gegen gezielte Strukturen des Virus richten – den Pentamerkomplex (gHgL-
UL128-131). Dieser virale Komplex ermöglicht dem Virus den Eintritt in Epithel- und 
Endothelzellen und scheint auch bei Dendritischen Zellen und Monozyten von Bedeutung zu 
sein (Hahn et al., 2004; Gerna et al., 2005; Wang et al., 2005). Zwei UL130 Peptide und ein 
rekombinanter Pentamerkomplex wurden verwendet, um Epitop-spezifische Antikörper aus 
Cytotect® zu depletieren und deren Einfluss auf die in vitro Neutralisationskapazität in 
retinalen Pigment-Epithelzellen (ARPE-19) zu untersuchen. Während die Depletion mit UL130 
Peptiden zu einer niedrigeren Reduktion der in vitro Neutralistionskapazität führte (maximale 
Differenz: 16%), konnte unter der Verwendung des rekombinanten Pentamerkomplex ein 
beachtlicher Anteil der in vitro Neutralisationskapazität (maximale Differenz: 42%) entfernt 
werden. Diese Ergebnisse bestätigen Studien von Fouts et al., 2012 und Loughney et al., 
2015. Sie zeigen, zusammen mit den Ergebnissen in dieser Dissertation die mögliche, 
vielversprechende Anwendung des Pentamerkomplex als Zielstruktur für die Impfstoff-
Entwicklung, da viele polyklonale HCMV-neutralisierende Antikörper in HIGs gegen den 
Pentamerkomplex gerichtet sind. 
In weiteren in vivo Untersuchungen wurden longitudinale LiHep-Blutproben von 9 
schwangeren Frauen untersucht, die Teil der Patientenkohorte der Tübinger HIG Studie 
waren. Die Proben wurden mit dem Ziel analysiert, die mögliche Stimulation von HIG 
Administrationen auf die zelluläre Immunantwort nach einer HCMV-Primärinfektion zu 
untersuchen. Für diesen Zweck, wurden zwei IFN-γ Release Assays parallel durchgeführt, um 
die indirekte IFN-γ Sekretion zu messen. Dabei erfasste der QuantiFERON CMV® (Qiagen) 
die IFN-γ Konzentrationen und der T-Track EliSPOT CMV® (Lophius) bestimmte die Anzahl 
der IFN-γ produzierenden mononukleären Zellen des peripheren Blutes. Die in vivo 
Untersuchungen in beiden Tests zeigten, dass mehrfache, zweiwöchentliche Applikationen 
von Cytotect® in wiederholten Stimuli der IFN-γ Produktion bei 8 behandelten Schwangeren 
resultierten, die HCMV-Non-Transmitterinnen waren. Die erfassten IFN-γ Messwerte 
schwankten stark zwischen den untersuchten Frauen und zeigten jeweils eine 
unterschiedliche Kinetik für IFN-γ, beginnend bei varierenden IFN-γ Ausgangsniveaus. Diese 
Beobachtung deckt sich mit Untersuchungen von Jackson et al., 2014, welche beschreiben, 
dass die individuelle zelluläre Immunantwort stark schwanken kann.   
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Im Allgemeinen kann die Verabreichung von HCMV-spezifischen hochaviden Antikörpern an 
mehreren Stellen in die zelluläre Immunantwort eingreifen und beispielhaft die Opsonierung 
verbesseren durch effektives Binden und Neutralisieren des Virus, sowie Fcγ-Rezeptor 
Aktivierung (Corrales-Aquilar et al., 2011; Schwab et al., 2013).  
Eine HCMV-Transmitterin wurde während der Tübinger HIG Studie erfasst und in dieser 
Dissertation untersucht. Sie zeigte eine bereits erhöhte IFN-γ Produktion mit einer zeitgleich 
frischen HCMV-Primärinfektion zu Beginn der HIG Therapie. Interessanterweise bringt eine 
Studie von Saldan et al., 2015 erhöhte IFN-γ Messwerte und korrespondierende niedrige 
HCMV IgG Avidität in Zusammenhang mit einem erhöhten Risiko einer maternofetalen 
Transmission während der Schwangerschaft und bestätigt damit die Daten der analysierten 
HCMV-Transmitterin. Darüber hinaus waren die Ergebnisse aller untersuchten Schwangeren 
bei beiden IFN-γ Tests im proportionalen Verhältnis gesehen miteinander vergleichbar, auch 
wenn sie unterschiedliche Ausleseparameter besitzen. Aus den gewonnenen Daten lässt sich 
ableiten, dass IFN-γ möglicherweise als Surrogat-Marker in Kombination mit einer 
serologischen Auswertung dienen kann, um ein potenziell-erhöhtes Risiko für eine HCMV-
Transmission zum Feten nach einer Primärinfektion der Mutter abzuschätzen. Jedoch müssen 
weitere Untersuchen diese These bestätigen. 
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